WO2019023551A1

WO2019023551A1 - IMMUNO-ONCOLOGY BIOMARKERS AND METHODS OF USE

Info

Publication number: WO2019023551A1
Application number: PCT/US2018/044048
Authority: WO
Inventors: Patrick DANAHER; Sarah WARREN; Erin PIAZZA
Original assignee: Nanostring Technologies Inc
Current assignee: NS Wind Down Co Inc
Priority date: 2017-07-28
Filing date: 2018-07-27
Publication date: 2019-01-31
Anticipated expiration: 2020-01-28

Abstract

The present disclosure relates to compositions and methods for the detection and quantification of individual target molecules in biomolecular samples. In particular, the disclosure relates to coded, labeled compositions comprising at least two probes hybridized to each other that are capable of binding to and identifying target molecules based on the probes' label codes. Methods of making and using such compositions are also provided. The compositions can be used in diagnostic, prognostic, quality control and screening applications.

Description

IMMUNO-ONCOLOGY BIOMARKERS AND METHODS OF USING SAME

CROSS-REFERENCE TO RELATED APPLICATIONS

[001] This application claims priority to, and the benefit of, U.S. Provisional Application No. 62/538,124, filed July 28, 2017, the contents of which is incorporated herein by reference in its entirety.

SEQUENCE LISTING

[002] The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on July 25, 2018, is named NATE034-001WO_SeqList_ST25.txt and is 292,259 bytes in size.

FIELD OF THE INVENTION

[003] This disclosure relates generally to compositions and methods for detection and

quantification of individual target molecules in biomolecular samples. In particular, the disclosure relates to a multiplexable reporter system for labeling a plurality of target molecules with a unique reporter code utilizing compositions comprising a capture probe and a labeled reporter probe, wherein the capture probe and/or reporter probe are associated directly, or indirectly via intermediate oligonucleotide molecules, to a specific target molecule through hybridization.

BACKGROUND OF THE INVENTION

[004] Although all cells in the human body contain the same genetic material, the same genes are not active in all of those cells. Alterations in gene expression patterns can have profound effects on biological functions. These variations in gene expression are at the core of altered physiologic and pathologic processes. Therefore, identifying and quantifying the expression of genes in normal cells compared to diseased cells can aid the discovery of new drug and diagnostic targets.

[005] Nucleic acids can be detected and quantified based on their specific polynucleotide sequences. The basic principle underlying existing methods of detection and quantification is the hybridization of a labeled complementary probe sequence to a target sequence of interest in a sample. The formation of a duplex indicates the presence of the target sequence in the sample. The recent development of DNA microarrays has enabled the detection of the presence or absence of thousands of genes in a biological sample in a single experiment.

[006] Despite significant advances, many drawbacks still exist in molecular hybridization and microarray techniques. Microarray methods still require significant amounts of biological sample, which can be a critical limitation for drug and diagnostic assays that rely upon biological samples with limited supply, such as biopsies of diseased tissues or samples of a discrete cell type. In addition, the kinetics of hybridization on the surface of a microarray is less efficient than hybridization in small amounts of aqueous solution. Moreover, while methods exist to estimate the amount of nucleic acid present in a sample based on microarray hybridization result, microarray technology thus far does not allow for detection of target molecules on an individual level, nor are there microarray-based methods for directly quantifying the amount of target molecule in a given sample.

[007] Thus, there exists a need for accurate and sensitive detection, identification and quantification of target molecules in complex mixtures. In addition, there exists a need for detection reagents that can be produced with high efficiency and consistency, and allow flexibility in experimental design and target selection. It is important for the productivity and effectiveness of scientific research to be able to rapidly and inexpensively accommodate changes to the selected list of target molecules from one experiment to the next.

SUMMARY OF THE INVENTION

[008] The present disclosure provides a composition comprising a plurality of first probes, wherein a first probe comprises: (i) a first region comprising a first target-specific sequence that independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table 1 A; and (ii) a second region comprising: a first label attachment region hybridized to at least one first RNA molecule, wherein the at least one first RNA molecule is attached to one or more label monomers that emit light constituting a first signal, and an at least second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to at least one second RNA molecule, wherein the at least one second RNA molecule is attached to one or more label monomers that emit light constituting a second signal; and wherein the second region does not overlap with the first region and does not independently base-pair hybridize with the target nucleic acid.

[009] The present disclosure provides a composition further comprising a plurality of second probes, wherein each second probe comprises: (i) a first region comprising a second target- specific sequence that independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table 1 A; and (ii) a second region comprising an affinity moiety; and wherein the first target-specific sequence and the second target-specific sequence base-pair hybridize to non-overlapping regions of the same target molecule.

[010] The first region of a first probe can comprise any one of SEQ ID Nos 1-770 or a complement thereof.

[011] The first region of a second probe can comprise any one of SEQ ID Nos 771-1540 or a complement thereof.

[012] The first region of a first probe comprises any one of SEQ ID Nos 1-770 and the first region of a second probe comprises any one of SEQ ID Nos 771-1540 or a complement thereof.

[013] The present disclosure provides a method of detecting a target molecule in a biological sample comprising: (i) contacting said sample with a composition of the present disclosure under conditions that allow hybridization of a first target-specific sequence of a first probe to a target molecule, wherein when a first target-specific sequence of a first probe is bound to a target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule; and (ii) detecting the code that identifies the target molecule.

[014] The present disclosure provides a method of detecting a target molecule in a biological sample comprising: (i) contacting said sample with a composition of the present disclosure under conditions that allow hybridization of the first target-specific sequence of a first probe and the second target-specific sequence of a second probe to a target molecule, wherein when the first target-specific sequence of a first probe and the second target-specific sequence of a second probe are bound to the target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule; and (ii) detecting the code that identifies the target molecule. [015] A composition of the present disclosure can comprise at least 50 first probes, or at least 100 first probes, or at least 770 first probes.

[016] In compositions and methods of the present disclosure, when a first probe is hybridized to a target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other can constitute at least part of a code that identifies the target molecule.

[017] A first probe can further comprise a third, fourth, fifth and at least sixth label attachment region, wherein: (i) the third label attachment region is hybridized to at least one third RNA molecule, wherein the at least one third RNA molecule is attached to one or more label monomers that emit light constituting a third signal; (ii) the fourth label attachment region is hybridized to at least one fourth RNA molecule, wherein the at least one fourth RNA molecule is attached to one or more label monomers that emit light constituting a fourth signal; (iii) the fifth label attachment region is hybridized to at least one fifth RNA molecule, wherein the at least one fifth RNA molecule is attached to one or more label monomers that emit light constituting a fifth signal; (iv) the at least sixth label attachment region is hybridized to at least one sixth RNA molecule, wherein the at least one sixth RNA molecule is attached to one or more label monomers that emit light constituting a sixth signal; and wherein none of the label attachment regions overlap.

[018] In compositions and methods of the present disclosure, when a first probe is bound to a target molecule, the identity of the first, second, third, fourth, fifth and sixth signals emitted from the first probe and the locations of the signals relative to each other can constitute at least part of a code that identifies the target molecule.

[019] The present disclosure provides a composition pair comprising a first composition and a second composition, wherein the first composition comprises a first probe and a second probe, wherein a first probe comprises: (i) a first region comprising a first target-specific sequence that independently base-pair hybridizes to a target molecule comprising any of the genes listed in Table 1 A; and (ii) a second region that does not overlap with the first region and does not bind to the target molecule; and wherein a second probe comprises: (i) a first region that hybridizes to the second region of the first probe; and (ii) a second region comprising a first label attachment region hybridized to at least one first RNA molecule, wherein the at least one first RNA molecule is attached to one or more label monomers that emit light constituting a first signal, and an at least second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to at least one second RNA molecule, wherein the at least one second RNA molecule is attached to one or more label monomers that emit light constituting a second signal, and wherein the second region does not overlap with the first region and does not independently base-pair hybridize with the target nucleic acid; and wherein the second composition comprises a third probe and a fourth probe, wherein a third probe comprises: (i) a first region comprising a second target-specific sequence that independently base-pair hybridizes to a target molecule comprising any of the genes listed in Table 1 A; and (ii) a second region that does not overlap with the first region and does not bind to the target molecule; and wherein a fourth probe comprises: (i) a first region that binds to the second region of the third probe; and (ii) a second region comprising at least one affinity moiety, and wherein the first region does not overlap with the second region; and wherein the first target-specific sequence of the first probe and the second target-specific sequence of a third probe hybridize to different regions of the same target molecule.

[020] The first region of a first probe can comprise any one of SEQ ID Nos 1-770 or a complement thereof.

[021] The first region of a third probe can comprise any one of SEQ ID Nos 771-1540 or a complement thereof.

[022] The first region of a first probe can comprise any one of SEQ ID Nos 1-770 and the first region of a third probe can comprise any one of SEQ ID Nos 771-1540 or a complement thereof.

[023] In methods and compositions of the present disclosure, when a first probe, a second probe, a third probe and a fourth probe are bound to a target molecule, the identity of the first and second signals emitted from the second probe and the location of the signals relative to each other can constitute at least part of a code that identifies the target molecule.

[024] The present disclosure provides a kit comprising a composition of the present disclosure and instructions for use.

[025] Any of the above aspects can be combined with any other aspect.

[026] While the disclosure has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. [027] The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.

[028] While this disclosure has been particularly shown and described with references to preferred aspects thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the disclosure encompassed by the appended claims.

[029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the Specification, the singular forms also include the plural unless the context clearly dictates otherwise; as examples, the terms "a," "an," and "the" are understood to be singular or plural and the term "or" is understood to be inclusive. By way of example, "an element" means one or more element. Throughout the specification the word "comprising," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term "about."

[030] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present

Specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the disclosure will be apparent from the following detailed description and claim.

BRIEF DESCRIPTION OF THE DRAWINGS [031] Figure 1 is an illustration of a direct binding (non-tag-based) nanoreporter system utilizing a reporter probe and capture probe. Both reporter and capture probes contain unique target-specific sequences for direct binding to different regions of the target nucleic acid. In this example, the reporter probe contains a 6-position fluorescently-labeled reporter code which uniquely "barcodes" the target sequence. The capture probe also contains an affinity moiety, biotin (B).

[032] Figure 2 is an illustration of an indirect binding (tag-based) nanoreporter system utilizing a reporter oligo (Oligo A) and a capture oligo (Oligo B) as intermediate probes that bind to the reporter or capture probe. Both Oligo A and Oligo B contain unique target-specific sequences that bind to different regions of the target nucleic acid, and distinct tag sequences that bind to either the capture probe or the reporter probe. In this aspect, the tag sequence in Oligo B can be a universal tag associated with all target-specific capture sequences. However, the target-specific sequence in Oligo A is associated with a unique tag sequence. Each species of Oligo A carries a unique tag sequence which is associated with a specific reporter code. Under the appropriate hybridization conditions, Oligo A and Oligo B will bind to the target nucleic acid. The universal capture probe will bind to Oligo B, and a specific reporter probe will bind to its associated Oligo A, uniquely barcoding the target sequence.

DETAILED DESCRIPTION OF THE INVENTION

[033] The present disclosure pertains to a multiplexable reporter system and methods for production and use. The present disclosure is based upon the discovery that nanoreporters comprising a reporter and capture probe and probes that bind to the reporter or capture probe and a target molecule can be utilized for the accurate and efficient detection and quantification of a plurality of target molecules in complex mixtures. Moreover, these nanoreporters allow more reliable and reproducible methods for manufacturing nanoreporters.

[034] These compositions and methods comprise a reporter probe, or a reporter probe and capture probe, for direct binding to the target specific sequence of the same target molecule. These compositions can also be referred to as a standard, or non-tag based nanoreporter system. In the non-tag-based reporter system (Figure 1), the reporter and capture reagents (e.g., the label attachment regions and attached labels, and affinity moieties) are covalently attached to the target-specific regions. [035] Examples of reporter and capture probes related to the non-tag based nanoreporter system, as well as, methods of using these probes is described in U.S. Patent Nos. 7,473,767; 7,919,237; 8, 148,512; 8,492,094; 8,986,926; 8,519, 115; and 9,376,712; and PCT Publication Nos. WO 2003/003810; WO 2007/076128; WO 2007/076, 132; and WO 2010/019826.

[036] Various compositions of the present disclosure are described in full detail herein.

[037] The present disclosure provides a composition comprising a plurality of first probes, wherein a first probe comprises: (i) a first region comprising a first target-specific sequence that independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table 1 A; and (ii) a second region comprising: a first label attachment region hybridized to at least one first RNA molecule, wherein the at least one first RNA molecule is attached to one or more label monomers that emit light constituting a first signal, and an at least second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to at least one second RNA molecule, wherein the at least one second RNA molecule is attached to one or more label monomers that emit light constituting a second signal; and wherein the second region does not overlap with the first region and does not independently base-pair hybridize with the target nucleic acid.

[038] In some aspects, the preceding composition can further comprise a plurality of second probes, wherein each second probe comprises: (i) a first region comprising a second target- specific sequence that independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table 1 A; and (ii) a second region comprising an affinity moiety; and wherein the first target-specific sequence and the second target-specific sequence base-pair hybridize to non-overlapping regions of the same target molecule.

[039] The present disclosure provides a composition comprising a plurality of first probes and a plurality of second probes, (a) each first probe comprising: (i) a first region comprising a first target-specific sequence that independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table 1 A; and (ii) a second region comprising: a first label attachment region hybridized to at least one first RNA molecule, wherein the at least one first RNA molecule is attached to one or more label monomers that emit light constituting a first signal, and an at least second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to at least one second RNA molecule, wherein the at least one second RNA molecule is attached to one or more label monomers that emit light constituting a second signal; and wherein the second region does not overlap with the first region and does not independently base-pair hybridize with the target nucleic acid; and (b) each second probe comprising: (i) a first region comprising a second target-specific sequence that

independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table 1 A; and (ii) a second region comprising an affinity moiety; and wherein the first target-specific sequence and the second target-specific sequence base-pair hybridize to non- overlapping regions of the same target molecule.

[040] In some preferred aspects of the preceding compositions, a first region of a first probe can comprise a first target-specific sequence that independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table IB.

[041] In some preferred aspects of the preceding compositions, a first region of a second probe can comprise a second target-specific sequence that independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table IB.

[042] The present disclosure also provides a composition comprising a plurality of first probes and a plurality of second probes, (a) each first probe comprising (i) a first region comprising a first target-specific sequence capable of independently base-pair hybridizing to a target molecule comprising at least five of the genes listed in Table 1; and (ii) a second region that does not overlap with the first region and does not bind to the target molecule; (b) each second probe comprising (i) a first region that binds to the second region of said first probe; (ii) an at least first label attachment region which is hybridized to an at least first RNA molecule, wherein the first RNA molecule is attached to one or more label monomers that emit light constituting a first signal; and (iii) an at least second label attachment region, which is non-overlapping to the at least first label attachment region, and which is hybridized to a second RNA molecule, wherein the second RNA molecule is attached to one or more label monomers that emit light constituting a second signal, and wherein the label attachment regions do not overlap with the first region of the second probe.

[043] The composition can further comprise a plurality of third probes and a plurality of fourth probes, (a) each said third probes comprising (i) a first region comprising a second target- specific sequence capable of independently base-pair hybridizing to a target molecule comprising at least five of the genes listed in Table 1; (ii) a second region that does not overlap with the first region and does not bind to the target molecule; (b) said fourth probes comprising (i) a first region that binds to the second region of said third probe; and (ii) an affinity moiety; wherein the first target-specific sequence and the second target-specific sequence bind to different regions of the of the same target molecule.

[044] The present disclosure also provides a composition pair comprising a first composition and a second composition, wherein the first composition comprises a first probe and a second probe, (a) said first probe comprising (i) a first region comprising a first target-specific sequence capable of independently base-pair hybridizing to any of the genes listed in Table 1; and (ii) a second region that does not overlap with the first region and does not bind to the target molecule; (b) said second probe comprising (i) a first region that binds to the second region of said first probe; and (ii) a second region comprising an at least first label attachment region which is hybridized to a first RNA molecule, wherein the first RNA molecule is attached to one or more label monomers that emit light constituting a first signal; and (iii) an at least second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to a second RNA molecule, wherein the second RNA molecule is attached to one or more label monomers that emit light constituting a second signal; wherein the second

composition comprises a third probe and a fourth probe, (c) said third probe comprising (i) a first region comprising a second target-specific sequence capable of independently base-pair hybridizing to any of the genes listed in Table 1; and (ii) a second region that does not overlap with the first region and does not bind to the target molecule; (d) said fourth probe comprising (i) a first region that binds to the second region of said third probe; and (ii) a second region comprising at least one affinity moiety, wherein the first region does not overlap with the second region; wherein the first target-specific sequence and the second target-specific sequence bind to different regions of the same target molecule, wherein the first and second probes of the first composition cannot bind to the third or fourth probe of the second composition, and wherein when said composition pair is bound to its target molecule, the identity of the first and second signals and their locations relative to each other constitute at least part of a code that identifies the target molecule.

[045] The probes of these compositions can comprise two regions, a first region comprising a target-specific sequence and a second region that does not bind to the target. The first region and the second region do not overlap. The second region contains a tag sequence which can bind or hybridize to a region of a reporter probe or a capture probe. A probe that binds or hybridizes to a reporter probe is referred to herein as a reporter oligo (e.g., Oligo A in Figure 2). A probe that binds or hybridizes to a capture probe is referred to herein as a capture oligo (e.g., Oligo B in Figure 2). These compositions can also be referred to as tag-based nanoreporter system.

Examples of reporter and capture probes related to the tag-based nanoreporter system, as well as, methods of using these probes is described in U. S. Patent Publication No. 2014/0371088; and PCT Publication No. WO 2014/201232.

[046] In preferred aspects, a label attachment region can comprise an artificial nucleic acid sequence. In other preferred aspects, the second region of a first probe, the second region of a second probe, the second region of a third probe, or a second region of a fourth probe can comprise an artificial nucleic acid sequence. An artificial nucleic acid sequence can comprise a non-naturally occurring nucleic acid sequence that has limited to no homology to any sequences found in nature as to avoid off target-binding.

[047] While the compositions of the present invention are capable of detecting, or hybridizing to, any gene within a biomolecular sample, the present disclosure is particularly directed to detecting, or hybridizing to, any of the genes listed in Table 1 A. In some preferred aspects, the present disclosure is particularly directed to detecting, or hybridizing to, any of the genes listed in Table IB.

[048] Table 1A

GENE GENE GENE GENE GENE GENE NAME NAME NAME NAME NAME NAME

ADAM 12 CXCL1 GNLY ILIA PDCD1 TBX21

ANLN CXCL10 GZMA IL1B PDCD1LG2 TIGIT

AQP9 CXCL11 GZMB IL1RN PDGFA TNFAIP6

A REG CXCL13 GZMH ITGAV PDGFB TNFRSF17

ARFRP 1 CXCL2 GZMK ITGB3 PDGFRB TPI1

B2M CXCL3 GZMM ITPK1 PFKFB3 TPM1

CCL20 CXCL5 HEY1 JAG1 PGPEP1 TRAT1

CCL5 CXCL6 HIF1A JAG2 PKM2 TREM1

CCNB 1 CXCL9 HIST1H2BJ KCNQ3 PRF1 TYMP

CCND2 CXCR3 HK2 KIF2C PSMB 10 UBE2C

CCNE1 CXCR4 HLA.DQA1 KLRB 1 PTGS2 VAV2

CD19 CXCR6 HLA.DRB 1 KLRD1 PTK2 VCAN

CD2 DDX17 HLA.E KLRK1 RALGAPA2 VEGFA

CD27 E2F3 HLA-A LAG3 RBM5 VEGFB

CD274 EDN1 HLA-B LCK RDH10 ZAP70

CD276 ENO HLA-C LDHA RNASE2 ZNF75D CD300A ERBB2IP HLA-DMA LIF RNF169

CD3D EXO l HLA-DOA LRRC32 RPL7A

CD3E EZH2 HLA-DPA1 LY9 RRM2

CD3G FAM108A1 HLA-DPB 1 MAGEA1 S100A12

CD40LG FAP HLA-DQB l MAGEA12 S100A8

CD44 FCGR1A HLA-DRA MAGEA3 S100A9

CD48 FCGR2A HLA-DRB 1 MAGEA4 SERPINB5

CD5 FCGR2B HLA-DRB5 MAGEB2 SERPINH1

CD6 FCGR3A ICOS MAGEC1 SESN3

CD79A FCGR3B IDOl MAGEC2 SH2D1A

CD8A FCGRT IER3 MELK SLAMF7

CD8B FGF18 IFI16 MKI67 SLC16A1

CD96 FGFR1 IFI27 MMP9 SLC2A1

CDC20 FHIT IFI35 MS4A1 SLC7A5

CENPF FHL3 IFIH1 MYC SPP1

CEP55 FOSL1 IFIT1 NFIL3 STAT1

CES3 FSTL3 IFIT2 NGFRAP1 STC1

CMKLR1 FUK IFITM1 NKG7 TAP1

COL6A3 FYN IFITM2 NOTCH 1 TAP2

CTSW G0S2 IKZF3 OLFML2B TAPBP 49] Table IB

CXCL10 PDGFA CD48 FYN LDHA SLC16A1

CXCL11 PDGFB CD5 HLA-DQA1 LIF SLC2A1

CXCL13 PDGFRB CD6 HLA-DRB1 LRRC32 SPP1

CXCL2 PFKFB3 CD79A HLA-E LY9 STAT1

CXCL3 PGPEP1 CD 8 A HLA-A MAGEA1 STC1

CXCL5 PRF1 CD8B HLA-B MAGEA12 TAP1

CXCL6 PSMB10 CD96 HLA-C MAGEA4 TAP2

CXCL9 TBX21 CDC20 HLA-DMA MAGEB2 TAPBP

CXCR3 TIGIT CENPF HLA-DOA MAGEC1 VCAN

GNLY TNFAIP6 CEP55 HLA-DPA1 MAGEC2 VEGFA

GZMA TNFRSF17 CES3 HLA-DPB 1 MELK VEGFB

GZMB TPI1 CMKLR1 HLA-DQB 1 MKI67 ZAP70

[050] The first region of a first probe can comprise any one of SEQ ID Nos 1-770 or a complement thereof. The first region of a second probe can comprise any one of SEQ ID Nos 771-1540 or a complement thereof. In some aspects, the first region of a first probe can comprise any one of SEQ ID Nos 1-770 and the first region of a second probe can comprise any one of SEQ ID Nos 771-1540 or a complement thereof.

[051] In some preferred aspects, the first region of a first probe can comprise any one of SEQ ID Nos 1, 2, 5, 6, 13, 14, 15, 16, 24, 28, 30, 31, 34, 36, 38, 41, 46, 54, 70, 78, 81, 83, 95, 96, 108, 1 12, 1 18, 121, 125, 126, 127, 135, 137, 144, 147, 148, 156, 157, 163, 171, 179, 192, 203, 206, 215, 219, 226, 231, 234, 251, 256, 263, 272, 279, 284, 296, 297, 301, 303, 306, 310, 312, 315, 317, 318, 319, 323, 324, 327, 332, 333, 336, 358, 366, 370, 376, 377, 379, 381, 401, 402, 407, 416, 417, 424, 425, 436, 440, 445, 454, 455, 459, 478, 481, 489, 499, 507, 516, 518, 523, 526, 533, 538, 547, 564, 575, 579, 585, 586, 595, 599, 606, 615, 616, 618, 619, 620, 624, 631, 638, 640, 642, 649, 650, 656, 657, 658, 660, 666, 672, 674, 676, 679, 682, 683, 685, 686, 689, 690, 697, 703, 705, 708, 715, 723, 725, 726, 727, 733, 742, 743, 752, 758, 761, 763, 766 or 767 or a complement thereof. In some preferred aspects, the first region of a second probe can comprise any one of SEQ ID Nos 771, 772, 775, 776, 783, 784, 785, 786, 794, 798, 800, 801, 804, 806, 808, 81 1, 816, 824, 840, 848, 851, 853, 865, 866, 878, 882, 888, 891, 895, 896, 897, 905, 907, 914, 917, 918, 926, 927, 933, 941, 949, 962, 973, 976, 985, 989, 996, 1001, 1004, 1021, 1026, 1033, 1042, 1049, 1054, 1066, 1067, 1071, 1073, 1076, 1080, 1082, 1085, 1087, 1088, 1089, 1093, 1094, 1097, 1 102, 1 103, 1 106, 1 128, 1 136, 1 140, 1 146, 1 147, 1 149, 1 151, 1 171, 1 172, 1 177, 1 186, 1 187, 1 194, 1 195, 1206, 1210, 1215, 1224, 1225, 1229, 1248, 1251, 1259, 1269, 1277, 1286, 1288, 1293, 1296, 1303, 1308, 1317, 1334, 1345, 1349, 1355, 1356, 1365, 1369, 1376, 1385, 1386, 1388, 1389, 1390, 1394, 1401, 1408, 1410, 1412, 1419, 1420, 1426, 1427, 1428, 1430, 1436, 1442, 1444, 1446, 1449, 1452, 1453, 1455, 1456, 1459, 1460, 1467, 1473, 1475, 1478, 1485, 1493, 1495, 1496, 1497, 1503, 1512, 1513, 1522, 1528, 1531, 1533, 1536 or 1537 or a complement thereof. In some preferred aspects, the first region of a first probe can comprise any one of SEQ ID Nos 1, 2, 5, 6, 13, 14, 15, 16, 24, 28, 30, 31, 34, 36, 38, 41, 46, 54, 70, 78, 81, 83, 95, 96, 108, 112, 118, 121, 125, 126, 127, 135, 137, 144, 147, 148, 156, 157, 163, 171, 179, 192, 203, 206, 215, 219, 226, 231, 234, 251, 256, 263, 272, 279, 284, 296, 297, 301, 303, 306, 310, 312, 315, 317, 318, 319, 323, 324, 327, 332, 333, 336, 358, 366, 370, 376, 377, 379, 381, 401, 402, 407, 416, 417, 424, 425, 436, 440, 445, 454, 455, 459, 478, 481, 489, 499, 507, 516, 518, 523, 526, 533, 538, 547, 564, 575, 579, 585, 586, 595, 599, 606, 615, 616, 618, 619, 620, 624, 631, 638, 640, 642, 649, 650, 656, 657, 658, 660, 666, 672, 674, 676, 679, 682, 683, 685, 686, 689, 690, 697, 703, 705, 708, 715, 723, 725, 726, 727, 733, 742, 743, 752, 758, 761, 763, 766 or 767 or a complement thereof, and the first region of a second probe can comprise any one of SEQ ID Nos 771, 772, 775, 776, 783, 784, 785, 786, 794, 798, 800, 801, 804, 806, 808, 811, 816, 824, 840, 848, 851, 853, 865, 866, 878, 882, 888, 891, 895, 896, 897, 905, 907, 914, 917, 918, 926, 927, 933, 941, 949, 962, 973, 976, 985, 989, 996, 1001, 1004, 1021, 1026, 1033, 1042, 1049, 1054, 1066, 1067, 1071, 1073, 1076, 1080, 1082, 1085, 1087, 1088, 1089, 1093, 1094, 1097, 1102, 1103, 1106, 1128, 1136, 1140, 1146, 1147, 1149, 1151, 1171, 1172, 1177, 1186, 1187, 1194, 1195, 1206, 1210, 1215, 1224, 1225, 1229, 1248, 1251, 1259, 1269, 1277, 1286, 1288, 1293, 1296, 1303, 1308, 1317, 1334, 1345, 1349, 1355, 1356, 1365, 1369, 1376, 1385, 1386, 1388, 1389, 1390, 1394, 1401, 1408, 1410, 1412, 1419, 1420, 1426, 1427, 1428, 1430, 1436, 1442, 1444, 1446, 1449, 1452, 1453, 1455, 1456, 1459, 1460, 1467, 1473, 1475, 1478, 1485, 1493, 1495, 1496, 1497, 1503, 1512, 1513, 1522, 1528, 1531, 1533, 1536 or 1537 or a complement thereof.

[052] In some preferred aspects, the first region of a first probe can comprise any one of SEQ ID Nos 34, 78, 81, 121, 126, 148, 156, 219, 231, 251, 256, 272, 297, 301, 319, 377, 401, 407, 481, 499, 518, 523, 526, 533, 564, 585, 619, 640, 650, 657, 660, 686, 703, 705, or 742 or a complement thereof. In some preferred aspects, the first region of a second probe can comprise any one of SEQ ID Nos 804, 848, 851, 891, 896, 918, 926, 989, 1001, 1021, 1026, 1042, 1067, 1071, 1089, 1147, 1171, 1177, 1251, 1269, 1288, 1293, 1296, 1303, 1334, 1355, 1389, 1410, 1420, 1427, 1430, 1456, 1473, 1475 or 1512 or a complement thereof.

[053] In some preferred aspects, the first region of a first probe can comprise any one of SEQ ID Nos 34, 78, 81, 121, 126, 148, 156, 219, 231, 251, 256, 272, 297, 301, 319, 377, 401, 407, 481, 499, 518, 523, 526, 533, 564, 585, 619, 640, 650, 657, 660, 686, 703, 705, or 742 or a complement thereof and the first region of a second probe can comprise any one of SEQ ID Nos 804, 848, 851, 891, 896, 918, 926, 989, 1001, 1021, 1026, 1042, 1067, 1071, 1089, 1147, 1171, 1177, 1251, 1269, 1288, 1293, 1296, 1303, 1334, 1355, 1389, 1410, 1420, 1427, 1430, 1456, 1473, 1475 or 1512 or a complement thereof.

[054] The first region of a first probe can comprise any one of SEQ ID Nos 1-770 or a complement thereof. The first region of a third probe can comprise any one of SEQ ID Nos 771- 1540 or a complement thereof. In some aspects, the first region of a first probe can comprise any one of SEQ ID Nos 1-770 and the first region of a third probe can comprise any one of SEQ ID Nos 771-1540 or a complement thereof.

[055] In some preferred aspects, the first region of a first probe can comprise any one of SEQ ID Nos 1, 2, 5, 6, 13, 14, 15, 16, 24, 28, 30, 31, 34, 36, 38, 41, 46, 54, 70, 78, 81, 83, 95, 96, 108, 112, 118, 121, 125, 126, 127, 135, 137, 144, 147, 148, 156, 157, 163, 171, 179, 192, 203, 206, 215, 219, 226, 231, 234, 251, 256, 263, 272, 279, 284, 296, 297, 301, 303, 306, 310, 312, 315, 317, 318, 319, 323, 324, 327, 332, 333, 336, 358, 366, 370, 376, 377, 379, 381, 401, 402, 407, 416, 417, 424, 425, 436, 440, 445, 454, 455, 459, 478, 481, 489, 499, 507, 516, 518, 523, 526, 533, 538, 547, 564, 575, 579, 585, 586, 595, 599, 606, 615, 616, 618, 619, 620, 624, 631, 638, 640, 642, 649, 650, 656, 657, 658, 660, 666, 672, 674, 676, 679, 682, 683, 685, 686, 689, 690, 697, 703, 705, 708, 715, 723, 725, 726, 727, 733, 742, 743, 752, 758, 761, 763, 766 or 767 or a complement thereof. In some preferred aspects, the first region of a third probe can comprise any one of SEQ ID Nos , 771, 772, 775, 776, 783, 784, 785, 786, 794, 798, 800, 801, 804, 806, 808, 811, 816, 824, 840, 848, 851, 853, 865, 866, 878, 882, 888, 891, 895, 896, 897, 905, 907, 914, 917, 918, 926, 927, 933, 941, 949, 962, 973, 976, 985, 989, 996, 1001, 1004, 1021, 1026, 1033, 1042, 1049, 1054, 1066, 1067, 1071, 1073, 1076, 1080, 1082, 1085, 1087, 1088, 1089, 1093, 1094, 1097, 1102, 1103, 1106, 1128, 1136, 1140, 1146, 1147, 1149, 1151, 1171, 1172, 1177, 1186, 1187, 1194, 1195, 1206, 1210, 1215, 1224, 1225, 1229, 1248, 1251, 1259, 1269, 1277, 1286, 1288, 1293, 1296, 1303, 1308, 1317, 1334, 1345, 1349, 1355, 1356, 1365, 1369, 1376, 1385, 1386, 1388, 1389, 1390, 1394, 1401, 1408, 1410, 1412, 1419, 1420, 1426, 1427, 1428, 1430, 1436, 1442, 1444, 1446, 1449, 1452, 1453, 1455, 1456, 1459, 1460, 1467, 1473, 1475, 1478, 1485, 1493, 1495, 1496, 1497, 1503, 1512, 1513, 1522, 1528, 1531, 1533, 1536 or 1537 or a complement thereof. In some preferred aspects, the first region of a first probe can comprise any one of SEQ ID Nos 1, 2, 5, 6, 13, 14, 15, 16, 24, 28, 30, 31, 34, 36, 38, 41, 46, 54, 70, 78, 81, 83, 95, 96, 108, 112, 118, 121, 125, 126, 127, 135, 137, 144, 147, 148, 156, 157, 163, 171, 179, 192, 203, 206, 215, 219, 226, 231, 234, 251, 256, 263, 272, 279, 284, 296, 297, 301, 303, 306, 310, 312, 315, 317, 318, 319, 323, 324, 327, 332, 333, 336, 358, 366, 370, 376, 377, 379, 381, 401, 402, 407, 416, 417, 424, 425, 436, 440, 445, 454, 455, 459, 478, 481, 489, 499, 507, 516, 518, 523, 526, 533, 538, 547, 564, 575, 579, 585, 586, 595, 599, 606, 615, 616, 618, 619, 620, 624, 631, 638, 640, 642, 649, 650, 656, 657, 658, 660, 666, 672, 674, 676, 679, 682, 683, 685, 686, 689, 690, 697, 703, 705, 708, 715, 723, 725, 726, 727, 733, 742, 743, 752, 758, 761, 763, 766 or 767 or a complement thereof, and the first region of a third probe can comprise any one of SEQ ID Nos , 771, 772, 775, 776, 783, 784, 785, 786, 794, 798, 800, 801, 804, 806, 808, 811, 816, 824, 840, 848, 851, 853, 865, 866, 878, 882, 888, 891, 895, 896, 897, 905, 907, 914, 917, 918, 926, 927, 933, 941, 949, 962, 973, 976, 985, 989, 996, 1001, 1004, 1021, 1026, 1033, 1042, 1049, 1054, 1066, 1067, 1071, 1073, 1076, 1080, 1082, 1085, 1087, 1088, 1089, 1093, 1094, 1097, 1102, 1103, 1106, 1128, 1136, 1140, 1146, 1147, 1149, 1151, 1171, 1172, 1177, 1186, 1187, 1194, 1195, 1206, 1210, 1215, 1224, 1225, 1229, 1248, 1251, 1259, 1269, 1277, 1286, 1288, 1293, 1296, 1303, 1308, 1317, 1334, 1345, 1349, 1355, 1356, 1365, 1369, 1376, 1385, 1386, 1388, 1389, 1390, 1394, 1401, 1408, 1410, 1412, 1419, 1420, 1426, 1427, 1428, 1430, 1436, 1442, 1444, 1446, 1449, 1452, 1453, 1455, 1456, 1459, 1460, 1467, 1473, 1475, 1478, 1485, 1493, 1495, 1496, 1497, 1503, 1512, 1513, 1522, 1528, 1531, 1533, 1536 or 1537 or a complement thereof.

[056] In some preferred aspects, the first region of a first probe can comprise any one of SEQ ID Nos 34, 78, 81, 121, 126, 148, 156, 219, 231, 251, 256, 272, 297, 301, 319, 377, 401, 407, 481, 499, 518, 523, 526, 533, 564, 585, 619, 640, 650, 657, 660, 686, 703, 705, or 742 or a complement thereof. In some preferred aspects, the first region of a third probe can comprise any one of SEQ ID Nos 804, 848, 851, 891, 896, 918, 926, 989, 1001, 1021, 1026, 1042, 1067, 1071, 1089, 1147, 1171, 1177, 1251, 1269, 1288, 1293, 1296, 1303, 1334, 1355, 1389, 1410, 1420, 1427, 1430, 1456, 1473, 1475 or 1512 or a complement thereof.

[057] In some preferred aspects, the first region of a first probe can comprise any one of SEQ ID Nos 34, 78, 81, 121, 126, 148, 156, 219, 231, 251, 256, 272, 297, 301, 319, 377, 401, 407, 481, 499, 518, 523, 526, 533, 564, 585, 619, 640, 650, 657, 660, 686, 703, 705, or 742 or a complement thereof and the first region of a third probe can comprise any one of SEQ ID Nos 804, 848, 851, 891, 896, 918, 926, 989, 1001, 1021, 1026, 1042, 1067, 1071, 1089, 1147, 1171, 1177, 1251, 1269, 1288, 1293, 1296, 1303, 1334, 1355, 1389, 1410, 1420, 1427, 1430, 1456, 1473, 1475 or 1512 or a complement thereof.

[058] Exemplary reporter probe and capture probe sequences are shown in Tables 2A and 2B, respectively.

[059] Table 2A

SEQ ID NO: Probe ID Reporter Probe Sequence

20 NM 000122.1:1 GCAACCATCCCTTTTTTAGCTCGAAGCACCCGCCCTAGCCTTTG

950 GGCTTC

21 NM 000129.3:3 AATCAGTGGCTGCAGTCCTTCTATATATCTGGTCACTAGATCCG

196 C

22 NM 000135.2:7 GTACTCCAGCAGCCAAAGCGTCAAGTGCAAAAATCAGCATTCTC

98 TGCAGT

23 NM 000139.3 : 6 TCATAAACACGATCCTCTGGAACCTTGTTTCCTTTGAGTTCTTC

61 CCCAGC

24 NM 000163.2:1 TCTGTGCTCACATAGCCACATGATGAGAGAAACTCTTTGTCAGG

835 CAAGGG

25 NM 000167.5:2 AAGTGTTTGAGTATGTTCGATGGAAGATTCCAATGGTAAGGATC

012 CGAATT

26 NM 000168.5:9 AGAGCTGCTACGGGAATTATTGAGAATCGTGACCAAGGAGTTGG

75 GAGACG

27 NM 000179.1 : 3 AGGCACCAAGTCTAGTAAACACTCTATCAATTGGTGTGAGCCTG

525 CACACT

28 NM 000188.2:3 AGACAAACAGAATGCAAGACTGTCACACGCGGCTAGGACTGGTT

355 CCACGG

29 NM 000189.4:6 TTTGAGATGATTCGCTATTCATCACACCCCGAAGATTGAGATCC

880 ACTGTA

30 NM 000201.2:2 CTTTGTGTTTTGATGCTACACATGTCTATGGAGGGCCACTTCTT

253 CTG

31 NM 000206.1:5 AAAGCGGCTCCGAACACGAAACGTGTAGCGTTTCTGCCCATCCA

95 CACTAG

32 NM 000210.1 : 3 CAGTCTTTGAGGGAAACACAGTCACTCGAACCTGAGTGCCTGCA

065 TTTGGC

33 NM 000211.2:5 CGGAGCAGGTCGCCACCTAGCTTCTTGACATTCCTGA

20

34 NM 000212.2:4 ATTTATCCCTCTACCATACTGCCATTCCCTACAGTAAGGAGTAA

485 TCCATG

35 NM 000214.2:5 TGAGAACTCCAGATGAGTTTTGTGGTTGAAAAGCCTTTCAGTTC

766 TTCCTC

36 NM 000215.2:1 CGGTACGACACTTGGCTCATCAAGCTCGCTGCTTCCAGG

715

37 NM 000222.2:2 CCTTCCTTGATCATCTTGTAGAACTTAGAATCGACCGGCATTCC

644 AGGATA

38 NM 000228.2:3 CCAGCATGGAACTCTGACCCAACCGGTCCTTCAACTCAG

350

39 NM 000235.3:1 CAGTCGGCACAAGCATGTCCTTCACATTGTATGTGGGAGGATAA

220 CT

40 NM 000239.2:3 ACCCTCTTTGCACAAGCTACAGCATCAGCGATGTTATCTTGCAG

05 CAAAGC

41 NM 000249.2 : 1 GGTATAACTTGGTTTGATGCTGTGCCAAGGCCCACTGAGGATTC

605 ACACAG

42 NM 000251.1:2 CTACTCGGGCTAAGATGCAGTCCACAATGGACACTTCTGCTGAC

105 TCACAT

43 NM 000264.3:5 GCATGTCACCGAATTCTCTAACACCCACCATGATGAACTGATGT

420 GAGCTC

44 NM 000289.5:2 TATTGGCAAAGATCCGCCCATTACGGTAACTCTCTTTGATTTTC

195 CCAGAC

45 NM 000295.4:7 AGCTCCTTGACCAAATCCACAATTTTCCCTTGAGTACCCTTCTC

60 CACGTA

46 NM 000300.2:7 TGAGGGATGCTTTCTGCATGGCCAAGGAACTTGGTTAGGGTAGG

15 GAGG SEQ ID NO: Probe ID Reporter Probe Sequence

47 NM 000314.4:4 GAGCTACAAAGGACTTGGGATGGTACAGGGCCCAACTGTAAGCT

830 TTCTTA

48 NM 000321.1:2 TCATTCTGCAGGGTGTGCTGGAAAAGGGTCCAGATGATATGTTC

110 TAATTC

49 NM 000325.5:1 TATAAACATACGGAGGAGTCGGCGGCGCGTAAGGACAGGCAGGC

381 GTCG

50 NM 000361.2:1 CGCAGACGCAGAGGTAGCTAGTTTGGTTCAGGGGC

246

51 NM 000362.4:1 ATGCAGGCGTAGTGTTTGGACTGGTAGCCAGGGTAACCGAAATT

640 GGAGAG

52 NM 000365.4:1 CTTGGCCTCACGGTGTAAGAAGGGAGAGGATGGTTTCTCTTCTG

020 CCCTCA

53 NM 000366.5:8 CAATTTAGTTACTGACCTCTCCGCAAACTCAGCCCGAGTCTCAG

42 CC

54 NM 000389.2 : 1 AGGAGCTGTGAAAGACACAGAACAGTACAGGGTGTGGTCCCTG

975

55 NM 000395.2:3 ATGAGAATCATGTCATGTGCATCAGCGACTGCCGGGGACAGG

300

56 NM 000397.3:2 TCTGCATTTATTTTATAGCACAAGGAGCAGGACTAGATGAGCCA

686 GAGTCA

57 NM 000402.2:1 TGCATCACGTCCCGGATGATCCCAAATTCATCGAAATAGCCCCC

155 GCGACC

58 NM 000417.1:1 GCAGGCAAGCACAACGGATGTCTCCTGGGCGACCATTTAGCACC

000 TTTGAT

59 NM 000435.2:1 GGAAGCACACTCATTGATCTCCACGTTACAAAGGGGCCCTGTGA

965 AGCCAG

60 NM 000442.3:1 GGGCATCATAAGAAATCCTGGGCTGGGAGAGCATTTCACATACG

365 ACTATC

61 NM 000450.2 : 1 TCCATTGTCCCTGAGATGTGCACTCAAGTTGAGTTGATCCATGT

505 AA

62 NM 000474.3:1 CAAACAACTGTTCAGACTTCTATCAGAATGCAGAGGTGTGAGGA

151 TGGTGC

63 NM 000491.3 : 8 GATGTGAAGCAGCCCACAGGTCAGGCCTCCATATCTGGAAAGAG

19 C

64 NM 000493.3:1 TGTAGGGAATGAAGAACTGTGTCTTGGTGTTGGGTAGTGGGCCT

35 TTTATG

65 NM 000494.3:5 TCTTAGCCAACTGACTAGAGAATGCAGAATGAACAGGGGAGGAA

070 GGAGCT

66 NM 000507.3:5 GGATCAAAACAGACCACATATTTACCCCTTTTCTCCGGTTCCAC

90 TATGAT

67 NM 000537.3:3 GCTGGAGGAATCCGAAGCATCGAAGAGCTTGTGATACACACAGG

55 CAGTGT

68 NM 000544.3:9 GAAAGGAGGGTGAGTCGAGGCGATATGCTGAGCATGAAGCCATA

09 CAGCCC

69 NM 000545.4:2 CCCTTCAGTTCCAAGTAAGAAGACTGTATCCCACGAAGCAGCGA

125 CAGTCC

70 NM 000546.2:1 GTCTGAGTCAGGCCCTTCTGTCTTGAACATGAGTTTTTTATGGC

330 GGGAGG

71 NM 000551.2:1 CTCTGACAAACCCTGACTGAAGGCTCATGATGTGCAGGCACTGG

280 GGT

72 NM 000565.2:9 GGCGGATCAGGCTGCAAGATTCCACAACCCTGAAAGGTTTGAGT

93 TTTGCT

73 NM 000566.3:1 CTCAGTCTCACAGTCCCTTAGGAGTCATTTGTAAGTACTATTTC

545 CTTCCT SEQ ID NO: Probe ID Reporter Probe Sequence

74 NM 000569.6:1 TACTCCTAGCATTAAGAGGACTCATCGTTATATACTTGGAGATG

644 GTCCAG

75 NM 000572.2:2 GGTAAAACTGGATCATCTCAGACAAGGCTTGGCAACCCAGGTAA

30 CCCTTA

76 NM 000575.3:1 TGCTACTACCACCATGCTCTCCTTGAAGGTAAGCTTGGATGTTT

085 TAGAGG

77 NM 000576.2:8 TTGAGTCCACATTCAGCACAGGACTCTCTGGGTACAGCTCTCTT

40 TAGGAA

78 NM 000577.3:4 CTTCGTCAGGCATATTGGTGAGGCTGACGGGCTGG

80

79 NM 000578.2:1 GTTAAAGTGCTTAACCTCCATGGCAAGGGTGGTGGCGTCTCCAT

965 TTTACA

80 NM 000579.1:2 CCTGTGGTTGCCTCATAGAATCCTCCCAACAACCCATGAAATGA

730 CTACTA

81 NM 000582.2:7 TTGTGGCTGTGGGTTTCAGCACTCTGGTCATCCAG

60

82 NM 000584.2:2 AGCCACGGCCAGCTTGGAAGTCATGTTTACACACAGTGAGATGG

5 TTCCTT

83 NM 000586.2:3 GCTCCAGTTGTAGCTGTGTTTTCTTTGTAGAACTTGAAGTAGGT

00 GCACTG

84 NM 000587.2:3 TTGCTGATGCACTGACCTGAAAAGCACCTGAAACGCTCTCCACA

10 TCCCTC

85 NM 000589.2 : 6 CCAGAGGTTCCTGTCGAGCCGTTTCAGGAATCGGATCAGC

25

86 NM 000591.2 : 8 CAGGATTGTCAGACAGGTCTAGGCTGGTAAGGGCC

85

87 NM 000593.5:2 CTGTGATTTCCTCCATAGTTGGCTTCTGGGTCAGGCCATAGGCA

075 ATATTT

88 NM 000594.2:1 TTCTGGAGGCCCCAGTTTGAATTCTTAGTGGTTGCCAGCACTTC

010 ACTGTG

89 NM 000600.1:2 TGCCAGTGCCTCTTTGCTGCTTTCACACATGTTACTCTTGTTAC

20 ATGTCT

90 NM 000601.4 : 5 AAGCTGTGTTCGTGTGGTATCATGGAACTCCAGGGCTGACATTT

50 GATGCC

91 NM 000609.5:2 TCAATGCACACTTGTCTGTTGTTGTTCTTCAGCCGGGCTACAAT

10 CTGAAG

92 NM 000615.5:1 AGAGGGGGTGTTGTAGATCTTGATATTGCTGTAATTGGAGCTTG

620 GCAGCA

93 NM 000616.4 : 9 TTAGGGTCCTGGGTAACCCGTTTTACAGACACTTCCTTGTTCTT

75 C

94 NM 000619.2 : 9 ATCAGGGTCACCTGACACATTCAAGTTCTGTCTGACATGCCATT

70 AAAGCA

95 NM 000625.4:1 CTGCCATCTGGCATCTGGTAGCCAGCATAGCGGATG

005

96 NM 000627.3:1 CACAGACGTCCGGCCTCAGGCATTCGTCAACATCTATGCAGTTA

970 G

97 NM 000632.3:5 CAAACTCCTTCATCCGCCGAAAGTCATGTGGGATGATGCTACCA

15 GAGCCA

98 NM 000638.3 : 1 CTGAAGTCTCCGCTCTGATGCCTGAGGAAGGGAGGGAGAGG

2

99 NM 000639.1 : 6 AGTACAGCCCAGTTTCATTGATCACAAGGCCACCCTTCTTATAC

25 TTCACT

100 NM 000641.2 : 1 TTACCCAAGCATCCAGCCCCAGCTCTCAGACAAATC

145 SEQ ID NO: Probe ID Reporter Probe Sequence

101 NM 000657.2:9 TACTCAGTCATCCACAGGGCGATGTTGTCCACCAG

47

102 NM 000660.3:1 CACTTTTAACTTGAGCCTCAGCAGACGCAGCTCTGCCCGGGAGA

260 GCAAC

103 NM 000675.3:1 CTGCGAATGATCTTGCGGAAGGTCTGGCGGAACTCGCGGATACG

095 GTAGGC

104 NM 000700.1 : 5 GCAAAGCGTTCCGAAAATCTCCAGATGTGTCTGAGGTTATGTCT

15 TTGGCC

105 NM 000732.4:1 TCACTTGCGAGAGAAGGGTAGCCAGTACCAGGCCA

10

106 NM 000733.2:7 CATTACCATCTTGCCCCCAAACGCCAACTGATAAGAGGCAGAGG

5 CCCAGA

107 NM 000757.4:8 GTTCTTGCTGAAAATATTCCAGTCCTTGTCAAGGAGATTCTTTG

23 TTTCAT

108 NM 000873.3:4 AGGTGAAGTGGCATTGGAGGACCGTGTCATGGGAGATGTTTGAG

15 ACCAAG

109 NM 000875.2:4 CACAATGTAGTTATTGGACACCGCATCCAGGATCAGGGACCAGT

55 CCACAG

110 NM 000876.1:2 GCCATTCCCAAGTTACTGATGGAAACCACTTCAGTGAAGGAGCC

605 CTGATC

111 NM 000877.2:4 TCTTCCTCCACCCACGCTTATCCATTGATTCTTGTCCCTCCTTA

295 AATTCC

112 NM 000878.2:1 GCTTCTGAGCCTAAATTCGTGGGATCCTGTGATTAACGAGGGAG

980 TTGGGG

113 NM 000885.4:9 CTGTTCGCACGTCTGGCCGGGATTCTTTCCGATCCTGCATCTGT

75 AAA

114 NM 000887.3:7 CATATGAGGCATGGAACAATCGGTGCACGACATTTTGGATGGCG

00 GTGGCC

115 NM 000902.2:5 CCAAAGGAATATTGCAAATACCCAAGGTCACCCTGTCAGGAGTG

059 GCAGAA

116 NM 000920.3:2 CAGCATGTTGGGCAAGTAGTTGAGGGAGTCAAACACACGGAAGA

055 CATCCA

117 NM 000922.3:1 ATCAGGAAATTCTATGGGTGATCGATTAGTTAGAGAGCCAGTAG

870 ACACTG

118 NM 000937.2:3 CAGACGGCACAGAATATCCTTGGCTCTCTCAGCATCTCGAGCGG

775

119 NM 000944.4:3 AGGAAGCCAGAAGATGGCATCTGCTCTTTAAACAGGCTTCTCTT

920 ATCTGA

120 NM 000958.2:9 CTACCGAGACCCATGTTGGGCAGCGCGCAAAAGAGCACGTTGGA

76 C

121 NM 000963.1:4 TTACCTTTGACACCCAAGGGAGTCGGGCAATCATCAGGCACAGG

95 AGGAAG

122 NM 000972.2:6 GGATGTCCTGTCCAATGCCAAAATTCTTAGGCCTTTTCTCAAAC

6 AGGGGA

123 NM 001001392. CCTGCAAAGCGGCAGGTTATATTCAAATCGATCTGCGCCAGGCT

1: 429 CAGCGG

124 NM 001001523. GAGTCTTGCAGAGATGATGATGAAAGGCCAGCTCCAGATTGTAC

1: 1350 TGCAGC

125 NM 001001548. CTGTTCCAACTGATAGTGAAGGTTCGAAGATGGCACCATTGGGC

2:705 TGCAGG

126 NM 001002273. TAAATACGGTTCTGGTCATCAGGCTCTTCCAGAGCATCCGGGTG

1:870

127 NM 001005291. CGACACCAGATCCTTCAGAGATTTGCTTTTGTGGACAGCAGTGC

1: 1392 GCAG SEQ ID NO: Probe ID Reporter Probe Sequence

128 NM 001005731. CGTAGAACGTCATCGCTGTACATAAGGAAGCTGTCGTAGTCCTC

1: 4151 CCCGCT

129 NM 001012662. CCGGCAAGAAGGAAGTCAGGAGCCTTGCCTGAGACAAACTCCAG

2: 1505 C

130 NM 001014432. TGTGCCGCAAAAGGTCTTCATGGTGGCACCGTCCT

1: 1275

131 NM 001024736. ATATTGCATCTTTTGGAGAAAAAAGGCAGCCAGATGGTCCACGC

1:2120 AGCACT

132 NM 001024847. TTTACTTCTCCCACTGCATTACAGCGAGATGTCATTTCCCAGAG

1: 1760 CACCAG

133 NM 001025159. TTGGTTTGTCTTGTCCAAGGGTGACGAAAGAGCCAGGCACCAGG

1: 964 GTC

134 NM 001025366. TCTGCATTCACATTTGTTGTGCTGTAGGAAGCTCATCTCTCCTA

1: 1325 TGTGC

135 NM 001031683. TCTTTATTCATCTTCTGCAGTTTCAGGCCCAAGAGAACCTTGAC

3: 712 GTATTG

136 NM 001031709. TATCAATGGAGACGAAGCGTATGCAGGGATTACTGGTGATGTAC

1: 605 TGCCCA

137 NM 001032409. GCTGGTAGTTTATGACTAATTCCAAGACCGTCCGAAATCCCTGG

1: 805 GCTGTG

138 NM 001033044. GCCTGCTTTAGTGACATGCTATTCCTACCAGAAAATAACCCCAA

2:2645 TACCCC

139 NM 001033667. GGTAGCTTTTGACCATAATGGTTACATTTTCTTTGGGACGTGCG

1:260 AAAGCA

140 NM 001034.1:1 AAATCTGCGTTGAAGCAGTGAGGCTGCATCTTTTAACTGGCTGT

615 GCTGGT

141 NM 001039664. GCAGCCTCTGCAACAAAACAGACCAATCTTCTTGTGGAAGTCAC

1: 151 C

142 NM 001040168. CGGCTGATGCAGAAGCCAGCGCCGCCCGTGGCAAACCA

1: 717

143 NM 001050.2:1 AAGATGAAGACAGCCACCACGATGGACACCATTCGGGTGACCTT

060 CTTCTC

144 NM 001065.2:5 TGACCCATTTCCTTTCGGCATTTGGAGCAGCTGAGGCAGTGTCT

15 GAGG

145 NM 001066.2:8 GACACAGTTCACCACTCCTATTATTAGTAGACCCAAGGCTGTCA

35 CACCCA

146 NM 001071.1:5 GATTCCAAGCGCACATGATGATTCTTCTGTCGTCAGGGTTGGTT

55 TTGATG

147 NM 001078.3 : 2 TACTGTTCTTCAGGCAGCAAGTTTTACTTTGACTTCTTGCTCAC

535 AGCAAG

148 NM 001079.3 : 1 CTGGCGCACTGAGCCAAAGTTGCCGCAGCCAAGTTCAATGTCAG

175

149 NM 001079821. CTCGAAAGGTACTCCAGTAAACCCATCCACTCCTCTTCAATGCT

2:415 GTCTTC

150 NM 001090.2:8 GTCTGCATTGACGAACAGCTCCTTGCCATGAGCGGAGATGCTGA

50 ACTTCT

151 NM 001098175. TCTAAACCATTTTTAAAGGATGCGTGTGAGCTGGCATAACCTAC

1:8830 CTACTC

152 NM 001098210. GCGCTGGGTATCCTGATGTGCACGAACAAGCAACTGAACTAGTC

1: 1815 GTGGAA

153 NM 001098479. GTAGGTCCTGAACTCCTCTGCATATTCCTCTGCCTCATA

1: 575

154 NM 001099692. CAATAGCCATAGACAGGAAGGTATGCTATCTGTCAGAGTCCCCA

1:2600 T SEQ ID NO: Probe ID Reporter Probe Sequence

155 NM 001100812. TGGTAGGAAGTAAATGCTTCTGGTGGGCCACAATCCCCGAGTAA

1:850 GCA

156 NM 001113755. CAGCACTTGCATCTGCTCTGGGCTCTGGATGACATTG

2: 645

157 NM 001114614. CAGCTCCGGGACCCAATGCTGCAAACCCAAGAAGGTCACACGCA

1: 328 CAGACG

158 NM 001114937. CCGGAAATATCTTTTATGTACCCCAGGTGCTGTCTCAGCACTCC

2:495 AAGAAC

159 NM 001123041. ACAGCCCTGTGAATAATTTGCACATTGCATTCCCAAAGACCCAC

2:743 TCATTT

160 NM 001127500. GTCAAGGTGCAGCTCTCATTTCCAAGGAGAACTCTAGTTTTCTT

1: 1925 TAAATC

161 NM 001128128. ACACCAAACCAACTGTTGGCAGAACAACAGCTTGCACCATGCCC

1: 1450 TGAGGA

162 NM 001130852. TGGCTGAAAGAGCCTGGTGAAGACGTCGAACTCGAAGATGGACA

1: 623 CGTGCC

163 NM 001134836. CAGACAGGTATTGCCTGTTGGGTTTCCTCTGAAACTTTACACAG

1: 600 TAATAG

164 NM 001142593. TCAGGACCGATGACGACTCCGGCTTTGACACGTTGTGGCTGTTG

1: 805 AA

165 NM 001142633. TTCCAAAAGGAGATCAAGAGAGAATCTGTGCCGGGTTCTGAGAG

1: 3335 TAGACA

166 NM 001143836. ATGAGTTGTTCTGGTTACTCAGTTTATGAAGAGTCTTGGATAGT

2: 1795 GAATTG

167 NM 001145144. CTCATTGAAGGAGTTGAAGAAGCGGATAAGCAGCTCCCCTTCAG

1:180 GC

168 NM 001145646. AACCAGAAGAAAGCTCCGGCGATGAGGAAGATGATACGCAACGG

1: 102 CTCGGT

169 NM 001145648. TCTTTTCCAGTTTCATCCATCCTTGTCCGAAGAACTCCTCATAA

1: 3444 GGAATC

170 NM 001146.3:2 CGAGCCACGTGAGCACTGTCACCCCAAGTAGAGACTCTTGTGAA

080 CTCAAA

171 NM 001147.2:1 TGGGCTTAAGTCTTTGAAAATAGTTCGAGACAGTTCCTCAGGTG

775 GACTGG

172 NM 001159488. AATCTGCCTGTTCAGTGACTGCATCAAAGATGACCAGCAATGAC

1: 14 CACAGC

173 NM 001163771. ACAATGGCCAGCTCCTGGACATCACCCTCAAAGACTTCTTCATC

1: 760 CAGAAT

174 NM 001164239. TCATAGCACCACTGGGAAGAGTAACCACTCTCAGCCCACTGTGT

1:2490 GTAAAC

175 NM 001164759. CGGGAGCTGTGCTCAGACGGTGAGGGAGATGAAGCTGTTG

1: 1112

176 NM 001165414. GCACAAGACATGATATTGGATTTATACACTGGATCCCAGGATGT

1: 1690 GACTCA

177 NM 001171653. ACTGTACAAAAACCTCGCCAAGAGTGTCGGGAGGCAGGACCGTT

1:240 ATTCCT

178 NM 001172.3:1 TCATCTATCCCCTCAATGCCTCATAATTCTGGAATGCCTGTTGT

150 GAAACA

179 NM 001172085. TCCTCATGATTACCGCAGCAAACCGCTTGGGATTATATTCGGCG

1:587 TTTCGG

180 NM 001172698. GCCAGACGGTAGGGTTTGCTGACATCACAGAGCAC

1: 974

181 NM 001174097. AAGACATTAACATTTCTCTGCACCAGATTGAGCCGACTCTCCCC

1:586 TTCTTG SEQ ID NO: Probe ID Reporter Probe Sequence

182 NM 001178091. ATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCAC

1: 946 TTGAAA

183 NM 001184879. CAGGCAAAGGAGCAAGATCCATAGGTGGTGCTGAGCCATC

1:28

184 NM 001185177. AGACAGGGCTTCCAGAATCTCGAAGGTATCTTGAAAAACTGACG

1: 1288 GTGGGA

185 NM 001190709. CACCTTTTAGACCCATGTCACCTTTGAATCCTGGAAAACCATCT

1:2490 TCACCC

186 NM 001190848. TGCCTTAAGTGTTCTGCCATCTACTACCACATTGTTGACACACT

1: 795 GTATGG

187 NM 001191.2:2 AATAGGGATGGGCTCAACCAGTCCATTGTCCAAAACACCTGCTC

60 ACTCAC

188 NM 001192.2 : 6 TCAAAGCAGCTGGCAGGCTCTTGCAATAGTCATTCGTTTTCGTG

35 GTGACA

189 NM 001193300. GGAGCCTCTCAAAGAAGTCAAACTCGCTGGCTGTCTCCTCGAAG

1: 935 AAGAAG

190 NM 001196.2:1 CTCCAGTGGCCTCATGTTGTGGTCACAGGAGTTTC

875

191 NM 001199140. AAAGCAAGAGGAACCCAAGCATTTCCATTGCTGGACTTGTGTGG

1: 3564 GAGCAT

192 NM 001199723. TAGGACTGCTGACTTGGGGAGGCGGGGAGTGAACCCGG

1: 802

193 NM 001200.2 : 1 TGGAGAGGATGCCCTTTTCCATCATGGCCAAAAGTTACTAGCAA

515 TGGCCT

194 NM 001202.3:6 GCGCTCAGGATACTCAAGACCAGTGCTGTGGATCTGC

59

195 NM 001203.1:4 AGTGTCCCGACACTGAAAATCTGAGCCTTCTAGTCCTAGGCAAC

30 C

196 NM 001204318. CCCAGCAAAATGGATCTCCCACTCAGCTGCTTTCTCGGGTTTTA

1: 563 ATCGAA

197 NM 001220.3:3 CTCCTCGGAGATGCTGTCGTGGAGACGCACGATGTTGG

65

198 NM 001220488. CATTTTGTCCGACTAGAAGCGCCCGGCGGCGTTTTCATTCAT

1:210

199 NM 001235.2:8 TAGTAGTTGTAGAGGCCTGTCCGGTGCATCATCATG

80

200 NM 001238.1 : 1 CCCTCCACAGCTTCAAGCTTTTGTTGTTGTGGGAGTCCCTTAGG

635 TC

201 NM 001242.4:3 AGAAGGAGACCCCCGGTATGCAAGGATCACACTGAGCAGCCTTT

30 C

202 NM 001243078. CAGGCCTTACCCAGTCCCTTAAGAACTCTGATGCTCTCTTCAAA

1:2065 AGACAC

203 NM 001243266. TATCGAAGTTGGATACTGGTAATTTCTCATGTGAGGCTCTTGTG

1: 692 TCACAG

204 NM 001244.3:5 TTTAGATGCTTTGCCACTTGGAGGTAGGCCCATGACTTCTTGAA

18 TGGAGC

205 NM 001250.4:1 TATTTAGCCAGTCTCCTGCTGATGGACAGTTAAGCAGCTTCCAG

265 TTGTTC

206 NM 001251.2:1 GATGGGCGTCTCCGGATGATGCAGAAAGCAATAAGCACCAGGGC

140 GAG

207 NM 001252.2:1 TGTGCGAAGCGCTGGATGCACACCACGAGGCAGATCAC

90

208 NM 001255.2:4 ACCCTCTGGCGCATTTTGTGGTTTTCCACTGAGCCGAAGGATCT

30 TGGCTT SEQ ID NO: Probe ID Reporter Probe Sequence

209 NM 001256600. CAGAGAGGTGGGCAGAAGAGAGCCCCTGGGTCAAGAGAAAACTG

1:2508 TG

210 NM 001256741. ATTTGAAGAGATCCCTAAGGAGACATCAGTGACATTCTCCGGGT

1: 1962 TCAAGT

211 NM 001256841. TGGGTGGCACCCACTGCAAACAGGGTAGTGGATGATACAGGTGG

1: 370 AAATGC

212 NM 001259.6:2 GGATACTTTGCCAACAAGGCAGTGTGTGGCAGAAAGTACAGTGT

404 AATAGA

213 NM 001267.2:8 GTAGCTGGTTCAAGCGGTTGTTCTCCAAATGGACGTGTTTCAG

10

214 NM 001278.3 : 8 ACAAAACATCTTGGCTGCTTCAAAGTAAGGTCAACAGGTCCTCC

60 TCTCTG

215 NM 001278405. TAATACTGACAGCCATATCGCCCTGTGTGTTCCCAGG

1:256

216 NM 001284244. CGCTGGCTGGACTGCATGCTCAGGACCAAGTATTGCCTCATAAA

1:416 CT

217 NM 001287582. AGAGTTGGCTGGCTTGTGAGAAGACATGAGGAGTTGGGAAAAGG

1: 1944 AATGCC

218 NM 001289.4 : 5 TGCTTTAAGAAGACCGTCTAGCTTGTAGTGGACTGAGTCAGACC

0 TGGAG

219 NM 001335.3:1 GGCAGGAGACTCGGGGCTTCATATCCGGTTTCTGCACACG

075

220 NM 001337.3:1 CTCCATCACTCGTGTGGTAAGTAAAATTGCTGCTCAGAACACTT

040 CCATGC

221 NM 001343.2:4 TTTCTACTTCGTTAGACATGGCAAGAAGGCAGGCAGCAAACCTC

50 AGTACC

222 NM 001379.2 : 1 CCTCCATCAAAGCCAGTGATCCACCATTCATTTATGGGGCCAAG

495 ATTTTT

223 NM 001406.3:2 GAACTTGACCTCTGGTGGACAAAGCAACCATCTTGGCTGGTGAT

935 TGAGGT

224 NM 001428.2:1 ATTTTGAGCACAAAACCACCGGGGATCTAGCCTGTGGCCACCCC

689 GGAGAT

225 NM 001429.2:7 CCCATGTTGGGAGAAGTCAAGCCTGCCTGTGTCATTGGGCTTTT

15 GAC

226 NM 001448.2 : 8 GAGACCTTGCTCACGACATCTCCCGCAACCGCTAAGCCTTGAGC

20 GAAAG

227 NM 001504.1:8 AGCACGAGTCACTCTCGTTTTCTCCATAGTCATAGGAAGAGCTG

0 AAGTTC

228 NM 001511.1:7 TTCACAATGATCTCATTGGCCATTTGCTTGGATCCGCCAGC

42

229 NM 001530.2:1 CTGTAACTGTGCTTTGAGGACTTGCGCTTTCAGGGCTTGCGGAA

985 CTGCTT

230 NM 001546.2:5 CAGGTCCAGGATGTAGTCGATAACGTGCTGCAGGATCTCCACT

88

231 NM 001547.4:1 GCGATGGGGGATACTGAGCCCTATTTAGACTTTGGTCCGCCAGC

995 TTTTGG

232 NM 001548.3:1 CAGGGCCCGCTCATAGTACTCCAGGGCTTCATTCATATTTCCTT

440 CCAATT

233 NM 001556.1:1 CATCCTCATTCATTAAGCTCACCACCTCTTCCACCTTGGGCAAC

995 AGTTCC

234 NM 001558.2:1 ACTTCATAGCAGGTACTTTCAGACTGATTTGGGATGGGTGTCCA

50 GTGGAG

235 NM 001559.2:1 ATCTGAGTCGATTAAGCAGTACCAGTCCCTCATCTCTCCAATAA

315 AGGGTA SEQ ID NO: Probe ID Reporter Probe Sequence

236 NM 001561.4:2 TTCCTGGTCCTGAAAACACCTTTACACTGCCTGCATATGTCACA

55 GGTCCT

237 NM 001562.2:4 TGCAGCAGGTGGCAGCCGCTTTAGCAGCCAGAGTT

8

238 NM 001565.1:4 GAGAGAGGTACTCCTTGAATGCCACTTAGAGTCAGAAAGATAAG

0 GCAGCA

239 NM 001570.3:1 CGGTGCTGCTTGGAATATCACTGAGGAGTAAGTCCTTCAGGTAA

285 ACCGGG

240 NM 001627.3:7 GGGAGCCATCGGGCTTTTCATATTTCCATTTGCCAAACATGAGA

89 TTCTGA

241 NM 001629.2:3 GAATATGCCAGCAACGGACATGAGGAACAGGAAGAGTATGATGC

67 GTTTCC

242 NM 001657.2:5 CATGGATTTTTCTTCTTTCTGTTTCTTCTATTTTTTCCATTTTT

47 GCCTCC

243 NM 001674.2 : 1 TCACAGCTGCAAACACCCTGGGCCAGATTTCTTAAAACAGCTAC

757 ATGACA

244 NM 001712.3:2 ATAATCGCTGAAGGGCAGCTCTCTGATTCCTTTCCCAAGTTCCT

455 AGCAGA

245 NM 001715.2:9 TGGGTGGTGACATCCTTCACAGACAGGGAGAAGGCACCTTTGTT

90 GGTTTC

246 NM 001718.2:1 CTGTGGAGTCACAACCCACAGATTGCTAGTGGCCGTGATGTCAA

045 ATTCCA

247 NM 001733.4:7 GAACTCGCCAATGTTCTTCCCGTTGGCATAGATCTGTAGCTGGT

60 CATAGG

248 NM 001734.2:7 CTTGGAACCCTTTCTCCAACCGGATCTGGTATTCACACCTTGAG

75 TTCTCT

249 NM 001735.2:2 CTTTCTGGCGCACACATTTGGAGGACTTTGTGCCCTGATGATCA

592 ATGACT

250 NM 001736.2:1 GGGAGGGTGCTCCCTAGAAGGAAGTGTTCACCTTGCAAATGAGG

195 AAGGAT

251 NM 001759.2:5 AGGACAGGCACCTGTCAAAAGACATTGGATACTGTAATGGCTAC

825 AGTCAG

252 NM 001760.2:1 CCCAGCTAGAGTTGGGAAAGGCGCTGCTGGTCAGA

215

253 NM 001765.2:7 GGGGCAAGTGCTTCTTATGAGATTATACACTGTTTCTGTGACGC

50 CTTCAT

254 NM 001767.3:6 CTCCTCATCATTTCTCCGACTCCTCTGTTTTTTCCT

87

255 NM 001768.5:1 AAGTACTTGTTCCCTTGCCGTTGGAGACTCAAGCACCTCACCCT

320 GAGACA

256 NM 001770.4:1 CACACACACTTACACACATGCACACATCCTAAGCAACATTGCTC

770 CAGAGG

257 NM 001775.2:4 CTCCAGGGTGAACATGTCCCGCTGGACCTGTGTGA

60

258 NM 001777.3:8 AAATCAGAAGAGGGCCATGCATTGGTATACACGCCGCAATACAG

97 AGACTC

259 NM 001778.2 : 2 TTCAACACCCTCATGATGTAGGTGCTGTTGTCCTCTTTCTGGAC

70 CTTAGA

260 NM 001781.1:4 TCTTTGCCATTTGACCACTTCCATGGGTGACCAGGTTCCTTTTT

60 CAGTCC

261 NM 001783.3:6 CTCATACATGGAGCAGTCGTCCAGGTTCAGGCCTTCATAA

95

262 NM 001792.3:9 CCGCAGTGAAAGGTTTTTATCTCTATCAGACCTGATCCTGACAA

41 GCTCTT SEQ ID NO: Probe ID Reporter Probe Sequence

263 NM 001795.3:3 AAGGCCACATCTTGGGTTCCTCTAAACCAAGGGATAAGGAGTAG

405 ACAGAG

264 NM 001797.2:1 GATCACTCTCACAGATGAAACCTTCATAAGGGGCAGCAAACTTG

835 GGAGCA

265 NM 001798.2:2 CACCTCTCCCGTCAACTTGTTTCTGGCTTTGTACACAACTCCGT

20 ACGTGC

266 NM 001815.3:5 CAAGGAGCAGGAAACACACCAGCGCGGCCACCAGCGCCAC

27

267 NM 001870.2:2 CATAGTGCATTTTATTTTGATCCAAGGCAGACTGGATGGCTTGG

20 GATTCC

268 NM 001876.3:1 TTCTGTATCCTTCTTCAGTTTCATCTAACGTCACGAAGAACGCT

355 GCTTTC

269 NM 001935.3:2 CTGCTAGCTATTCCATGGTCTTCATCAGTATACCACATTGCCTG

700 G

270 NM 001949.2 : 3 AAAACCCCACAGTGCATTTCCAGTAGGCACTTAACACAAAGCTC

415 CCTCTC

271 NM 001951.3:4 TCTATTATTAATGGAATCGTCCATCACATTTTTGATGCTTTGCT

44 GTAGCC

272 NM 001955.2:7 CCCCGAAGGTCTGTCACCAATGTGCTCGGTTGTGG

70

273 NM 001963.4 : 1 CAGCCGCTTATCAAGCACATCCAATGACACAGCTGT

022

274 NM 001964.2 : 1 ACGGGTAGGAAGAGAGAGAGGAGGTGGCCGAAGAGGCCACAACA

505 C

275 NM 001974.3:1 AGCCGTCTTTCTTCTCTCCAGTCATTATGCCCCCAACGACTCGA

520 GAATTC

276 NM 002000.2 : 1 GGTGGGTGCAAATCGATCAGTCCTGCATAAGAAAACACCATTTG

415 ATTGGT

277 NM 002003.3:9 CTTCGCCGCACTCCAGTTGATACCATTGGCATAGCTC

32

278 NM 002010.2 : 1 CAGCCCTCCAGGAGGAGAAGCCTTTAAGTGCAGAACAAAATCAG

565 CATATT

279 NM 002019.4 : 5 TGAAGTAGGTACAGCTAGATATTTGCAGCTGTAGAAGCCAGTGT

30 GGTTTG

280 NM 002029.3:3 TGAGGGCGATCAGGAAGACACTTCCGAACAAGTTGATGTCCACT

50 ATGGTA

281 NM 002030.3:1 CGTGGACTAGCAATGAGAAGATCCACAGAACGGTGTGGCCAGCA

90

282 NM 002033.2:1 CTCGGTGATATAATCCAGGTGCTGCGAGTTCTCGAAAGCCAGGT

345 AGAACT

283 NM 002037.3:7 CTTCATAGTCATAAAGGGCCACAAAGAGTGTCACTCCTGTTCCT

65 CCT

284 NM 002038.3:4 TATCGAGATACTTGTGGGTGGCGTAGCCCATCAGGG

10

285 NM 002048.2 : 1 TGCCCAGAGTCGTGGCCGGGGAACCGGCTACACCAAGTTGACTT

525 GGAAAA

286 NM 002079.2 : 6 CAATCCTCTCTTCTCTGCATCCCAGTAGCGATAGGACCGAATGT

15 CTTTAA

287 NM 002080.2:2 AAGGGAGGAGGTCCAACCGGGCAGAGACAACATCCCAACTGGAG

145 AAACTT

288 NM 002089.3 : 8 GTTACAAAATAGACACACATACATTTCCCTGCCGTCACATTGAT

54 CTCACT

289 NM 002090.2:5 GAACCCTCGTAAGAAATAGTCAAACACATTAAGTCCTTTCCAGC

40 TGTCCC SEQ ID NO: Probe ID Reporter Probe Sequence

290 NM 002104.2:7 GGTATTTCTTGGTTAACAGGGTGTAGATTCCAGGCTTTGTGGCA

00 A

291 NM 002105.2:1 CAACGGAGGCTCAGTCCAGACAGGGATTAACCGACTTGTGCTGG

392 TAT

292 NM 002110.2:2 CTTGATGGTGGATGTGGGATCCGGCACGTACACAGGACAGT

60

293 NM 002112.3:1 GCACCATCATCCACTTGGAAGGATTAAAGGTGAAGGAGTCGGCA

170 TACTCA

294 NM 002116.5:1 TCTCACACTTTACAAGCTGTGAGGGACACATCAGAGCCCTGGGC

000 ACTGTC

295 NM 002117.4:8 CACAGCTCCAAGGACAGCTAGGACAACCAGGACAGCCAGGCCA

95

296 NM 002118.3:2 GAGCAGAATACTATATTGCCCGGGTCCCTTGACCCCCCAAATGA

0 GTGATG

297 NM 002119.3:3 TTCCAGTAATTTAAAGCTGTGACTAGGAGACACAGCCTCTGTGG

075 GTTGTG

298 NM 002120.3:2 TTGGTCAATGCCACAAACATCCCCACATCACTGTCGAAACGTAC

30 ATACTC

299 NM 002121.4:9 TGGTTGGAGGCCCAGTGAGAGAAACAGTGCTTTGAATCAAAGAG

31 CAGAAT

300 NM 002122.3:2 TAGCGTTTAATCATGATGTTCAAGTTGTGTTTTGCCACAGCCAT

61 GTTTCT

301 NM 002123.3:3 TGGGCTCCACTCTCCTCTGCAAGATCCCGCGGAACG

84

302 NM 002124.3:7 CCTGAAGTAGATGAACAGCCCGGCCCCAAGGAAGAGCAGGCCCA

47 GCACAA

303 NM 002162.3:1 GGCACTGCAGGACGTGTCTCGTTTTATCTTTCCATTTCAAGTGC

225 TGGGGG

304 NM 002163.2:2 GACCGGTCCGTCACTTCCTCAAAATCTGGGCTCTTATTCAAAGC

53 ACAGCG

305 NM 002164.3:5 ACTGATTGTCCAGGAGTTTTCCATAGCGTGTGCCATTCTTGTAG

0 TCTGCT

306 NM 002181.2 : 1 ACACAGAACTCTGCCCACAGACAGCAACAGTCTCTGGATGTGTC

693 TTGAGG

307 NM 002182.2:4 TTCCTTAACATGCAGGTATAGTTGCCAGTGTCATTGAGGAGAGT

60 GGGCC

308 NM 002185.2:1 TGGGTCACCTTAAACCTTGTGACCAAATCCACATGGTAGAAGCA

610 GGATGC

309 NM 002190.2:2 GCACTTTGCCTCCCAGATCACAGAGGGATATCTCTCA

40

310 NM 002192.2:1 CACACAGACATACCTTATGACCTGGGTAATTGGGTAGGAAAGTG

914 CCTGTG

311 NM 002198.1:5 TTCCTCTTGGCCTTGCTCTTAGCATCTCGGCTGGACTTCGACTT

10 TCTTTC

312 NM 002200.3:1 CTTAGGCAATTCCTCCTATACAGCTAGGCCCCAGG

845

313 NM 002203.2:4 ACAACCACAACATCTATGAGGGAAGGGCAGGGCTGAGTTGCAGG

75 TGAGAA

314 NM 002208.4:3 GTCCACCAACGCTGCCTTTAATGATGATAGGCAAAGAATGGTAC

405 TTCTCA

315 NM 002209.2:3 TCCTGAGACTACAGTTTCTCCACATTTAGATCAGACATTCTCTT

905 CCAAGG

316 NM 002210.2:2 GACCATTGTTTCTCAGCTCATAGATGTGCTGAACAACTGGCCCA

615 ACATCT SEQ ID NO: Probe ID Reporter Probe Sequence

317 NM 002214.2:2 ATGCTGTTGTTCCATGAGAGCACATGAGGTTTTGCACTGATCAA

609 GTATAG

318 NM 002227.1:2 AATTGGTGAAATAGAACCTCATCCGGTAGTGGAGCCGGAGGGAC

85 ATCTTG

319 NM 002258.2:8 CAGGGCAAATTGATGCCAAGGTGAACCCTGACAGACATCCCGAG

5 GAAGAG

320 NM 002262.3:5 AGGCGGTGTGCTCCTCACTGTAAGAGAGTCCAATCCAGTAAAAT

42 TGTTGA

321 NM 002286.5:1 CCTGCGGAGGGTGAATCCCTTGCTCTAAGGCAGAAAATCGTCTT

735 GGT

322 NM 002309.3:1 CCTGAATGCCAAGTGACCTCCTTCTGGAAACTTCTGCCAGATTG

240 TTC

323 NM 002318.2:4 TGGAGAAAGCAAGCACCAAGCGTAGGTAGCCGCGCGCTGGAGTC

0 G

324 NM 002341.1:3 TAGAGGTAATAGAGGCCGTCCTGCGGGAGCGCCAG

30

325 NM 002354.1:4 CTTGGCCTTAAAGAGCCCGCTCTCATCGCAGTCAGGA

15

326 NM 002405.2:1 AAATGAGCAAAAAGGATCATCACAATTGGCTGGGACCCGTTATG

681 CTCCAT

327 NM 002412.3:3 GCTTCCATAACACCTGTCTGGTGAACGACTCTTGCTGGAAAACG

23 GGATGG

328 NM 002416.1: 1 GCTAACTGGGCACCAATCATGCTTCCACTAACCGACTTGGCTGC

975 T

329 NM 002417.2:4 GTCTTTCTCTTCACCTACTGATGGTTTAGGCGTGTGCATGGCTT

020 TGCCTG

330 NM 002421.3:1 GTGTAGCACATTCTGTCCCTGAACAGCCCAGTACTTATTCCCTT

117 TGAAAA

331 NM 002423.3:3 GCGGTAAGTCTCGAGTATATGATACGATCCTGTAGGTGACCACT

11 TTGGAA

332 NM 002438.2:5 AAACTTGAACGGGAATGCACAGGTTGCTCCATTGGCATTGCCTA

25 GTAGCG

333 NM 002460.1:3 TTGTTCAAAGCGCACCGCAGGCGCGTCTTCCAGGTGGG

25

334 NM 002462.2:1 ATTTGTGGAACTCGTGTCGGAGTCTGGTAAACAGCCGAATGTCT

485 TCCTCC

335 NM 002467.3:1 TCTGGTCACGCAGGGCAAAAAAGCTCCGTTTTAGCTCGTTCCTC

610 CTCTGG

336 NM 002468.3:2 TAGATGAGTGCCCAATTTTTGTTCAGGGACATGGTTAGGCTCCC

145 TCAGTG

337 NM 002483.4 : 1 AGGGCTTCAGGAGCAGAGCAGACCTTGTTTTTAGTGGTTCCATG

217 GGATAA

338 NM 002485.4 : 1 TTCATCAACTGACACGCCTTGTGAAAGGCTTGGTCCTGGAGTTG

060 TTGTCT

339 NM 002502.2:8 CTGCACCTTGTCACAAAGCAGATAAACTTCATCTCCACCCCGCA

25 CAGAGC

340 NM 002507.3:2 GTCTAGAGCTGGGAGAAATCCCCACAGGTCACAGT

730

341 NM 002524.3:8 GTACTAAACTACTGAGAGCTGGGGAAGTAGCAGGAGCTTCTCTG

77 TGAGAC

342 NM 002526.2:1 GGATTGCCTGTGTAAAGAAATGTGTTGGAGTGTCCTCCCACCAC

214 GACGTC

343 NM 002543.3:2 GCTTCTTCTGCTTGTTGCCGGGCTGAGATCTGTCCCTCCAGTTT

95 CTTTTT SEQ ID NO: Probe ID Reporter Probe Sequence

344 NM 002546.2:1 TCCCACTTTCTTTCCCGGTAAGCTTTCCATCAAGCTACGAAGCT

075 GCTCGA

345 NM 002608.2:1 CGTTGGTGCGGTCTATGAGGCGCCGGGAGATCTCGAACAC

245

346 NM 002609.3:8 CACCAGCTGTGGGTCTGTTACTCGGCATGGAATGGTGATCTCAG

40 TTATTT

347 NM 002610.3:1 CTTAATGTAGATAACTGCATCTGTCCCGTAACCCTCTAGGGAAT

170 ACAGCT

348 NM 002619.2:0 GCCCGGGGCGTGAGGCGCAGAACCCGGCTGCGGAG

349 NM 002639.4:1 AGGGCCACTCCCTTGGTCTCTGACATTCCAGAGAAA

014

350 NM 002649.2:2 TCTGAGAAGTTGCAGTCCAGGAGCTGCATTGTTAACCCAACATC

125 C

351 NM 002658.2:7 GGTTTTCCACCTCAAACTTCATCTCCCCTTGCGTGTTGGAGTTA

93 AGCCTT

352 NM 002691.2:2 CCGCGTAGCGCTTCTTGCTGATAAGCAGGTATGGGAAGTAGACC

392 T

353 NM 002736.2:1 TTGCTCCATACTTTTGCTTCATGCAGTGGGTTCAACAATATCCA

350 TGTTCG

354 NM 002737.2:6 CCCAGATTTCTACAGACAGTCGTCGGTCTTTGTCTGAAGGTTTC

80 AATTTG

355 NM 002800.4 : 4 ATATGCTGCATCCACATAACCATAGATAAAGGTGCTGCCGGAGC

55 CACCAA

356 NM 002801.2:2 AGCTCTTGTCCGCCACGACCGAATCGTTAGTGGCTCGC

21

357 NM 002834.3:1 TTCTCTTAGCGTATAGTCATGAGCGGCGCTTTCTTTGACGTTCC

480 TAACAC

358 NM 002838.4 : 2 GGTCACTTGAAAGTGGAACACTGGGCATCTTTGCTGTAGTCAAT

58 CCAGTG

359 NM 002852.3:1 TCCCCACCCAACAATATTCCCCCGGATGTGACAAGACTCTGC

152

360 NM 002856.2:1 AAAGATGACCTGCTCAGCGCGGCCCATGCCCACGGCAT

337

361 NM 002876.2:3 TTTTCATTAAGGGCACTCCACCCCCAAGAATATCATCTAGTGCT

00 GAACAG

362 NM 002964.3:1 AGACGTCTGCACCCTTTTTCCTGATATACTGAGGACACTCGGTC

15 TCTAGC

363 NM 002965.2:7 CTTTGAATTCCCCCTGGTTCAGGGTGTCTGGGTGC

5

364 NM 002982.3:1 GCTCGCGAGCCTCTGCACTGAGATCTTCCTATTGGTGAAGTTAT

23 AACAGC

365 NM 002983.2 : 1 TCTCAAAGTAGTCAGCTATGAAATTCTGTGGAATCTGCCGGGAG

59 GTGTAG

366 NM 002984.2 : 3 GAGCAGAAGGCAGCTACTAGCATGAGGAGAGACAGGACAGTCAC

5 GCAGAG

367 NM 002985.2:2 AAATTTGTGTAAGTTCAGGTTCAAGGACTCTCCATCCTAGCTCA

80 TCTCCA

368 NM 002988.2 : 5 AGATTTGTCATTTGATACATATGGCACAATGTCTGCTGAGAAAG

85 CTAATC

369 NM 002989.2 : 1 CAAGAACAGGATAGCTGGGATGGAGCAGCCTAAGCTTGGTTCCT

80 GCTTC

370 NM 002990.3:7 CCCAAGAATCTGCGGAGACTGTGACTAGGGTTATTAAGAGGGGA

97 CAGAGG

371 NM 002993.3:5 ACCAACCCTTCCTTCTTATTCTTACTGGGTCCAGGGATCTCCAG SEQ ID NO: Probe ID Reporter Probe Sequence

39 AAAACT

372 NM 002994.3:2 CCTTGGAGCACTGTGGGCCTATGGCGAACACTTGCAGATTACTG

50 ATCATT

373 NM 002996.3:1 CATGATGCCTGGTTCTGTTGATAGTGGATGAGCAAAGCTACAGG

40 TATCTT

374 NM 003005.2:1 CCAAGTTATCACACCGAACTATATCGGCTCCTCTCAGCATGAAA

295 CCTTCA

375 NM 003012.3:3 AGAATTCCCATTTAGAGAGCTGCACAGCACAGTCACCTGCTCTT

320 CCGTAT

376 NM 003014.2:1 CCCGGCTGTTTTCTTCTTGTCCTGAACTGTTCTCCGCTGTTCCT

060 G

377 NM 003051.3:6 AAGCCCAAGACCTCCAATGACTCCAATACAGACGTATAGTTGCT

35 GTACGG

378 NM 003068.3:7 ACCTGTCTGCAAATGCTCTGTTGCAGTGAGGGCAAGAAAAAGGC

40 TTCTCC

379 NM 003106.2:1 GGCAAACTGGAATCAGGATCAAAAAAAGCGCTTCCCTCCTCCTC

51 TGGCCG

380 NM 003108.3:5 TATAATAAACAGCAGGATCCCCACTGGCTAGGCTGCCGTGCACA

650 CAGCAC

381 NM 003121.3:1 AAGAACTGCTACCCTGCCTCCCCGAGTATAGTGGTCCATAG

029

382 NM 003151.2:7 GCCTCCTTTCTCTTGAAATCGAGGCTGTTAAGCATTTCCTGCAG

89 TGTCAA

383 NM 003155.2:2 TATTTATACTCTCTCAGCCCCAAGTCCCCCGGACTAAAGACCTA

265 AAGGCT

384 NM 003161.2:3 CATAGCCCCCTTTACCAAGTACCCGAAGTAGCTCAAAACATTCT

10 GGTCTG

385 NM 003175.3:3 CATGCAGTGCTTTCATAAAAGGTGAGTATAATCTCAGTCCATGA

77 GGGTGT

386 NM 003177.3:1 GTAGTTGATGCATTCCGGAGCGTACCACTTGACAGGCCACTTTC

685 CATGGG

387 NM 003190.4 : 1 CAGTGCCTTGAAGAGCCCAAGCAGAAGAAAGGCAGACAGGAAAA

536 GGCCTA

388 NM 003200.3:8 AAGGAGGATGCAGATGGGAGCCCACCGTTCACCTCTGCT

58

389 NM 003205.3:1 GATCGACTGCTTGCAACAAGGCTTGATCCTCCATAGTTTGAATT

579 GAGGCT

390 NM 003236.2:7 ACACTGAATAACCCCAAGCAGACGGAGTTCTTGACAGAGTTTTG

80 AAGGCC

391 NM 003238.2:1 TTCACAACTTTGCTGTCGATGTAGCGCTGGGTTGGAGATGTTAA

125 ATCTTT

392 NM 003239.2:1 GTGAATGTTTTCCAGGATATCTCCATTGGGCTGAAAGGTGTGAC

485 ATGGAC

393 NM 003246.2:3 TTCCCTTCATACATCACCACTCTAATGAAACCCGTCTTTGGCCT

465 GTGGCT

394 NM 003263.3:5 TTAAATGACAGGTCCAAGTGCTTGAGGTTCACAGTAGGGTGGCA

45 AGAAAT

395 NM 003264.3:1 CTTCCTTGGAGAGGCTGATGATGACCCCCAAGACCCACACCATC

80 CACAAA

396 NM 003265.2:2 GCTGGCTATACCTTGTGAAGTTGGCGGCTGGTAATCTTCTGAGT

30 TGATTA

397 NM 003268.3:2 GAAGTCCAGTATAGCATCCCTGGTTTGGTGACTGTGGAGAAGC

15

398 NM 003294.3:5 GACGATGCGGACGTCGTCTCCCGTGTAGGCGCCAAGGT SEQ ID NO: Probe ID Reporter Probe Sequence

79

399 NM 003326.2:5 GAAGTCATCCAGGGAGGTATTGTCAGTGGTCACATTCAAGTAGA

45 CTTTGT

400 NM 003327.2:2 CACTCCCACTTCTGAGGTTACACCACGTGCAGGGC

00

401 NM 003377.3:6 TCTTTGTTCCCCCACTGGGATATAGCCTCTGAGGCAAG

87

402 NM 003391.2:2 GGGACAGTAATGCAAAGCAATCCCTTTCTGAGGCTTTTGCTCTT

014 ACAAAG

403 NM 003392.3:4 TACAAGTGGCACAGTTTCTTCTGTCCTTGAGAAAGTCCTGCCAG

75 TTGGCT

404 NM 003442.5:9 ATCTTCCGAACACCGATATGGCTTTTCTCCTGTATGAGTTCTGA

25 CGTGAC

405 NM 003465.2:4 GTCAAGGTCAAGGCCGTCAAAGCTGTATTTGCGCAGAAACCTGA

10 TGGCCG

406 NM 003467.2:1 TACACGCTCTGGAATGTTCAGTTCCCTTTTCTACAGTCCTACCA

335 CGAGAC

407 NM 003474.5:6 CGAGGGAGACATCAGTACCGTCTTGCAGATAGTGGGTTTCCGTG

38 AAACTG

408 NM 003486.5:7 GTAGGGGTTGATCATTTCCTCTGTGACGAAATTCAAGTAATTCC

85 ATCCTC

409 NM 003508.2:1 GCTGGCCACGTAGCAAAGCCCAGTCAGCTCATCAC

320

410 NM 003629.3:5 GGGCTGATTACTTGTAGCAAAAAAGAGACCCGTGGAAGACACAT

016 TGGCTC

411 NM 003639.2:4 GCCTCCTGGAACTTGCACATGAGGAACTCCTTCTCCTC

70

412 NM 003641.3:4 AAGGTTGCAGGCTATGGGCGGCTACTAGTAACCCCGTTTTTCCT

82 GTATTA

413 NM 003686.3:2 GCTCATTGAGTTTGATCTGTAACCCCGGCTTGTTCTCGGCATTA

715 TGATGC

414 NM 003747.2:1 AAGTAACAAAGAGCAGACTTCTACACGGTTCTTGGAAGCAGCCT

270 CGTGCA

415 NM 003749.2:7 AGGTACTTGTGCTTGGCGTCGGCGCGCTTGTTGAT

64

416 NM 003808.3:8 CAGCAGAGCCATGGCACAAGCCACGGCCCCCAGAG

10

417 NM 003809.2 : 3 GATGAACTTCATAATGGGCTGCGATCGCTCTTCGAGCCCGTGTT

39 TTCCGG

418 NM 003810.2 : 1 GTTGGTAAAGTACACGTAAGTTACAGCCACACAGAGAGACTGCA

15 GGAGCA

419 NM 003811.3 : 3 CACGCGCCGCAGCTCTAGTTGAAAGAAGACATAGTAGACTCCAG

98 CC

420 NM 003820.2 : 9 GACGATCACCTTGACTACATCACCCCTTGGCTTTCTTCTTTTCA

16 CACATA

421 NM 003830.2:2 GGAAGGGGAGTGACACCAACATATTGCTGCCCTGTTTTTTGTGC

145 CTGGTC

422 NM 003839.2:4 ATGTTCTACTCTCTTTCCAAGGAAGGTACAGTTGGTCCAGGGTC

90 TGCATT

423 NM 003840.3:2 CTTAATTCTCACTGTCCTCATCTGCTGTGGACAAGTCGGAAGAT

380 GCAGTC

424 NM 003841.3 : 6 AGTGGCATTGGCACCAAATTCTTCAACACACTGGATATCATCCC

82 AGGACG

425 NM 003842.3:5 CTTAGCTCCACTTCACCTGAATCACACCTGGTGCAGCGCAAGCA SEQ ID NO: Probe ID Reporter Probe Sequence

65 GAAAAG

426 NM 003855.2:2 CAGATCCATGGTGTTAGGGAGTGAAAGCAGCATTTCAGTTACTC

025 AGTCAC

427 NM 003862.1:8 TAGTTGTTCTCCAGAACCTTCTCGATGAACACACACTCCTTGCT

50 GGTGCC

428 NM 003883.2 : 1 ATCTCCATCCCTAATAGGTACCATTGTCAGGCCTTGGGAGAGAG

455 AGGAAA

429 NM 003884.3:1 GCACGTTGCAGTAACACAGCCACCTTGTGTAGTTCTCTTTGTAT

220 CCAGAA

430 NM 003897.3:5 CTGAGTTCAAGTTGCCTCGGAAGTCCCAGTTGGGGATACGC

27

431 NM 003914.3:1 CACAGGTACTTTGAAGCCTTGTACTTCTCCCTAATTGCTTGCTG

605 AGGTCG

432 NM 003998.2:1 CATGGTTCCATGCTTCATCCCAGCATTAGATTTAGTAGTTCCAG

675 GATGGA

433 NM 004048.2 : 2 CAGGCCAGAAAGAGAGAGTAGCGCGAGCACAGCTAAGGC

5

434 NM 004052.2:5 ACGCCTTCCAATATAGATCCCCAATCCGATGGCCAGCAAATGAG

84 AGAGCA

435 NM 004072.1:7 GTGGATGAGAAGGAAGTTGCTGATCTTGCACATGGCTGTCCCGA

70 AAACCC

436 NM 004079.3 : 6 TTGAGTCATATTGACATTTCTGATCCATGGCTTTGTAGGGATAG

85 GAAGCG

437 NM 004095.3:3 TTGGTAGTGCTCCACACGATGGCTGGTGCTTTAAATGTCCATCT

63 CA

438 NM 004107.3:1 CTCGTGTTATATTATCGAGGTGGAAAACAGCCATATGTATTAGG

366 AGGGGA

439 NM 004131.3:5 GGTCCCCCACGCACAACTCAATGGTACTGTCGTAATAATGGCGT

40 AAGTCA

440 NM 004152.2:3 TGTCGTTGGACGTTAGTTCCTCTGTTACATTCAGCCGATCATCG

13 GAGTAG

441 NM 004165.1:9 GTGGGACCTAGAGAACCGAGAGGTCGTGGCAGGACTTGGATTTG

60 GCG

442 NM 004168.1:2 TGCAACAGTGTGTGACCTGGTAGGAAACAGCTTGGTAACACATG

30 CTGTAT

443 NM 004195.2:4 CAAGGTTTGCAGTGGCCTTCGTGGCCCCCGGAGAA

45

444 NM 004203.3:7 CGGAATGGTGACATGGAACGCTTTACCGCATAGAGCCGGCCGTC

80 CTCCTT

445 NM 004221.4:3 CGTAATCCATCTCTTTCTTTTTCAAGTAGAGGAGTGAGCTCTGG

58 G

446 NM 004244.4:1 CAAAGTGAGCTCCCCCCAGGATAGAGACAACTGTGCCACACTGT

630 AATT

447 NM 004322.3:6 CCGCGCTCTTCGGGCGAGGAAGTCCCTTCTTAAAGGAGTC

52

448 NM 004350.1:2 TTGATGTCTGACCCAAAATGATCCCTCACCTCAATGCCTTCTGC

085 TAGGAC

449 NM 004360.2:5 ATGGGCCTTTTTCATTTTCTGGGCAGCTGATGGGAGGAATAACC

35 CAGTCT

450 NM 004369.3:2 AGCTCATCGATAATCTTGTAGAGAAAGTCACGGACAACAGGGAA

782 CTGGCC

451 NM 004385.3 : 9 CATCTTGTCATTGAGGCCTATCCACTGATAATCATGGCCCACAC

915 GATTAA

452 NM 004416.2:2 GGTAGGGAGGATGGGAGAACAGCGCCTTTATCTGGGACAGACAG SEQ ID NO: Probe ID Reporter Probe Sequence

855 AA

453 NM 004417.2:9 TTGACTCGATTAGTCCTCATAAGGTAAGCAAGGCAGATGGTGGC

87 TGACCG

454 NM 004418.3:1 TCCACGGTATAGCGTCTAGCTGATTTCTGCCAGAGGATGGG

235

455 NM 004419.3 : 6 AAGCTGGCCTGTAGCTGACATTTACCACTGGTTTTCCACACTGG

75 CTGATG

456 NM 004456.3:1 ACATACTCTTTACTTCATCAGCTCGTCTGAACCTCTTGAGCTGT

90 CTCAGT

457 NM 004460.2:1 TACTTGGCGTAGTCGCTGAAACTTGCTGTGTAATATTGGCACCT

490 TTCTTT

458 NM 004485.2:2 TGTCCATACAGGCTTCCATCTTTAGCTGCTCCACAGCTTTCC

15

459 NM 004513.4:1 CAGCTCTGAAAGGTTGAGCGAGAACCCTGTGTCCAAGGCAGATG

262 TTTCAG

460 NM 004525.2:1 ACAAGATTATTGCGGCCGGATTCAAAGTTGGGGATGTAGGCACG

2505 TTTGAT

461 NM 004556.2:1 TCAATGTCAGCTCCATTCCGAAGCAGCAATTCCATGAGTGGTTG

115 GTTCTT

462 NM 004560.2:7 CATGGTGAAGGCCGCTGTGATTCGGTTTTCAATCTCCCCCTGCA

35 TCTGAA

463 NM 004563.2:7 CGAAGGAGATGATCTCCCGCTGGTCGGGCACGTGG

95

464 NM 004566.3:7 TTTGGCAAAATGAAGGATCATGTGTCTCCTCTCTCTAGTAGTAT

10 TGGTGG

465 NM 004591.1:3 GCTTCTGATTCGCCGCAGAGGTGGAGTAGCAGCACTGACATCAA

5 AGCAGC

466 NM 004599.3 : 1 TCAGCACCATGTTCTCCTGGCGCAGTTTATGATTGACCTGCTGC

275 AAGTAT

467 NM 004612.2:1 GCAGTTGGTAATCTTCATGAATTCCACCAATGGAACATCGTCGA

255 GCAATT

468 NM 004626.2:9 CAGCTGTCGCTTCCGTTGGATGTCTTGTTGCACTGCCTG

60

469 NM 004654.3:8 CACAACTCTGTTAATCACTACACTCTCTCAGTCAGTCAGAAATG

5 CTGCTG

470 NM 004658.1:2 TGAAGTAGAGACCCCAGTCTCAGTCAAATAAGTCAGGTTCCTTA

900 TCC

471 NM 004756.3:5 GAAAACAGTGGCAGATCCAGCGGCGGGTAGTCCCGTCACGACAG

91 ATATAG

472 NM 004829.5 : 6 TGTTCTCAATGTCGCCTGTGACCAGGAGCTTCACT

02

473 NM 004850.3 : 3 TTGAACGAGCCAGTTGCTCAGAATCTGCTTTGGTCAAGGTGATC

140 TCCAGT

474 NM 004887.4:1 TCCCAAGCTAGGAATGGAGCAACACTGCAATGAAATGTGTCCAC

125 CAAGCT

475 NM 004931.3:4 CCTGGGTAACCGGCACACTCTCTTCTTGAGGGTGGAC

40

476 NM 004936.3:1 CTTCAGGTTTTCCTTTCTGCCGCTAGGGCCTAAGTTGTGGGTTC

175 ACCATA

477 NM 004958.3:1 TGCTCACTGTTCAGGAAATGATCCGCACAGTGGCGAACAAATTG

865 GGTCAG

478 NM 004972.2:4 GATATATAGAAGAGGTGGATGTTCCCTCCATTTCTGTCATCGTA

55 AGGCAG

479 NM 004985.3 : 3 AAATACACAAAGAAAGCCCTCCCCAGTCCTCATGTACTGGTCCC SEQ ID NO: Probe ID Reporter Probe Sequence

27 TCATTG

480 NM 004994.2:1 CCCATCCTTGAACAAATACAGCTGGTTCCCAATCTCCGCGATGG

530 CGTCGA

481 NM 005018.1:1 CGGTACCAGTTTAGCACGAAGCTCTCCGATGTGTTGGAGAAGCT

75 GCAGG

482 NM 005026.3:2 CGGAACCGTTCAAATTTCTCACTATTATTAGTCTTCCCCTGCTG

978 AATCAC

483 NM 005027.2:3 CCGAATGTCACGGCCGAGGTTCTCGGAAGCAGCAGAGTGAAGTT

100 CCTT

484 NM 005041.3:2 TGACTGCAGGGCTTGAGAATGGCGGAGGGCTTAGGCAGTTTGGA

120 CA

485 NM 005044.1:2 CTCGAACTCCTAGGCTCAATCTTCCTGCCTCAGCT

590

486 NM 005045.2:3 TAGATGTGTATAGTCCTGTCACCAGCAAGCCGTCAAAAAAGGTG

45 CTTGTT

487 NM 005084.3:2 GGATTTATGTATTGCCAGTCAAAAGGATAAACCACAGCCAGGCA

55 GCCGCA

488 NM 005092.2:1 CCAGTCAGACACCTTATTCACGCAAGGAGGTTCAGAAGATGCCA

75 TTTGCC

489 NM 005101.3:3 TGCTGCTGCGGCCCTTGTTATTCCTCACCAGGATG

05

490 NM 005103.4:4 GATCTGTAACTGGTTCTTCACGGGAGCTAGGTTCTCGG

26

491 NM 005191.3:1 AAGAGCAGATACGTAAAGGGCAAGGTGGGGTAATCTTGTCCATC

288 TGAGGA

492 NM 005194.2:1 GGCAGAGGGAGAAGCAGAGAGTTTATCATTCATCTGTACACATA

420 GACGTT

493 NM 005204.2:2 AGCCTCCAGGAGATCAATGCTGTCTTAATTTAGAGCAAACATGG

050 CATCCT

494 NM 005211.2:3 CCTGCCTTCTAGCCCAGAATGACGGGACTGGGCAGAA

775

495 NM 005214.3:4 GATAGTGAGGTTCACTTGATTTCCACTGGAGGTGCCCGTGCAGA

05 TGGAAT

496 NM 005238.3:4 TATATAGACCCCAACAGAGTAAGCGGCATGCACAGCATGACTAG

625 AAGAGA

497 NM 005242.3:9 ACATGGCCAGGACAGTGACAATGAGTTTGATGGCCCTCTTCCTT

40 TTCTTC

498 NM 005269.1:2 GGTGGGATAGGAACCTGACTTGTGATTGGGCAAGTTGGGTC

885

499 NM 005317.2:6 GAGGCTTGAAGATGTCAGTGCAGACCCTGGAGCTG

69

500 NM 005342.3:2 TACACATCAGCCTTCAAAATGGTATTTAGTGTCACCACTTGCTA

332 CTGTGG

501 NM 005343.2:3 CCGTTTGATCTGCTCCCTGTACTGGTGGATGTCCTCAAAAGACT

96 TGGT

502 NM 005356.2:1 CGTGGGTGACAATTTCCGTCAGCAGGATCCCAAAAGACCACACA

260 TCTGAC

503 NM 005384.2:1 ATCACAGTGAAATGACATCACAGGTCCAGTGAAAATTCAGCATA

795 ATACAA

504 NM 005406.1:2 GCTTTCTTGCGTCAATTCAAAATACTGTTCTTCCAGAAGGCCTC

660 GCGCCA

505 NM 005408.2:3 AAAGTCATTTCACGTACTCCAGCTTGATTTCAGTAGGGGTAGCA

20 GAGTTC

506 NM 005409.4:2 CACAGTTGTTACTTGGGTACATTATGGAGGCTTTCTCAATATCT SEQ ID NO: Probe ID Reporter Probe Sequence

82 GCCACT

507 NM 005419.2:1 AGCGCAGTGGGTTTTCAGGTATATTCTCCTCAGTGAGCAACTGG

965 TAATGG

508 NM 005429.2:5 TCCAATATTCTGGGTAGAGTACAGTCATGAGTTCATCTACACTG

65 GACACA

509 NM 005438.3:1 GCCCCAAGCTGGCTCTACTGTGAAGCACAATATGGTC

086

510 NM 005442.2:1 CATCTTCCTCTGGTAAGAACCTCGACCTCCCCACC

670

511 NM 005445.3:3 TACAGCAAGTTCCATAATCATATCTGACACAGCCTTTCTGTGCT

525 GAGCA

512 NM 005474.4:3 CACCCAGAGGAGACAGATGTCCTTCAACAGCATCAAACCCGGCG

160 G

513 NM 005508.4:3 GGGCCCAACCAGAAGCAGCTTGCTTTTCTGAAAGCGGCTCTGAG

5 GAAGGT

514 NM 005514.6:9 CACAGCTCCGATGACCACAACTGCTAGGACAGCCAGGCCAGCAA

37 C

515 NM 005516.4:1 TGGACTGTTTCTCTACCTCCTCACATTGTGCTAACAGGGACACA

204

516 NM 005524.2:8 CGCTGTGCGCGAAGGCCCCGTTGGGAATGAGGAAAGCAAACTGG

60 CCATCG

517 NM 005531.1:2 TACAGATCTCAACTCCCCGGTATTCCCACTTTTCGGTGCCAATT

255 CAAAGC

518 NM 005532.3:3 GGAGCTAGTAGAACCTCGCAATGACAGCCGCAATGGCAGACCCA

90 ATG

519 NM 005533.3:4 TTGATCGTGTGCTCCTTTTGTTGCAGCACCTGCTCAGCC

15

520 NM 005559.2:5 ATACCTCCAATTCTTCCAGCGGCTTCTGGTAATTTTCCTGAATT

230 TGTGAC

521 NM 005562.2:4 AAGAGAACCTTTGGAGTTACAATTGCAGGGCAAACAGCGGTCCC

90 TTTCTC

522 NM 005591.3:5 CAAAGTGCATCTGCCCCTGTGGGATCGTCATGATTGCCATGAAT

05 ACTAAA

523 NM 005601.3:6 AGGCTCCAGATGAGGCCTTTGGAATACAACGCTCAAAACTCATC

33 TTGCCG

524 NM 005611.3:1 GTGTGAAGACGACTCAAGCTATGCGTAGCTGTAGAAACTGGAGT

310 CACACA

525 NM 005618.3:2 TTTAAGAGAAACGGGAGTCTTGCCATCTCACTTCCATTTTACAC

580 CTCAGT

526 NM 005621.1:2 TTCAGAGAGCTACCTACTCTTTGTGGGTGTGGTAATGGGCAGCC

60 TTCAG

527 NM 005623.2:6 TTCAAGCTCTGACTCTCAGTCCATGTATGAAGGCTCATGGCTTC

89 AGATTT

528 NM 005627.2:1 AACAATGTCCCACGTTGTAGTGTCCTGCAAGTGTCACATTGATG

790 CTTATA

529 NM 005631.3:1 CAGCCTGGTTGAAGAAGTCGTAGAAGTGGCAGCTGAAGGTAATG

615 AGCACA

530 NM 005651.1:0 TCCAAAGTTGTTTCCTAAAAATGGGCACCCACTCATGGTGAAAA

GGCACT

531 NM 005732.2:5 CCCAGTTGAGAAAAGCTGTCTAGGCAAACATGCTCATTATAGCT

397 ACAGAT

532 NM 005764.3:2 CTCCTGGCACCAGAAGTGGTTGACTGCAAAGGCGATTGCAACGA

40 GGAC

533 NM 005816.4 : 1 AGTTGAAGCCTCGGGTAGTCATACTGGAATTGCTGGGTTGAGGA SEQ ID NO: Probe ID Reporter Probe Sequence

355 GTGGTG

534 NM 005860.2:2 CCGTCGCACGAATCTTTGCAGGGAAGGCAGTGGACAAGGCCC

45

535 NM 005903.5:1 GCTGAACATCCCTGCTGGATATACTGGGCATAATCTGAGGAATC

044 ATATTA

536 NM 005905.2:1 CAATATCGCCTCTCAAGTGTTTCCTCCCACAAAATCTGCTGCTT

595 ATAGCA

537 NM 005923.3:1 CTTGAATGACTCTCATGTGGTCATTGGCTAGGACGCTGGC

760

538 NM 005931.3:1 ATCATATAGCCTCCAATGGAATGTTGAGTTGGTCATGATCCCTT

387 TGCTGG

539 NM 005944.5:6 CTGATTCTTAGGGTCTTTGATATGGAGGATGCTGGTAACAGACG

65 TGGTCC

540 NM 005985.2 : 6 TAAACTCTGGATTAGAGTCCTGCAGCTCGCTGTAGTTAGGCTTC

3 C

541 NM 006015.4:5 TGTCCTGGGTCACCCACCTCATACTCCTTTAAAATGCCAAAGAT

495 CTCAAT

542 NM 006017.1:9 GGTTGCTATTCAGCTGGCTTAGAGACAATCTGATGCTGTTGCAG

25 GTTTCA

543 NM 006037.3:6 CCTGGACGCTTGCTGTGGAGAAGAGCCGAGTGTGTCTTCAAAGA

965 AAAGGC

544 NM 006039.3:3 TTGGCATACATCAAAGGCTCCTGCTCCACCCACTGGAAGT

482

545 NM 006084.4:3 TGGCAGCAACTGATACACCTTGTAGGGCTCAGCAACATCC

85

546 NM 006120.3:3 ACACTTCAGCGATAGGAAACCCTCTGGACACCGGGATTTTCCCA

80 TCAAGT

547 NM 006137.6:4 CATCCTTGGGACTGTTCCTCTGTCACCAGGACCAG

40

548 NM 006142.3:5 TCGAAAGTGGTCTTGGCCAGAGAGATGGCCTCCTCGGG

79

549 NM 006144.2:1 TCAAGTTACAGTGAGCTGCAGTCAACACCCAGTCTTTTGCAATC

55 AAAGCC

550 NM 006158.3:3 GTTTTGTTTCTGAGGAGACGCCTCATCTTTACAGAAGCCAATAC

300 ACTGAG

551 NM 006187.2:4 CAATAATGAGGGAAGGCTCTTCCCATCCCATTCAATCTAGCATT

980 CCTAGC

552 NM 006218.2:2 GTTCTGAAACAGTAACTCTGACATGATGTCTGGGTTCTCCCAAT

445 TCAACC

553 NM 006252.2:9 CTAGAGGCGAGGTAGAACTCACTGGCTTGGTTCATTATTCTCCG

75 ATTGTC

554 NM 006254.3:2 GGAACTCCTGGTCAAAGTTACTGTAGTCTCTGGGTGACTTCACT

165 TTGGGC

555 NM 006274.2:4 CCCAGGTTAGGTAATAATTCACAATGCTTGACTCGGACTCCGGG

01 CTCCC

556 NM 006288.2 : 1 TTCTTTGTCTCACGGGTCAGGCTGAACTCGTACTGGATGGGTGA

35 ACTGCT

557 NM 006290.2:2 GTTCGTTTTCAGCGCCACAAGCTTCCGGACTTCTCGACACCAGT

60 TGAGTT

558 NM 006291.2:3 CAGCTGACCTGAAAATAGAAAGACGACCTGGGTTCTCTGGGTAG

525 GCGCAA

559 NM 006301.2:8 TCTTGGTGCTCTTGTCACTCAGCTCCTTGGAAGTGCCAAAATCT

00 GAGATC

560 NM 006343.2:6 TGAAGGCTGTGTTTCTGGTGACATTCATGCTCTCAGGCTGCTTA SEQ ID NO: Probe ID Reporter Probe Sequence

65 GTAAAG

561 NM 006350.2:5 ACTGGAGTAGGTGACTCCATCATTCCCACAGAGATATTGCTCAG

75 AGGAAG

562 NM 006419.2:2 CCACACACACAATTGACTTGTTCTTCTTCCAGACTATGATTTCT

10 TTTCTT

563 NM 006433.2:3 TCGCAGCATTGGAAACACTTCTCTGGGTGGGCTTATCCACCATC

05 TTCTTC

564 NM 006435.2:3 CTGATCTATCGCTGGGCCTGGACGACCAACACTGGGATGATGAT

90 GAGCAG

565 NM 006437.3:1 ATTCTGTTCAACATGCTCAATTTTGCACCTCAAAGCTCGGTATT

170 TGGCCA

566 NM 006500.2:1 GTTGTGTTGGAGTCTGGTGTGAGGGTGGTTAAATTGACCAGCTC

515 CAGGAA

567 NM 006505.3:6 CTGCCCTGCGGGAACGTGACGAACAGGCAGGTGTAGTTGC

04

568 NM 006509.2:2 CCGTCCAGGCCGAAGCCGTTCTCCTTGATGTACTC

50

569 NM 006516.2:2 TCCCTGCACTCCAGTGCTCCCAACTGGTCTCAGGTAAAGAAAGA

500 TTAATT

570 NM 006564.1:9 GTACATGCAGGGCAGAAAGACCTTGCTGAACTGCAGGAAGTCTT

5 GATGCT

571 NM 006573.4:1 TTAATGTCCTAGAGATGTGGGCACTTGCTCCATAGTAAATTATG

430 GATGCC

572 NM 006623.2:5 CCCAGGCCAAGAATTCCCAGGGTCTTTCCATTCAGCTCTGTT

05

573 NM 006705.3:2 ACTTCTTCCAGAGTCATAGTGCGATCAACCAGCAGCTAGTTATC

7 CACAAG

574 NM 006725.3:1 GAAGATTCTATAGTGACTGTCTGAACACTTGCAGGGACTTCGGG

280 AGTGGA

575 NM 006737.2:8 GTCACTTGAGTTTGACCACACGCAGGGCAGGGCACG

84

576 NM 006770.3 : 1 CTTTGGAGTAACCCAGCATGCGGCAGAAGACAATGGCATCAGAA

434 TTTTGC

577 NM 006845.3 : 1 CTGATCTGAGTCATGGCTTCGTTAAAGCTGGACATCTGGGAAGA

940 CAGTTC

578 NM 006846.3:2 GGCCTCGAACAGGGTTATTTTCTCTGGTGCAGATAAGCTTTCCA

595 T

579 NM 007108.2:8 CGTCTTGGGGTTCCCTCGTTGAACATGCTGTCAAACCAGGACAC

00 TGG

580 NM 007115.2:2 CTCTGCCCTTAGCCATCCATCCAGCAGCACAGACATGAAATCCA

50 ATTTTT

581 NM 007129.2 : 1 TACACAGTTTGTCAGAAGACTGGGAACAGGGTGGGAAAGAACGT

849 GGGCAT

582 NM 007199.1 : 1 TCATATTCATCCCAGGAAAATTTGGAGGAACAGCTGCTCTCCAC

735 TGGCCT

583 NM 007305.2:1 TCCTCCACATCAACAACCTTAATGAGCTCCTCTTGAGATGGGTA

275 GTTTCT

584 NM 007315.2:2 AGCAGCTACGCACAGCACGTTAGGTGCCAAGACTGTCGAGGTTA

05 TATACA

585 NM 007360.3:5 CCAGTTTAAGTAAATCCTGGTCCTCTTTGCTGTATACTTTCAGA

22 AGGCTG

586 NM 007361.3:1 AGAATGTAACTTCCATGTCATGGGTAAAGGCAGCACCTGCGAGG

995 CTGAAG

587 NM 007371.3:2 TTCCTTGGAAAAAATTCTTTCTCGAGCTATCGACCAGGTTGGGC SEQ ID NO: Probe ID Reporter Probe Sequence

645 CTAAGC

588 NM 012092.2:6 GTAGTTAAGTCAGACTCTCCGTGGTCCCGGAAATAAGAGAATCT

40 TGCACT

589 NM 012242.2:7 CGCTGCGCCCAGAGCCATCATCTCAGAAGGACTCAAGAGGGAGA

5 AAGAAA

590 NM 012252.3:7 TTTGTAGCCACTTGATGTACTCCACTGATGCTTTTAGAATGGTT

33 CCTTTG

591 NM 012258.3:5 GCGTAGTTGTTGAGATGCGAAACCAGTCGAACTCGAAGCGGGTC

85 AGAGGC

592 NM 012340.3:1 GTTAGATGCAGTCTGTAAAGAGACGATTCTGCCACTGGACTCTG

815 GGATGT

593 NM 012342.2:1 CTTGTCTCATTTTATCACAGGTCAGACAGCAGTTCTCGTGCCCA

010 CT

594 NM 012435.2:6 CACGTAATCCGTCATGTCCGTGTCTCCGCCTGACGCGAAGGAGA

98

595 NM 013252.2:6 GCAGCATCAAATGTCTTTGTTAGGCCAATGGTCGCACAGTTGAA

15 ATTCTG

596 NM 013261.3:1 GGAGAATTGTTCATTACTGAAATCACTGTCCCTCAGTTCACCGG

505 TCTTGT

597 NM 013289.2 : 1 CACGTGGGTAAGTGCCACGTCAAGAGGGAGCCTCTT

691

598 NM 013351.1:8 AGCACAATCATCTGGGTCACATTGTTGGACGCCCCCTTGTTGTT

90 TGTGAG

599 NM 014009.3 : 1 CAGGTGGCAGGATGGTTTCTGAAGAAGGCAAACATGCGTGTGAA

230 CCAGTG

600 NM 014143.3:1 GAACTGACCCTCAAATTAGGGATTCTCAACCCGTCTTCCTAGGA

245 T

601 NM 014176.3:5 CTAGCTGACTGGCCTTCCTTTTCTGTGTTGAGTTGTGTACTCTG

95 GAGTCA

602 NM 014207.2:1 GTTCTCAGCATGGGATCGGACGGTTGCCGTGTGGTTGCGATGGA

295 AAGACA

603 NM 014261.1:5 GAGAGGTGGTATCTTCTACAGAAAGTTGGAGTGGCGTCTGGTCT

18 TTGACA

604 NM 014299.2:7 GTCTGCGGAGGAGTCGATGCTTGAGTTGTGTTTGGTACCGTGGA

45 AACGCC

605 NM 014358.2:5 TACATCCCAGAAGCTCAGAGACTTTGTCAAAGGTGTGCCGTCCA

70 CC

606 NM 014417.4:1 CGGGCTGGAGCAACCGGCAAACGAGCCCCACTCTCTGG

310

607 NM 014442.2:4 GGGCTGTCACAAACACAGACAGCTGCTTAGTTTTGTAATTCAAC

24 TGTGAT

608 NM 014511.3:5 ACGCAGTGATTCAACTGTGCATATGTCACCTCCTGAGGGT

92

609 NM 014729.2:5 GGAACTGTACTGAGTTCCTTCTGGGTTTCGTATATCTGGCATCA

74 CAGAAA

610 NM 014791.2:8 CATAGAAATCCGTTTCTTTGGGTCCACCTGCAGCATTTGTTGAA

00 GAAGCA

611 NM 014805.2:1 TCACAAGGTCATCCCAACCGGGCTCCATTTCAGTTGTGGCAACC

925 CGAAAC

612 NM 014905.3:9 GAATGCCTCTGTCCATCTACTGTACAAACAGACACACCCCACAA

85 ATCGGG

613 NM 014963.2:2 TGTCCCGCTTTCTCTTGGTGGACGGAAAGTGCTTCTGAATTAGC

002 GAC

614 NM 015091.2:2 TGCTTAAATCAGCTTTATCAGGCAAAAGGCTTATTCCCCTTGGT SEQ ID NO: Probe ID Reporter Probe Sequence

900 ATGGGA

615 NM 015177.1:4 CTAAGACCATGAAAGGGAAGGCATGGAATCCCCTACTTGGGCCA

820 GGAGAG

616 NM 015259.4:1 CGGGGAGCCCACTCACTTGGGGACATTTGCCTTTGGTGTGG

190

617 NM 015364.2:3 TATTCCCTTGAAGGAGAATGATATTGTTGTATTCACAGTCTCTC

60 CCTTCA

618 NM 015366.3:1 AGACAGAAATACAAAGTGACCAAGGCCAGTGACGAGGCCGATAG

635 GGCTGG

619 NM 015441.1:2 CCTCCTGCAAGACCCAGATGAAGAAACCTTTTCAATGGTCGAGA

920 TCTGAG

620 NM 015527.3:2 TCCAGTGCATGTCCCCTTAAATAAACTGGGTACAGGAGCATTAT

915 GGAAGG

621 NM 015714.3:7 AGTGCTGCACAGCAGCAAAACTCAATCCCAAACTCCTTTGGTGG

07 ATGCTT

622 NM 015850.3:1 TTCAAGATCTGGACATAAGGCAGGTTGTCTGGGCCAATCTTGCT

775 CC

623 NM 015869.3:1 AAAACCAGGAATGCTTTTGGCATACTCTGTGATCTCCTGCACAG

035 CCTCCA

624 NM 015900.2:1 TTCAGGTAAGCAGACCATCTTTTCTCTGTCATTGACAGGCAAAA

250 GGGCAG

625 NM 015991.2:7 AAGATGAGGAAGCCGCTGAAGACGCTGTCGGCCTCAGAGCCC

18

626 NM 016270.2:1 CGATCGCACAGATGGCACTGGAATGGCCGGTGGCC

015

627 NM 016343.3:5 ATGCTCAATGCTAGCTTTCTCCGATCTGATCCTACTCAGCTCAT

822 TTTCCA

628 NM 016382.2:1 GCTCTTTGCGGCTCAATCGAGCAGGGTTCTGGGCTTTAGGTTGA

150 CTCTTT

629 NM 016388.2:7 GGCATGCATAAGTGTAAGCTGTGAATAAGAGGTAAGCCACCATC

70 CCATCA

630 NM 016524.2:1 CCGCCCTTGACCAGGTCAACTTCACACAAAGGCACAGAAACTTT

150 CCCA

631 NM 016562.3:4 GTGTCTTTCTTTCTTACTGTTTCCCTATGGAACCCAGAAGCAGG

120 CCCAAG

632 NM 016610.2:2 GACTTCAGAAAGAAAGCCAGAGGGTAGGTGGGAAATCCTGTTAT

310 GACTCA

633 NM 016817.2:4 TTGAAGGCGGCCAGCACCTCGAAAGAGATTCTCTGATTTTTTGT

80 GAACAC

634 NM 017412.3:7 CATGAGCTTCGAACACTCACTGTAAGCCCGCTGACACAGCCTAC

72 GACAG

635 NM 017617.3:7 TCCACACAGGCACCCCCGTTCTTGCAGTTGTTTCCT

35

636 NM 017712.2:6 AGGCTCAGATGCCACAGGCCTTGGCAAGCAGAAAGCCTAATTCA

600 AATCCC

637 NM 017778.2:4 TGAGTTGAGGTGGTTGCTGAATTGTGTTTCCCATGATCCCTTGC

85 ATGAAA

638 NM 017970.3 : 3 AAGGCTCCAAGGGTTTGGCAGACCTGGTGATTGTGTCAAAAAAT

233 CTCCTG

639 NM 018063.3:2 GGCCACCAGCTCGTGTACTCACTAAGAAGATAAACACCTCTGGA

040 TCCGTG

640 NM 018131.3:5 TTCAATACGTCTTTCTCTTCAGATAAGGCTTTCAACACCTGCTC

70 CCTCCT

641 NM 018245.2:3 TGGTACACATGAGCTGTGGCTGCATTTCACACAGAAGCTGACAC SEQ ID NO: Probe ID Reporter Probe Sequence

615 ATCTCG

642 NM 018326.2:3 GGAGGTCAGAAGAATGCAGCGAATAATCTCCTTGGACGTTTCAG

15 CATTGG

643 NM 018404.2:4 ACTCCACAATACTGTCGTCCCAGAAGTCAAGTCGCACAGATTTA

05 ACTCTG

644 NM 018643.3:3 AAAACCCTTGGTCACCACCAAGCGGATGCGATCGAACAGCATGT

75 GAGGCT

645 NM 018664.2:7 CAGGGTGGATGAGAAGTCACTCCTGAGGGTGGCCT

70

646 NM 018685.2:1 CTGTTCTTCGCTGCTTTCTGCTAATGCTTGATCCATCTCCTCTT

900 GGCT

647 NM 018955.2:7 TTGGGGCAAATGGCTATAGTGCAGAGTAATGCCATCACTGGGCA

95 CTGCGA

648 NM 018965.3 : 6 GCAGCCCAGAGGGCGCTGGCTGCTAGAATCTTGATGAGAA

11

649 NM 019074.2:8 CCGAAAGACAGATAGGCTGTTGGCAATATTCCCCAGTCCAACCG

93 GGCAGG

650 NM 019111.3:3 CGTGAGCACAGTTACCTCTGGAGGTACATTGGTGATCGGAGTAT

35 AGTTGG

651 NM 020056.4:2 CTGTCTCATCATGAATTCCAAGGTGTGTTTTCCCACAGCCATAT

64 TTCTCA

652 NM 020529.1:9 GCCTCCAAACACACAGTCATCATAGGGCAGCTCGT

45

653 NM 020761.2:6 CGTTTGGTAAAATAAATAGATAATGAGCCTCTAGGCCGGCGCTC

665 TCTCGA

654 NM 020980.3 : 1 CATTTCATACAGATAGTGCAGCTGAAACCACCCAAATGGGACTA

502 TCGTCA

655 NM 021147.4:1 ACTTCTCGCAGATCTGAACGGGCAGCATGTGAGTCAAGGAAGTA

121 CTGTTT

656 NM 021155.2:1 TGCAAAATGAGCTCTTGCAACCAGTAAGTCCCCGATCAAAGGGG

532 TGCAGG

657 NM 021181.3:2 TGAGTCATTCTTCTTCAGTTTGCTGAGCTTCAGGGAGTAGCCTC

15 CATCTG

658 NM 021258.2:2 TTGTGAGTGGTGAGGCTGGAATTTGAGCCCAGATGGGCTGAACC

524 CAAG

659 NM 021602.2:2 ACAGGAGACAACGCCAGCCTGGCCATGGTCACCGC

4

660 NM 021642.3:6 GCAGCTTGACTGTCTGCAGAAGCCAGCAGCAGCAAAACTGTCAA

0 TGGTTG

661 NM 021798.2:2 CTGATCCCACAAAGCCCCGGAGATGCTGTGGACCAACTTGCAAC

080 AC

662 NM 021913.2:2 TCTCGTTCAGAACCCTGGAAACAGACACCGATGAGCCTCATGAC

190 GTTGGG

663 NM 021940.3:1 TGGTGCTTGTGAGGTAAATGGTATATTTGTGGGTCCCATAAATA

075 CACCAG

664 NM 022136.3:5 TCTATGATGTCTCCTTTCTTGATTTTGAGGGAGTCAGTGTCATA

60 GGGACT

665 NM 022153.1:1 CAGATTTAAACTGGCTCTTACAATCCATCTCCAGGGTTTGCACC

955 TGTTT

666 NM 022162.1:4 TGGAACTGCCTCTTGTGGGTCTATTTCAGAAGTCTGTTGTCAGA

080 GTTCAG

667 NM 022168.2:1 CCTGGCCCTGAAGCACGAGATGAGATAGCGGAAATTCTCGTCTG

85 TGGAAT

668 NM 022754.6:1 TCGAGTTGTTCGTTGGTTAACAGAATGTTCCTGGGGTCAGTTAC SEQ ID NO: Probe ID Reporter Probe Sequence

85 AGTGAA

669 NM 022783.3:1 GATACCCGGTTCTTCCACATTCAGTGTATAAAACTCAACTTTAG

497 ACATGT

670 NM 023068.3:5 CATAAAAAGTCAGATGTCACAGAGCTGTTTTCGTAGAGGCGGGC

165 AGGACT

671 NM 024013.1:5 GACCTGGTGTATGAGTCAATAAGAATTGTTTTCATGTTGGACCA

85 GATGTT

672 NM 024070.3:1 CACACACGCACACACAGAGACCACATCCGCAGCAGGTGGG

390

673 NM 024107.2:1 AAGGTGAAGGCGGCTAGGTGCCCATAAGAGAAGGCTGGCACAAT

485 CTTCAT

674 NM 024408.3:2 CAGGGCTTGGAGATACACTCGTCAATGTCAATGGTACACCGCTG

842 ACCTTG

675 NM 024494.1:1 GGGACATGCCATTCATCTTTGTCCCATCTAACTTTGGCCAGGTA

530 GAAACA

676 NM 024608.2:1 TGCACCTTCAGATATTGCCTGCTCCCAAAAATTCAGACCCCCAG

675 ATGCAG

677 NM 024626.2:1 AGTGAATCATTTGACCCATTACTAAAATGCAGCCGCCCCTGAGT

375 TGCGAA

678 NM 024689.2:3 GATCTCCACAGGGCGCCAGATTTTGGAATCATCTGAGTAATTTG

14 CAGGAT

679 NM 024756.2:3 CATGTGGTTACAGGGAAGCCACGTACACCACACCATCTTTGCAG

040 AAGG

680 NM 024827.3:2 TGTTGGGTGTGAATGGATGTTAGGTGCCTCGAGTCAGCGA

601

681 NM 024829.5 : 8 GCATGGCTGCATACGTGTACCAGCTTGAGTGAGCAAAAAGGATG

24 TTCTCA

682 NM 024908.3 : 1 ACATGTATCTTCCCGCTGGAATTACCTCCAGCCAAAATATACCG

875 AGTTGG

683 NM 025107.2:1 CCTCCAAGTACCAGCCCGATTGCCATGGATACAGTGAAGGACAT

59 GATAAG

684 NM 025216.2:2 CCTCCCCCCAGCAAGAATGTAACCTCCAAGAGGACAAGTG

255

685 NM 025217.2:9 TTGTTGGCAAAAGGAATCAAGGCAGTGAATGAGCTATTGGGTCC

05 ATGATG

686 NM 025239.3:2 AATAAAGCTGCTATCTGGTGAAGCTGCAATTCCAGGCTCAACAT

35 TAGCAG

687 NM 030761.3:6 TTGCTTCTCTCCCGCACATCCACAAACGACTGTGAGAAGGCCAC

25 ACCGTA

688 NM 030955.2:6 TTCACGGGTTCAATGAAAAAGTCTCCATGTGGTAGTTGGAAAAA

02 TCCAGT

689 NM 030964.3:1 TAGTGGGCAGGCGAGTCTGTGACTCAGTAAGAACCGAAGGACGG

900

690 NM 031866.1: 8 CTAGGTAGCCCACCGACACGAAGAGGTAGCAGGCCGAGAGGAAG

90 ATAATG

691 NM 031966.2:7 TGAACCTGTACTAGCCAGTCAATTAGGATGGCTCTCATGTTTCC

15 AGTGAC

692 NM 032043.1:1 GTCAGCATCTTGTATTAGTTCTCGGGCTGTGTAATATGGACAGG

130 CCTTTA

693 NM 032364.5:1 GTCACCTAGTCCCACCAGAAACCGCCATCCCAACTGTAGAAAGC

166 CCAAAA

694 NM 032427.2:1 CATAGGCAAGGTCCCTGACATAATCTGACTTTGTCCATTGTTTA

890 TTTGGA

695 NM 032514.2:4 CGTAGACCATATAGAGGAAGCCGTCCTCGTCTTTCTCCTG SEQ ID NO: Probe ID Reporter Probe Sequence

04

696 NM 032642.2:1 GCCAGAGATGACCTTGGACTTCTCATTTTAGGGAAGGAGCCGTT

745 CCTGTA

697 NM 032782.3:9 TGGATCTATGGCATTGCAAAGCGACAACCCAAAGGTTGTGAGGG

55 TTGCTG

698 NM 032963.3:2 CACTCAGTTCTCCTTCATGTCCTTGATATAGTCCTGGACC

74

699 NM 033035.4:8 CCTTTTTCAGGGAAAAGAGTTCTCCTGCTGCACTTTTGGATTTT

99 CCTCTT

700 NM 033119.3:2 AAACCACGCTTGTTTAAGTGGTTGGTTCCCTCCCTAGCAGTTTC

325 CAAAAT

701 NM 033381.1:5 GCTCTGGCGCATTGCTGAGGTACATCTGAATCTTCATGGTTACT

360 A

702 NM 033388.1 : 1 TGAAGCCATCGGCCCTGAACACCTGGCGGATGTTGCTGAC

586

703 NM 033423.3:7 GTTAGTCTCATGCCTGCTGTTAGAGGCGCTTCATTGTTCTCTTT

05 ATCCAG

704 NM 033439.2:1 AGGGATGGTAGGCCATGGACATGAGGGACAGTCAGTTACTGAAA

725 TTTTAA

705 NM 033554.2:8 AAGGGTCAGCAATTCAGTCAGCCACTGGAGTAGTTTTCACATGA

57 AGTGAG

706 NM 033642.1:6 TTCAACAGCACCTGGAGGTAAGGTTCTGTTACAGAGCCCTTCTT

20 TTGCCC

707 NM 033666.2:2 CCAACAGTCGTCAACATCCTTCTCCTTACAATGGGACACAGGAT

000 CAGGTT

708 NM 052902.2:5 GATTGTGGCTTAGGTTCAAGAAACGCAGAGCTGACAAGAGGCGC

65 AGGGAG

709 NM 052966.2:3 TAAGAAATTGATAGCAGGATGAGTAACAGGCCCAGACAGTCCCA

526 CAGATC

710 NM 053056.2:6 TTCACATCTGTGGCACAGAGGGCAACGAAGGTCTGCGCGTGTTT

90 GCGGAT

711 NM 057179.2:4 TTATTGTCCATCTCGTCGCTCTGCAGGACCTGGTAGAG

82

712 NM 058238.1:1 TAATTTGTGTCAACATCTGTCCCCACCGCCCCAGGGCCCAGCGG

535 CAGACC

713 NM 080792.2 : 3 GCATCCCAAGGCCAGGAGTCATGAACATTAGCGTCTCAACTCTA

115 AGA

714 NM 080921.2 : 9 ACAAATACATGGTCATATCTGGAAGTCAGCCGTGTCCCTAAGAA

0 ACAGCA

715 NM 080921.3:2 CTCAGAGTGGTTGTTTCAGAGGCATTAAGGTAGGCATCAGTG

58

716 NM 130386.2:9 ACTTTCTCCTTCAGCCAATCCGTGTCCTTCTTGGCTTGAAGAAA

00 AACCTG

717 NM 133487.2:5 TGTTCTGTAAAGGGCGGTGGCACTGTCTACAATAAGCAGTGCAT

66 ACCTAG

718 NM 138554.2:2 TTTTCCTCTTCAGATAGATGTTGCTTCCTGCCAATTGCATCCTG

570 TACCCA

719 NM 138761.3:3 GGGCCTTGAGCACCAGTTTGCTGGCAAAGTAGAAAAGGGCGACA

42 ACCCGG

720 NM 138981.2:4 AATGGAGGTGCTTAATGCCACACAACATTTGGTACAGCAGGTAA

50 GACATT

721 NM 144728.2:1 CATTGTCACACAACCGTCTCCACGCCCATCAGCTT

176

722 NM 145159.1:4 CAACCTCTGGTAACAAACGCTACGATTTGGTGACGACGCAGACA SEQ ID NO: Probe ID Reporter Probe Sequence

225 CCCTTT

723 NM 145259.2:5 TCAGACGATTTGCTAAGCAGGTTCCCTGGTGCTTTTGTGCAGAC

168 TCAAAG

724 NM 145333.1:6 CCTGTGAATTAGCGCTTTGGGTTGCATGCTGTGAAGATAAGCCA

70 CTCCTT

725 NM 145902.2:9 CCAGGGGAAAACTGCTCCCCACTCAGCCCATGGGAGCCCTGCAG

06

726 NM 145912.5:5 AAGGAATGGAGTGACGCCACTCAGCCTGGCTGGACTGAGCCAAC

290 G

727 NM 147162.1:4 TAGCGGGTGGGTAAACCGCTGATCTGGCTGGGACTCCAAGTGCA

00 AG

728 NM 147164.1:7 AATGGTGAACTCGTCAAAGGTGATAGCTGTGGCATTGTGGCCCA

84 GGGCAT

729 NM 147780.2:1 CATCATCTCTCCGGTGACGTGTTGGTACACTCCTGACTTGTAGA

054 G

730 NM 152275.3:2 TTGTTGCTTGAGGGCAAGACCAGATGATTGTCACTAGTAGGAAG

408 AAAGCA

731 NM 152456.1:8 CTGCCAGTTTAGGACGGAGCTTTGTTTACAGCAGGAGCAG

60

732 NM 152756.3:3 CTAGTAGAGCTGCTGCCAAACCGGTCATCCTCCAATATGAACAT

097 ACTCGA

733 NM 152852.2:1 GAGCCAACTAATATTTGTGAGAGTTCAGGAGTCATGGAGCCTTA

46 TGTGTG

734 NM 152866.2:6 CCAGGAGTGATCCGGAAATAATATACATAATGCCTCCCCAGAGA

20 GGGTAC

735 NM 152899.1: 1 CGTGCGGGTAGGCGGTGTGCTCGCCGGCAAAGTAGATG

452

736 NM 152942.2:2 CACTTAAGCTTCTTCTGGCCAATGTCCAGGTTCTGGTGTAACCA

030 CCTC

737 NM 153603.3:1 AAAAGCCGTCCAATCTTCCTGGAAGAGGGAGTTGGGAGGAATGT

492 GGTCCA

738 NM 156038.2:9 CAGCCTTGCCATAGCACCAACTTGATGTTCACCAGCTTTGTGAT

0 CTTGGA

739 NM 172174.1:1 CACACTGGCAGGAGCCTACCAGCATAGCTGTTGAC

685

740 NM 172195.3:1 TGCAGATCATCAGGGTCATCTAGCTCATTAGAGACAAAGGCATC

390 AGTCTG

741 NM 173343.1:9 GTGGTTAAGGGTGTGCCGGTTCCCAGAAACACCTT

05

742 NM 173799.2 : 1 TTCCTTGGCCCATGAAAGAAAATCAGTCACCAGTAAATCCAACC

968 TCCCCG

743 NM 175060.1: 1 AGTATCACCATCCTAAAGGCACTTCCACTTCCTCTATCATCAGG

930 GAAG

744 NM 175862.3:1 CATGAGCCATTAAGCTGGGCTTGGCCCATAAGTGTGCTCTGAAG

265 TGAAAA

745 NM 176894.1:2 AGGTAAGGCCAGAAAGGTAGGCAAGTTCTAGGGCCTTTGAGGCC

300

746 NM 178502.2:1 CTAGGTCCTTTCTCGGCTTGGTCGTGGAGCACAGCACATACCAG

620 AAAAAG

747 NM 181501.1: 1 CATTTCTCCGTGGATAGACTGGCCAAAAAATTTCAGTGTCTTAC

875 CATCCC

748 NM 181504.2:1 GCTCTCCCGGACAAGAAAAGTGCCATCTCGCTTCCCTCGCAACA

105 GGTTTT

749 NM 181755.1: 1 TCTCTTCCGATCCCTTTGCTGGCCCCTGTGACAATCACTTTCTT SEQ ID NO: Probe ID Reporter Probe Sequence

55 TCCT

750 NM 181780.2:3 TGTTGTTCCATTGAGCTTGCACCAAGTCACATGAGGCCTGTTAG

05 CACAGT

751 NM 181803.1:2 AAATTAAAAAGACGACACAAGGACAGGCTGGGCAGCCTGGGTCA

69 GGGCTC

752 NM 181879.2:5 CTCAGTCAGAATGAACCTGTCGAATCTCAGCCGTGAGCCACACT

45 GGAGGG

753 NM 182398.1:1 TAGGTCATAGTGTTGATAGAATGGAGAGTCCTTCATCATTGCAC

390 TCCTGG

754 NM 182471.1:2 TTGACCCCAAGCCAGGGTTGGGAGTCCTCTGGGCATCCATTTTT

105 TCTAAA

755 NM 182795.1:7 ACAGGGCTCTTGTCTCTAACGCTGGCTCTTATTTCCTC

45

756 NM 182797.2:9 CCGCCGAACTGTCTGCCAGTGAGATAAGTGTTATGGGAAGAACT

94 GATGAA

757 NM 182906.2:4 AAATCTGTTCTCAGGGTCACCAGGTCCCTCTGAAATTTGGAATT

30 TTGGAA

758 NM 182948.2 : 8 GCCCACCAATCCACTGCCTTATTGTAGCCCTTGCTGAGAATTAT

05 TTCTGG

759 NM 182962.2:2 TCTGAGACAGGAACCCCAGCAGGAAAAGTGGAATACGTAGACAT

75 TCGGTA

760 NM 184041.2:1 TTATTTGGCAGTGTGCCGGAAAGGGTGATGGACTTAGCATTCAC

455 AGACGA

761 NM 197954.2:5 TTGGGAGCTCTTTTCTTTCTGCTCCTGAGATGACTGTCTGTGGA

5 CAAAAG

762 NM 198053.1: 1 AGAAAAAAAGCAGAGCAGAGAGCGTTTTCCATCCATGGCCTGTG

490 CCCTGT

763 NM 198282.1:7 CCCGTAGCAGGTTGTTGTAATGCTGATTGTAAGTTCGAATCCGG

25 GCCTGG

764 NR 001434.3:2 CGATCCGCAGGTTCTCTCGTTCAGTCCGTGCTTGG

20

765 NR 003085.2 : 8 TGCAGACCTTTGCTGGGTCACAAGGCCGCCGGTTGATAAAGAAA

92 AACTGT

766 NR 024115.1:2 TTCTCATCCTGTCCAGTATCAGTACTTATAAACCCCGTCTGTAG

175 GAACAG

767 NR 026800.2:9 AGAAATTCAAACCAAGCTGTGGGTACTTGTTACCACTGGGAAGG

125 GAGTCG

768 NR 029467.1:1 AGCCAGTTAAATAGGATGGTCCAATTCACAGACGGCGAGGCTAC

585 AGTGCA

769 NR 049726.1:5 GGTACACTAAGCGCCAGAAACTGGAGTCTGAGGATCGGTATCGT

43 CCATCA

770 NR 104213.1:4 TTGTGGAAGAGTTGCTGGATCCTGCTGTTCTGAGC

75 [061] Table 2B

SEQ ID NO: Probe ID Capture Probe Sequence

797 NM 000179.1 : 3 TCAGCAGGGACGTAACAACCCATCTGGGCCATTACAGCTAATAA

525 GCCAGC

798 NM 000188.2:3 ACACACGATTTTGTGGCATTGACACACCACGATGCGATGCCAGG

355 CCACAG

799 NM 000189.4:6 TTTACACAAAGCAAAGCCATGTCAGCAAGGGACTGTCAACCTGA

880 TTCTGA

800 NM 000201.2:2 TAAGTCTGTGGGGCCTCAGCATACCCAATAGGCAGCAAGTTTCA

253 G

801 NM 000206.1:5 GCAAGGAGAACTTATGTCTATAATCCACTGATTGTTCAGTCCAG

95 CTGTGG

802 NM 000210.1 : 3 AGCCTGATATTTTCGGCAGCAGCAGTCACATCAATGAAGGCTCG

065 CATGAG

803 NM 000211.2:5 GGTCATCAAGCATGGAGTAGGAGAGGTCCATCAGATAGTAC

20

804 NM 000212.2:4 GGTGAGACAGGGCTCAGTCATTGCCCCATATCTAATTCCAAGGC

485 TTATTC

805 NM 000214.2:5 CATCCCTCTGTCAGGCAGAGCCTATTATACCCCGATTACCAGAA

766 CAG

806 NM 000215.2:1 AATGACTCCATGCAGTTCTTGTGCTTGGCATCCATGACCTTCAG

715 CAG

807 NM 000222.2:2 GGGGCTGCTTCCTAAAGAGAACAGCTCCCAAAGAAAAATCCCAT

644 AGGACC

808 NM 000228.2:3 CATACTTTTGTTTTATTCTCTCAAATCCCTCTTGGGCACTCAAT

350 GCCTGC

809 NM 000235.3:1 CTGGTTGTAATGAAAATAATTCTTGGCACTGCTTCCCCAGTCAA

220 AGGCTT

810 NM 000239.2:3 ACTGCAGGATAAATGACAGGCATTAACTGCTCCTGGGGTTTTGC

05 CATCAT

811 NM 000249.2 : 1 CCCACGAAGGAGTGGTTATGCAACATCTCCCGGAGAACCTCATG

605 TC

812 NM 000251.1:2 GGCACAAAACACCCAATTTGGGCCATGAGTACTATCACCCCAGT

105 TTGTCG

813 NM 000264.3:5 CATACCCTGAGGTTCCAGCATCCATCACAATGATCCGAGAGAAG

420 GAGATT

814 NM 000289.5:2 ATCCAGTTCATAGCCTTGGCGCCCATCTTAGTGGCAAAATTCCT

195 ATCAAA

815 NM 000295.4:7 ATCGTTGATCTGTTTCTTGGCCTCTTCGGTGTCCCCGAAGTTGA

60 CAGTGA

816 NM 000300.2:7 GAGGGTATGAGAGAGGGAAATTCAGCACTGGGTGGAAGGTTTCC

15 AGGGAA

817 NM 000314.4:4 AAAGTGATGCCTTCAAGTAACTTCAGACATGTAAGCTGCTGCAC

830 ATCCAA

818 NM 000321.1:2 TGGGTGCTCAGACAGAAGGCGTTCACAAAGTGTATTTAGCCGGA

110 GATAGG

819 NM 000325.5:1 GCACCGCGGAATTCAGCGACGGGCTACTCAGGTTGTTCAAGTTA

381 TTCAGG

820 NM 000361.2:1 TGGCACTGGTACTCGCAGTTGGCTCTGAAGCACGG

246

821 NM 000362.4:1 CATGTCGGTCCAGAGACACTCGTTCTTGGAAGTCACAAAGCAAG

640 GCAGGT

822 NM 000365.4:1 CTAGGGCCTAGGGAACCCAGGAGCAAATCCCACCACGCCTTCCA

020 TCTCTC

823 NM 000366.5:8 TCCTTCAGCTTGTCGGAAAGGACCTTGATCTCTTCCTCATATCT

42 GT SEQ ID NO: Probe ID Capture Probe Sequence

824 NM 000389.2 : 1 CCCTCGAGAGGTTTACAGTCTAGGTGGAGAAACGGGAACCAGGA

975 CACATG

825 NM 000395.2:3 CAGCCCACACAAGTCCTCAACACAACCAGCCGCATC

300

826 NM 000397.3:2 TGGCAGGAGGTTAATTCTCCACCTCCAACCCTCTTTTTTCATGC

686 TTCAAA

827 NM 000402.2:1 CTCAGTGCCAAAGGGCTCCTTGAAGGTGAGGATAACGCAGGCGA

155 TGTTGT

828 NM 000417.1:1 TTCACTTGGGCTTCATGACTTCTGTTGTCTGTTCCCGGCTTCTT

000 ACCAAG

829 NM 000435.2:1 GTTGGCAGACACAGTCGTAGCGGTTGATGCCATCACGG

965

830 NM 000442.3:1 TGGACTGTGTTGCTTTTCTTGACCACTTTGTCAATACCTGCAGT

365 G

831 NM 000450.2 : 1 TTCAAATCCCTCCTCACAGCTGAAGGCACAAGAGGACTTGTAGG

505 TGAATT

832 NM 000474.3:1 CGCTGCCCGTCTGGGAATCACTGTCCACGGGCCTG

151

833 NM 000491.3 : 8 AGGAACCCGGAAAAGATGCTGTTGGCACCCTCCATGCCCAGTAG

19 T

834 NM 000493.3:1 CCTGTGGGCATTTGGTATCGTTCAGCGTAAAACACTCCATGAAC

35 CAAGTT

835 NM 000494.3:5 GATGGCACAGCCTTAGAACAGTAACCAGAACACACCCCCATCAA

070 GTGTCA

836 NM 000507.3:5 GGCGTGTTTATCTTCTTCTGACACGAGAACACACGTGGCAAAGG

90 ATGACT

837 NM 000537.3:3 AGAGACGGCTGCACTTGGAGGAGGGCACCCAAACATTGGACGAA

55 CCAGTG

838 NM 000544.3:9 CACCACTTTCACCAGGCTTCGCAAGAGCACATTGGCATTTAAAG

09 GAAGCC

839 NM 000545.4:2 CTCCTACATCTGCCATGAACAGGCTTTGCTCCTAGCT

125

840 NM 000546.2:1 TAGACTGACCCTTTTTGGACTTCAGGTGGCTGGAGTGAGCCCTG

330

841 NM 000551.2:1 CTCAAAGAGGAGAAAGACTTGTCCCTGCCTCACGGATGCCTCAG

280 TCTTC

842 NM 000565.2:9 GAACTTGCTCCCGACACTACTGGCGACGCACATGGACACTATGT

93 AGAAAG

843 NM 000566.3:1 TATTGTCTATACTATTCCCTCTTGTCTCCCTGAAATCTACCCAC

545 TCCTGG

844 NM 000569.6:1 TTCTGATAGAGTCCCCTGGAAGACTCAATTCTACGTCACCCTCA

644 TGATTT

845 NM 000572.2:2 AAGTCCTCCAGCAAGGACTCCTTTAACAACAAGTTGTCCAGCTG

30 ATCCTT

846 NM 000575.3:1 TTTCAGAGATACTCAGAGACACAGATTGATCCATGCAGCCTTCA

085 TGGAGT

847 NM 000576.2:8 GACACAAATTGCATGGTGAAGTCAGTTATATCCTGGCCGCCTTT

40 GGTCCC

848 NM 000577.3:4 TCAGCTTCCATCGCTGTGCAGAGGAACCAACCGGGG

80

849 NM 000578.2:1 GATGAGGACACTGAGACCCAGAGGGTAATCACATGGCTGCGCTA

965 GGAAAC

850 NM 000579.1:2 GGTAATCAATCCTCACCTAGATCTCATGTGTGAGCTGAAGTATG

730 TTCCTA SEQ ID NO: Probe ID Capture Probe Sequence

851 NM 000582.2:7 CTGACTCGTTTCATAACTGTCCTTCCCACGGCTGTCCCAATCAG

60 AAGGCG

852 NM 000584.2:2 CCGGTGGTTTCTTCCTGGCTCTTGTCCTAGAAGCTTGTGTG

5

853 NM 000586.2:3 TTTGTGACAAGTGCAAGACTTAGTGCAATGCAAGACAGGAGTTG

00 CATCCT

854 NM 000587.2:3 CTCTGTTGGACATCCTCTTGTAGGTTCACAGGACTGTGTTTCAA

10 AAGCAT

855 NM 000589.2 : 6 TGCTTGTGCCTGTGGAACTGCTGTGCAGTCGCACC

25

856 NM 000591.2 : 8 GGGAAGGCGCGAACCTGTTCGCAGGAAAAGGCAGGCGAGTGTGC

85 TTG

857 NM 000593.5:2 TCTTGAAGACTTCTTCCAAATACCTGTGGCTCTTGTCCCACTGC

075 AGCCAC

858 NM 000594.2:1 CAGGCCACACATTCCTGAATCCCAGGTTTCGAAGTGGTGGTCTT

010 GTTGCT

859 NM 000600.1:2 CCTTTCTCAGGGCTGAGATGCCGTCGAGGATGTACCGAATTTGT

20 TTGTCA

860 NM 000601.4 : 5 ACTCTTAGTGATAGATACTGTTCCCTTGTAGCTGCGTCCTTTAC

50 CAATGA

861 NM 000609.5:2 GGCACAGTTTGGAGTGTTGAGAATTTTGAGATGCTTGACGTTGG

10 CTCTGG

862 NM 000615.5:1 GCTGGCCATCCCGAAACCATGAGATCGTGGCACTG

620

863 NM 000616.4 : 9 AGGTCAAAGGTGATCCAAGACTTGGAGGAGGAAGCCCTCTCCGC

75 C

864 NM 000619.2 : 9 CTGGCTCAGATTGCAGGCATATTTTCAAACCGGCAGTAACTGGA

70 TAGTAT

865 NM 000625.4:1 AGCTGAGCATTCCACACCCGGAAGTCGTGCTTGCCAT

005

866 NM 000627.3:1 TACCCTCCTCACTGGCCATAAATCCTGCTGGGCAAATGCACAAG

970 AAACTT

867 NM 000632.3:5 TCAATCAAGAAGGCAATGTCACTATCCTCTTGAGGACACCCTCG

15 GAGGGC

868 NM 000638.3 : 1 CAGAGACAGGGAAGGAGGGCACTGGAGAAGAGGAACTGCCTTTT

2 CTGCTG

869 NM 000639.1 : 6 CCAGAAAGCAGGACAATTCCATAGGTGTCTTCCCATTCCAGAGG

25 CATGGA

870 NM 000641.2 : 1 GCCCTCAAGTGGATATGTATGACACATTTAATTCCCTGTTCTCT

145 GTCTCA

871 NM 000657.2:9 GGGCGACATCTCCCGGTTGACGCTCTCCACACACATG

47

872 NM 000660.3:1 ACGGGTTCAGGTACCGCTTCTCGGAGCTCTGATGTGTTGAAGAA

260 CATATA

873 NM 000675.3:1 GTAGATGAAGGGATTCACAACCGAATTGGTGTGGGAGAGGACGA

095 TGGCCA

874 NM 000700.1 : 5 AGATCTCTCTTCAGTTCCTCTCTGTAGACCCTGTTAATGTCTCT

15 GATTTC

875 NM 000732.4:1 GAGAGAAACGTGCTATGTTCCATCTCCCAGCGGAACTCATCCAG

10 TAGATA

876 NM 000733.2:7 ACTCTCCAGTGAGTGCCCGACTGCATCTTTGTTTCATGGGACTG

5 TTACTT

877 NM 000757.4:8 TAAAGACATTCTTGACCTTCTCCAGCAACTGGAGAGGTGTCTCA

23 TAGAAA SEQ ID NO: Probe ID Capture Probe Sequence

878 NM 000873.3:4 TAATGTTTCCACTGAGCCTGTTCGTCCAGCAGAATCTTATCTAG

15 AGAGG

879 NM 000875.2:4 TGGAGAGGTAACAGAGGTCAGCATTTTTCTCAATCCTGATGGCC

55 CCCCGA

880 NM 000876.1:2 TTTTTCATACTTCATCTGGCAAGCCGATGCATATCGGTTGCAGC

605 CCGGCA

881 NM 000877.2:4 AGCTGCCATTCTACTTGTAATTCTTGGTCATCATCACCCCCACT

295 CT

882 NM 000878.2:1 AGTTACTGCCCCCCTGCAACACACACAGTTCCTGG

980

883 NM 000885.4:9 TCGCCCCGGGATTGATCACTGAAGCGTTGGCGAGCCAGTTG

75

884 NM 000887.3:7 GTGTATGTAAACCCTTGCAGCTGGTGAACAGAAGCCAACAGGCT

00 GAGGG

885 NM 000902.2:5 TAGGGCTGGAACAAGGACTCTTTTCTCTGGACAGCTTGCACCTA

059 CAATCC

886 NM 000920.3:2 TGCCATTCTCTTTGGCCACTTCACAGAACTTGAAGACCACGTTG

055 TCTG

887 NM 000922.3:1 GTCCATGGTTGGAAGAATTCACAGGACTCAGACTGGACAAAACA

870 CCAGCT

888 NM 000937.2:3 ACTGGCCCAACAGGAAGACAGTAAGCGAAGGAGTCTTTGGCTTC

775 TTGGAA

889 NM 000944.4:3 TTTGAGACACAAATCCACCAAGATTCTTTCTTACAGTGGAAGTA

920 GGCACC

890 NM 000958.2:9 GCATAGACTGCAAAGAGCGTGAGGCCCGCCAATCGCTTG

76

891 NM 000963.1:4 GGCTCTAGTATAATAGGAGAGGTTAGAGAAGGCTTCCCAGCTTT

95 TGTAGC

892 NM 000972.2:6 TTCACCACTTTCTTAGCCTCCTGCTTCTTCACGACAGCTG

6

893 NM 001001392. CACGAGGCAGAGTCCCCAGGCTGCGTGCCACCAAAACTTG

1: 429

894 NM 001001523. TGTTCTACTTTCCTTTTCTCTTGGAGCCCTGGCCGATGGGCATT

1: 1350 GATGAG

895 NM 001001548. AAAGAGACTGTGTTGTCCTCAGCGTCCTGGGTTACATTTTCCTT

2:705 GGCTAG

896 NM 001002273. CATGAGAAGTGAATAGGTGATTGTGTTCTCAGCCCCAACTTTGT

1:870 CAGCCT

897 NM 001005291. ACTTAGGTTCTCCTGCTTGAGTTTCTGGTTGCTGTGTTGCAGAA

1: 1392 AGCGAA

898 NM 001005731. CTGGGCGTCCACGATAGGGATGTCAGGGATGATGGGGATGGACA

1: 4151 TG

899 NM 001012662. TGCACCAGCGATTGCCAGTGGCATTCAAATACTGTGTGACTAGG

2: 1505 GATTTT

900 NM 001014432. TGATCCCCTCCTTGCACAGCCCGAAGTCTGTGATCTTAATGTG

1: 1275

901 NM 001024736. GGAAGAAGAGGGTGGTGATGTGGTCAGTGTACTGTGTCCCTAAG

1:2120 AAATGT

902 NM 001024847. AGCCATGGAGTAGACATCGGTCTGCTTGAAGGACTCAACATTCT

1: 1760 CCAAAT

903 NM 001025159. TCATGGGATGAGGTACAGGGTGGGAGATGGGGGAG

1: 964

904 NM 001025366. TGGCCTTGGTGAGGTTTGATCCGCATAATCTGCATGGTGATGTT

1: 1325 GGACTC SEQ ID NO: Probe ID Capture Probe Sequence

905 NM 001031683. GTTATCAGGACTCAGCTCAATGGCCTGCTTCAAAACATCAGTAG

3: 712 AGAACT

906 NM 001031709. GCCCAAGGGACATCAATCTTCGTACCAGCTTCATAAAAGAGGCC

1: 605 CAGAGC

907 NM 001032409. TTGAAATGTGTTTTCATGCTCCCTCGCTCCCAAGCATAGACCGT

1: 805 C

908 NM 001033044. CTCTGTCAGTAACATGCTCAAGTTGACCAGCCAACTCTTATCTC

2:2645 TAAACC

909 NM 001033667. AGAGCATTTTTGGGACCAATCCAGATGACGTTCTCAATCTCTGT

1:260 GTCTAC

910 NM 001034.1:1 TAAAGGACTGTTTAATCCCGCTGTGCTAAGCTCACTAAAGGGTC

615 ACCCCT

911 NM 001039664. GGCACAGTCACACCTGGGGCTACGAGTGCCGCCCTG

1: 151

912 NM 001040168. GAAGTGGACAGGACGCACCTTGTTCTCGCTGACCCGCT

1: 717

913 NM 001050.2:1 AGACTTCTTCCTCTTAGAGGAGCCCACTCGGATTCCAGAGGACT

060 TCAC

914 NM 001065.2:5 TGGTTTTCTGAAGCGGTGAAGGAGCCGCTCTCACACTCCCTG

15

915 NM 001066.2:8 CAATCAGTCCAACTGGAAGAGCGAAGTCGCCAGTGCTCCCTT

35

916 NM 001071.1:5 GTGTCAATCACTCTTTGCAGTTGGTCAACTCCCTGTCCTGAATA

55 ATCTGA

917 NM 001078.3 : 2 GGACATAGATGGGCATTTCTTTCCAAGTTCAATACATTCAGGGA

535 AGTCTG

918 NM 001079.3 : 1 CTATGAGGAGGTTATCGCGCTTCAGGAAGAGCTTCTTGTCCTTG

175 AGCTCC

919 NM 001079821. CTGGCATATCACAGTGGGATTCGAAACACGTGCATTATCTGAAC

2:415 CCCACT

920 NM 001090.2:8 CCAGCTTGATGTCAGATGCATTTTCTAACATGGCTTGGCGGGAG

50 GACATC

921 NM 001098175. TTTCCTATGGGCCTCTACTGAGAGCATGGAGGTAATACATCTAA

1:8830 TACACT

922 NM 001098210. TGGCACCCTGCTCACGCAAAGGTGCATGATTTGCGGGACAAAGG

1: 1815 GCAAGA

923 NM 001098479. GAAGCGCTGGGTGATCTGAGCCACGGTGTCCGCCG

1: 575

924 NM 001099692. AGTGTGGAAATGAGTTTGCCCTTTTAAGGGAAAGAACAGCTTCT

1:2600 GGCCCT

925 NM 001100812. TGTCCACATTCTTTGAGATCAAGACAGCTCATCAATTCCTGAAC

1:850 CCATGG

926 NM 001113755. AATCCAGGAATAGACTCCAGCTTATCCAAGGTGCCTCCTGTGTG

2: 645

927 NM 001114614. AGGCGGCGATCTGTGAGTTGGCAATGTTCCCATTC

1: 328

928 NM 001114937. CTGTTTCTGTCTGGGACACTCGGTATGTATAAATGTAACCGTGA

2:495 TACAGC

929 NM 001123041. GCAGCAGAGTGAGCCCACAATGGGAGAGTAATAAGAAAAAGCAG

2:743 ATCAGA

930 NM 001127500. AAATTTATTATTCCTCCGAAATCCAAAGTCCCAGCCACATATGG

1: 1925 TCAGCC

931 NM 001128128. GAACTGGTTGCCTGTAATGGGCCACCACCAGTGAAAACCCCATT

1: 1450 TTGTAA SEQ ID NO: Probe ID Capture Probe Sequence

932 NM 001130852. CGCTGCAGGTGAGGTCAATGGTGGTGCGCAAGGCCAGGG

1: 623

933 NM 001134836. GTGCCTGCATCCTCACTGGAGACGTTTTGCAGAAGAATGCTGAA

1: 600 GTCATT

934 NM 001142593. GAAGATGGACTCACGGTCTGATGTGCCTGCGGAGAAGTTCTTGA

1: 805 GTG

935 NM 001142633. GGTCCAGCGTTAGTGCTGTTTTTCTGGAGACTCAGGAAACTTGA

1: 3335 GAGAAA

936 NM 001143836. GGTCCACAACAGAAAACACCAACTGTTTTTCCTCTGTTATATTT

2: 1795 TGCTAT

937 NM 001145144. CCCAGCTTCCGCAGCGCCACACCAAAGACGATGGCAAACACTAC

1:180 CAAG

938 NM 001145646. GGCGATGGTGAAGACATAAAGGGCGAGCGCAGGCCCGAAGGCAA

1: 102 TGAAGG

939 NM 001145648. TTCTTGAAGACGAGGTGATCTAGCAGGGTCAGCTGCT

1: 3444

940 NM 001146.3:2 CGGCTCCAGATTCACGGTCAAGAACCTTGGTGACTTCACATAAC

080 TACCAC

941 NM 001147.2:1 GATGTTTAGAAATCTGCTGGTCGGATCATCATGGTTGTGGCCTT

775 GAG

942 NM 001159488. AGCATGAGGACCTAATCCAGCTATTTGAAAAGAGATGTACTCTT

1: 14 GGTCAC

943 NM 001163771. ACGGGCACCAAAGATGATCACTCCATGGGTGTCCAATACTGGAC

1: 760 GAGCAC

944 NM 001164239. ATTTAGCAGAACCAGGTGGTCACCGCCAGGGAGAAAGAAGTTGA

1:2490 CACGGG

945 NM 001164759. TAACGCTGAATGTTCCTCTTGAGGATCTCAGAGCAGGGCC

1: 1112

946 NM 001165414. CTGGGAAAAAATGTTGGACTAGGCATGTTCAGTGAAGGAGCCAG

1: 1690 GAAGTT

947 NM 001171653. GCAGAGCAGGTTAGAACTGATCTCTTTCGGCCACTCCAGGAAAC

1:240 ACAAAC

948 NM 001172.3:1 TGTCAGTGCACAGTGTCTCCTAAATTCTCACACGTGCTTGATTT

150 TCTGAT

949 NM 001172085. GCACGAAGTGCAATGGTCTTTAGGTCAAGTTTACAACCAAGATT

1:587 CACTGT

950 NM 001172698. GTCTTGAGCCAGAAGTTCCCTCAGAATGGAGAACTCAGCC

1: 974

951 NM 001174097. CTGACGGACTCCTGCAGTTACCACTACAATCTTAGAATTGGCGG

1:586 TCACAG

952 NM 001178091. AATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAGGGCTTTG

1: 946 GTAGG

953 NM 001184879. TCTTTCAGGGTCTAACCTTCTGTGGAAAAGCACGGCACTGTTCT

1:28 AG

954 NM 001185177. ACATTGATGAATACGTCACCCATGAATTCCTGGAACGCCTGGCA

1: 1288 TTTGGC

955 NM 001190709. TTTTCACCTTTAGATCCCTTGAGACCTCTGACACCATCTG

1:2490

956 NM 001190848. CTCTGAGAGCGTCTTCTGACCGGATATAGGTTACATAAGCACTG

1: 795 GCACTT

957 NM 001191.2:2 TGAGTCTCGTCTCTGGTTAGTGATTCTCTTCTAAGATCCAAAGC

60 CAAGAT

958 NM 001192.2 : 6 AGAATGGTTGCGCCTTCCTCCATAGCTGGGAGTGGAAAGCAATG

35 GT SEQ ID NO: Probe ID Capture Probe Sequence

959 NM 001193300. TAGACGACCTGGGTCGAAGGGATGGCTGCCACAAAGGAGGCGTC

1: 935 ATGATG

960 NM 001196.2:1 CTGTTCACAGCAATGTGTGTGATATGGACCCAGCATCCACTG

875

961 NM 001199140. GAGGGAATGTGCAGGGAGTAAGGCTTCTTCACTCCAAAAACCAC

1: 3564 TGAGCC

962 NM 001199723. AATGGGTGATCTGGGCTCTTGCAGCCATTCCTCTT

1: 802

963 NM 001200.2 : 1 TATCTGTGACCAGCTGTGTTCATCTTGGTGCAAAGACCTGCTTA

515 TCCTAA

964 NM 001202.3:6 TCTTCCTCCTCCTCCCCAGACTGAAGCCGGTAAAGATC

59

965 NM 001203.1:4 AGAAGTGACCACAGGCAACCCAGAGTCATCCTCTTCTATCATCG

30 TGAAAC

966 NM 001204318. TTTCATACAGGAGCGTGAACCAACCAGTTTTTAAGTCAATCAGG

1: 563 GTAGGT

967 NM 001220.3:3 AATGCTTCAGAAGGCGGCAGATCCGAGCCTCTCTCT

65

968 NM 001220488. GCACGCGGCTGCACTGAGCATATTTTCCGTGGGAG

1:210

969 NM 001235.2:8 ACACCCACGGTATAGGACCGAGTCACCATGAAGCCACGGTTG

80

970 NM 001238.1 : 1 AAGTAGCACCTTCCATAGCAGCATCGGGAGCACGCAC

635

971 NM 001242.4:3 TATGCTGGTCACAGTCCTTCACGAGGAATGTTCCTGGCTCACAC

30 A

972 NM 001243078. ATTCCAAAATACTTTCCCATGTGAATGGACCTCCAAGGTACAGG

1:2065 AGCAGC

973 NM 001243266. TCAGCATAGATTTCTGGAGCATTTGTCTGTTGATCTTTTGGTGG

1: 692

974 NM 001244.3:5 CCTTTTCAGGATACATAAGAGGTCTTCTGAGCAATTTCCTCCTT

18 TGAGGG

975 NM 001250.4:1 ACTATCACAAACAATGCTGCAATGGGCATCTGTGTATATGGCTT

265 CCTGGG

976 NM 001251.2:1 GAGGCCAAGAAGGATCAGGCCGATGATGAGAGGCAGCAAGATGG

140 AC

977 NM 001252.2:1 CAAGCCCGCGACCAATGGGACCAAAGCAGCCCGCAG

90

978 NM 001255.2:4 CCTCTACATCAAAACCGTTCAGGTTCAAAGCCCAGGCTTTCTGA

30 TGTTCC

979 NM 001256600. GGAAGACAGACACGGGAGAAGGAGCAGGGCCACATGGTAGGAGA

1:2508 G

980 NM 001256741. GAGTAATGGCATCAGATATTCTGTCGAGAGAGATGAGGGCTTCT

1: 1962 GCAG

981 NM 001256841. AGTTGTGATTGTTGAGGTCTTGGCCGCAGTGATACTTG

1: 370

982 NM 001259.6:2 TGAGGAAAATTTCAAGGCCACTCCTGTCTCTAGTTAGAGAGAAC

404 TACTCT

983 NM 001267.2:8 CGTGGTTACACCCAGGAAGGCACCATCTGAGAACTTCTCCAG

10

984 NM 001278.3 : 8 CTGAGGGTCCCAATTCAACATCAACTGTAGCCAGTTTTCCATGG

60 GTTCTA

985 NM 001278405. TGATGGATGGGATGTGGAACTGGCCGTTCTTCACAAGCTCTGG

1:256 SEQ ID NO: Probe ID Capture Probe Sequence

986 NM 001284244. CACTGAACCGCTTCTGATTGGCCAACTTCCTGGCCGACTTCCG

1:416

987 NM 001287582. AGAGTTCCCTGAACCAATACAAATCTCTATGCAACTCAAGGCTG

1: 1944 CCTTAT

988 NM 001289.4 : 5 CCAGTCTCTTCTCTCAAGAGGTGTGACGCAGAAAATTCTAGATG

0 CTTAAG

989 NM 001335.3:1 GGCAGTGAGCGGGAACTTGGTGATGCCACAGGTATTGCT

075

990 NM 001337.3:1 CTGCTCCTTTGTGATTCAGATGAGGAGAAATCAACGTGGACTGA

040 GCGCCC

991 NM 001343.2:4 AGTGGACACTTGGTGACACCAGGCGATCCCGATGGAGAAGTCTC

50 AAATAA

992 NM 001379.2 : 1 GCCATTAACACCACCTTCAAGAGATGGGTCATCATCATAGATTG

495 GTTTTG

993 NM 001406.3:2 GGCCAACCTGGTGCCCAACAACAGCTTTGATCTAATAAAACTGA

935 GCTGGG

994 NM 001428.2:1 GACACGAGGCTCACATGACTCTAGACACTTGGTGGAAAGTGAGG

689 CGAGAA

995 NM 001429.2:7 CATGCTATTTATCAAACCTAATCCAGGACTGCTCTGTTGGGCCT

15 GGCTGG

996 NM 001448.2 : 8 TACGGGCTGCTACAAAAGCACGAGTAACCTGGAGCTTCAATTTG

20 CGAGGG

997 NM 001504.1:8 TCCAGGAGGGCGGCAACCTCGGCGTCATTTAGCACTTGG

0

998 NM 001511.1:7 CTCTATCACAGTGGCTGGCATGTTGCAGGCTCCTCAGAAATATT

42 AACATA

999 NM 001530.2:1 TCTAATGGTGACAACTGATCGAAGGAACGTAACTGGAAGTCATC

985 ATCCAT

1000 NM 001546.2:5 TTGCTGACTTTCTTGTTGGGCGGGATGGTGGGCAC

88

1001 NM 001547.4:1 ATGAACTTAGCACATTACTGGCTATGCAGGACTAACCTCTATGG

995 GATGCA

1002 NM 001548.3:1 TGTAGACGAACCCAAGGAGGCTCAAGCTTTCCAGATCTAATGCC

440 TTTCTC

1003 NM 001556.1:1 AGCGCCTTCTGCTTGCAAACCACAGTTTTACTGAGCTGCGTATA

995 GATCAC

1004 NM 001558.2:1 GATGTGGTGGAAAAATTCTGCTTCAAACCACACAGACGGAGGGC

50 TGGGCA

1005 NM 001559.2:1 CATCTGCTCACAGAAGCCTTTTGAAATTTGATTCTAATGTCCCA

315 CGGAGG

1006 NM 001561.4:2 TTGTCCACCTGCGCTGGAGAAACTATTTGGAGGACAGGGACTGC

55 AAATCT

1007 NM 001562.2:4 GGCAGCCAGGAGGGCAAAATGCACTGGGAGACAATTCCTTGCTG

8 ACTGTC

1008 NM 001565.1:4 AATCAGAATCGCAGTTTGATTCATGGTGCTGAGACTGGAGGTTC

0 CTCTGC

1009 NM 001570.3:1 CTTCGGTTGTTATCCATTGCAGGGATGCCCGTGAGGACCTCGG

285

1010 NM 001627.3:7 GGTACGTCAAGTCGGCAAGGTATGATAATGGTATCTCCATATGC

89 TGAATT

1011 NM 001629.2:3 CAAATATGTAGCCAGGGGTGCTCTGCGTTCTCTCTCCTAGGTAA

67 C

1012 NM 001657.2:5 CTTTTTCTTTCTTTTGGGTTTATCTGAAGTATTTTCACTTTCCG

47 TCTTGT SEQ ID NO: Probe ID Capture Probe Sequence

1013 NM 001674.2 : 1 AAAACAATGCTATTGACATCCAATAATGCTAAAGCCTGGGTACC

757 ACCCAG

1014 NM 001712.3:2 TTGTGTTTATCAGAAGCTGGTTCCCTCCTGAAGCTATAACCCCT

455 CCC

1015 NM 001715.2:9 ACTCTCTCTGATAAGAAAGGAGCCGGCCTTGTTGATTGGAGCAA

90 GAAGCT

1016 NM 001718.2:1 GCCAGCCTTCTTCTGAGGCCCATACTACACGGGTGTCCAACAAA

045 AACAGG

1017 NM 001733.4:7 GGCAGTGTACTTGCTGGTGGTCATCAATATCAAAAGGCTCCAGG

60 AACTTG

1018 NM 001734.2:7 GGATATGGTTTGGGATAATTGGGACTTGCAATCTCCCCAATCAG

75 TGCAGT

1019 NM 001735.2:2 GGGCTTTCCGAAGTGCAGATTCCCTCCACAGCAGACATTTTAAC

592 ACAGAA

1020 NM 001736.2:1 GAGAAGAGTCCCGCTGGAAAAGGAGGGACAAGTCTGGGAAAGAC

195 AGGCAA

1021 NM 001759.2:5 TAAGGCACTTTATTTCCCCAAAGTAGGCTGCAGGCGAAGGGATG

825 CAGGCT

1022 NM 001760.2:1 TGCAGGGAGGAGGAGCTTGACTAGCCACCGAAATGCAGACATGG

215

1023 NM 001765.2:7 ACTGATGATTGAGTAGATGACAGACACTTTGGGCCAAACTTCCA

50 CAGCCT

1024 NM 001767.3:6 TTTGGTGATATAGAAAACGAGCAGTGCCACAAAGACCATCAAGA

87 GGCTGC

1025 NM 001768.5:1 GGGGCCTCGGAAAGAAAGACCTGAATGGTGTGGAGGAAAGAGCC

320 CTGAGC

1026 NM 001770.4:1 TTGGCATCATCTGCTCGAGGTCTTCAGATTTCAGAGTCAGGTGT

770 GAATCT

1027 NM 001775.2:4 ACTGATGGGCCAGATCTTTTATTCTGCTCCAAAGAAGAATCTTG

60 TTGCAA

1028 NM 001777.3:8 AGTCCAACCACAGCGAGGATATAGGCTATCACCTGAATAACCAA

97 TATGGC

1029 NM 001778.2 : 2 GATGTACAGTGCGCCACTCTGAGGATCAAGTCTGACCCTGCCTT

70 TAAATT

1030 NM 001781.1:4 AACCCAGTGTTCCTCTCTACCTGCGTATCGTTTTAGAAAGTTCA

60 TGTCCT

1031 NM 001783.3:6 AGGTTTTCATCTTCATATTCATCCCCGGCATCCAACCCGAGCTT

95 CTCGTT

1032 NM 001792.3:9 GAGGAAAAGGTCCCCTGGAGTTTTCTGGCAAGTTGATTGGAGGG

41 ATGACC

1033 NM 001795.3:3 AAAAGAAAGAGAGCATGGATTGGCGACCAGGTGAGGCAGAGAAG

405 GGGAGA

1034 NM 001797.2:1 TTATCGTTGACATCAAGGACCCTAATGGCCACTGGGACTTTGGC

835 TTCCTG

1035 NM 001798.2:2 CCTCTCCGATCTTTTCCACCTTTTGGAAGTTCTCCATGAAGCGC

20 CAGCGA

1036 NM 001815.3:5 TCCGACCAGGACCCCGGTCACGATGCCGGCGACGG

27

1037 NM 001870.2:2 TTCTCACTAACTCGGAAATCCACCATCATATTAGCAGCTACGTG

20 GTGGGT

1038 NM 001876.3:1 TCCACAGCATCAAGAGACTGCTTATTTTTCCCACGTCCAAAATA

355 GGCCTG

1039 NM 001935.3:2 AAATCCACTCCAACATCGACCAGGGCTTTGGAGATCTGAGCTGA

700 CTGCTG SEQ ID NO: Probe ID Capture Probe Sequence

1040 NM 001949.2 : 3 CCTCCCCCACCCCAATGCTTCATCTAGGACCACACCGACATTTT

415 G

1041 NM 001951.3:4 ACAACTTCTGCTGATCAAGTTCTCTTTCCTTCAGTTCTAGATCT

44 TCAATT

1042 NM 001955.2:7 GTCACATAACGCTCTCTGGAGGGATTGCCTTTCAGCTTGGGATC

70 ATGAAA

1043 NM 001963.4 : 1 TATTTTCTCTGATGTCTCCAACAGAGCCTTCACTCC

022

1044 NM 001964.2 : 1 TTTTGTCTGCTTTCTTGTCCTTCTGCCGCAAGTGGATCTTGGTA

505 TGCCTC

1045 NM 001974.3:1 ATCTTCAGCTTGATCTCAGAGGTGGTCAAGGGAGCCTG

520

1046 NM 002000.2 : 1 TTGAACATGCATCTGGCCAGGCGTGGTGGCTCATGCCTATAATC

415

1047 NM 002003.3:9 TCATGGGGTCCCATGAGGTAGAGACCATTGAGGTTTGAAGCATG

32 ACAGTC

1048 NM 002010.2 : 1 CCCATCCAAGCCTCCATCATACATTATGCATGCGACAAAGTTTG

565 GCAACA

1049 NM 002019.4 : 5 CTTGAGCTGTGTTCAAGGTTAAAGTACTGCAGAATTGTTTGCCA

30 TTTCTT

1050 NM 002029.3:3 AAGACGAATTTGCACAGGAACCAGCCGAAAGGCCAATGTCCTCC

50 CATGGC

1051 NM 002030.3:1 GGCTCAGGGAGCACCTCCTCAGTTTCATTCAGAGGAATGGAGAA

90 GTTGG

1052 NM 002033.2:1 TGTAGCGGGCCACTGTGTGCAGGAGCCCAATTTCG

345

1053 NM 002037.3:7 CTCGTACGCAAGGTCCCCGTATGAGACGAAGAGTTCACACCTCC

65 AAAGAC

1054 NM 002038.3:4 CACCAATATTACCTATGACGACGCTGCTGCCACCAGCCC

10

1055 NM 002048.2 : 1 AGTTTTGGGAAGTATCCCCAACCATCCCTTCTATCTGTCCCAAG

525 C

1056 NM 002079.2 : 6 AACCAGCAGCGGAAAACACAGCATTGTGATTCTCCCAGGTTGGT

15 GAGGAC

1057 NM 002080.2:2 GCACTATCATTCAAGAGGATGCCGAGATAAAGTACAGTTTCCTA

145 CTCTCC

1058 NM 002089.3 : 8 GGCCATTTTCTTGGATTCCTCAGCCTCTATCACAG

54

1059 NM 002090.2:5 TAGAAAGCTGCTGTTCTCTTTTTCATTTTCAGCTCTGGTAAGGG

40 CAGGGA

1060 NM 002104.2:7 CACCACATTCATGACCTCCAGAGACTATAGCGTGGAAGACACCT

00 TTACAG

1061 NM 002105.2:1 CTAGGTGCTTGGATTGCCGAGTTGAGTTTGCTGGAAGGGAAATG

392 GGGCGG

1062 NM 002110.2:2 GTGGGCTGGCGCTGGTTTCAGTTTTTGAGAATGTATTGCCTCCG

60 ACCTGG

1063 NM 002112.3:1 ATCCCCTTCAGAAACCCCCGGAACTCGGGGCACAGGAAGG

170

1064 NM 002116.5:1 ACTGCTTGCAGCCTGAGTGTAACTCCCTCCTTTTCTATCTGAGC

000 TCTTCC

1065 NM 002117.4:8 GCAACGATGCCCATGATGGGGATGGTGGGCTGGGAAGATGGCTC

95

1066 NM 002118.3:2 TGGGGATACCCAGCCCCTAGATATTAAATCTGTTCCTTCCAGCT

0 CACG SEQ ID NO: Probe ID Capture Probe Sequence

1067 NM 002119.3:3 AGGGTTGAGATGATATAAACTCAGGAGCTGTCGGGTGGACATGT

075 TCACTG

1068 NM 002120.3:2 CTCCAAGTTAAAGATGAATCTGACCACAAACTGCACCTTTTCTG

30 TCCCGT

1069 NM 002121.4:9 GATAGAAACTGACTTCAGAGCAACTTCTTGGCAGCAGTATCCAA

31 TTTGGA

1070 NM 002122.3:2 CAGTGCACCCTGCGGGTCAAAACCTCCAAATTTGCTGAACTCAG

61 GCCACC

1071 NM 002123.3:3 CCACCTCGTAGTTGTGTCTGCACACCGTGTCCAAC

84

1072 NM 002124.3:7 AGCCCCCGACTCCACTCAGCATCTTGCTCTGTGCAGATTCAGAC

47 CGTG

1073 NM 002162.3:1 CATGTGGCTCGGTCAATTTTGGGACCATACAGGACTCGCAGCTG

225 GACG

1074 NM 002163.2:2 TAACCTCGTCTTCCAAGTGGCTGGTTCAGCTTTGTCCCCTTCTT

53 TAAACT

1075 NM 002164.3:5 CCTCTGGTGCCCCTCAGTGTCTGAAGAGTTTTCAGAGCATCTTA

0 TAATAG

1076 NM 002181.2 : 1 AGTGTGGCCGGGGAGGAATGTCATACCTCAGAATGGCCGGGATG

693 G

1077 NM 002182.2:4 GGAACCACAGCACATCTTTCTCCTTACTAATGCGGTTCTCGGGG

60 AGGCGG

1078 NM 002185.2:1 TCTTGACTCATGTTGAGTGCCACTGAACTCAGGAAGAGTGGTCA

610 AAGCAA

1079 NM 002190.2:2 GGGTCCTCATTGCGGTGGAGATTCCAAGGTGAGGTG

40

1080 NM 002192.2:1 ATGGGCCCTTTCAAACTCATGGCTTTCTAGATGCTATTTGGGTT

914 G

1081 NM 002198.1:5 TTTTCTCTGGTTCTTGGTGAGAGGTGGAAGCATCCGGTACACTC

10 GCACAG

1082 NM 002200.3:1 GTTGGGAGAGTTCTTTCCCTGCTCATGGCTGAATTTCCCGAGAG

845 CCAG

1083 NM 002203.2:4 GCTGGCTGAGAGCTGAAAATCAGGACTGATGTCAGAACACACAC

75 CCGTTG

1084 NM 002208.4:3 TCTTTCAGGAAGACGACAGTGATCTTAGTTCTGTGGTTCTCTGC

405 ATT

1085 NM 002209.2:3 AAGGAAACCAAGAGAGGCTGGTGAACCGTCTGGTAATGACAAGC

905 CCTCAC

1086 NM 002210.2:2 TCTTCAGTCTCAGGGTTCTCCTTGTGCTCCCAGTTTGGAATCGG

615 AAGAAA

1087 NM 002214.2:2 CCTGAGACAAATTGTGAGGGTGAAGGCATTGCATACAATTCCAG

609 TTTTCC

1088 NM 002227.1:2 TCATCAACGGTGATGGTGCGATTTGGAGCATACCAGAGCTTGGT

85 GTTCTC

1089 NM 002258.2:8 ATGAAGGTGAAGAACTTTCTGGGCCTGAGTCTGTGGGTAAGTTT

5 AACTCA

1090 NM 002262.3:5 CTGGAGCTCATAAAATCCAGTTCATCTGTGTTTTGAAGCTGAAG

42 CAGGCT

1091 NM 002286.5:1 CGCCACTGTCTTCTCCAAAGGTGAAAGCCAAAGGCTCCAGTCAC

735 CAAAAG

1092 NM 002309.3:1 CTATGCCCAAGTTCTCTGATCATCCTCAAAAGAAGACAGCCTTC

240 CATCCC

1093 NM 002318.2:4 CGCGTTTACTCTTTTCCCCCTTACTTTTAACTAGAGGAGGATGG

0 CAAACC SEQ ID NO: Probe ID Capture Probe Sequence

1094 NM 002341.1:3 CCCCTCGGCGTCCGAGAACTGCGTCCCGCTCGTCA

30

1095 NM 002354.1:4 TCATAAAGCCCATCATTGTTCTGGAGGGCCCCTTCAGGTTTTGC

15 TCTTCT

1096 NM 002405.2:1 CATCTGGGCCCCGGCATGCTGAGGCTCCAAACAAAATCTGGTCC

681 T

1097 NM 002412.3:3 TGAAGAGCCGGCACGGGGAACTCTTCGATAGCCTCGGGCTGGTG

23 GAAATA

1098 NM 002416.1: 1 TCCTCTAGCGCTTAGTACTTCACCGTTCCCTTTCTTCATGGGAG

975 ATGGTG

1099 NM 002417.2:4 CTGATGGCATTAGATTCCTGCACGCTAAGAGTTCTCCCTCTACA

020 TCTG

1100 NM 002421.3:1 ACCGGACTTCATCTCTGTCGGCAAATTCGTAAGCAGCTTCAAGC

117 CCATTT

1101 NM 002423.3:3 GTCCATTTTGGGCTATTTGGAAATAGTGAGTATTCTGCAACATC

11 TGGCAC

1102 NM 002438.2:5 TATACATGGCTTCATAACCTCTGGAGCACAGATTGTCTGTGGTT

25 CCATAG

1103 NM 002460.1:3 AGGGTCCGGCTTGTCGATGCCTTCTCGGAACTTTCCTTTAAACA

25 GTGCCC

1104 NM 002462.2:1 CCTACAGTTTCCTCTCCTTGCATGAGAGCAGTGATGTCCTGATT

485 AAAGGC

1105 NM 002467.3:1 CGCTCCAAGACGTTGTGTGTTCGCCTCTTGACATTCTCCTCGGT

610 G

1106 NM 002468.3:2 ATGGGACTTTCCCACCTAGCTGTTCCTGGGAGCTGTACCTAGAA

145 AAACGT

1107 NM 002483.4 : 1 AATGGGATTGGAGGAGCTAGAAGAATTCAGGGTCTGGTCCAATC

217 TGCCAG

1108 NM 002485.4 : 1 TTAATCCTGTACTGGGATGGCCCTGAGGATCACAGTAATTCTTT

060 GTAGTC

1109 NM 002502.2:8 CTGCTGTCTTGTCCATTCGAGAAATCTTCAGGTTTGATGCCCCC

25 GGAGAT

1110 NM 002507.3:2 CGAAGTCAATTCCTTCTTGCCGCATTCCCACACTGG

730

1111 NM 002524.3:8 TGAAGACAGCAACAGGAATACTTCTCCTCCAGGGAAGTCAGGAC

77 CAGGG

1112 NM 002526.2:1 CACACCCCTCACTTTCTGAGCGATGAGTTTATCCATTTCAAAAC

214 CCGAAT

1113 NM 002543.3:2 CTGGTGAGTTAGGTTTGCTTGCTCTTGTGTTAGGAGGTCAGACA

95 CCTGGG

1114 NM 002546.2:1 AGGTGAGGTTAGCATGTCCAATGTGCCGCTGCACGCTGTTTTC

075

1115 NM 002608.2:1 CTCGGTGCGCGTCTTGCACTCGGCGATCATGGCCG

245

1116 NM 002609.3:8 CCGTGAGAAAGATGAATAGTTCCTCGGCATCATTAGGGAGGAAG

40 CCCACG

1117 NM 002610.3:1 TCAGGTCTCCTTGGAAGTATTGTGCGTAAAGACGTGATATGGGC

170 AATCCA

1118 NM 002619.2:0 CTCATGCTGCGGCAGAGCTTCCAGCAGGATCTCAGTG

1119 NM 002639.4:1 TCAGATGTGTCTTCACTGAAGATATGTTTCAGCCCT

014

1120 NM 002649.2:2 AAAGCACTTTGATCCCAGACTTCCCTTCTGGCCAACAATTGGTA

125 TGTTTT

1121 NM 002658.2:7 GAGCGACCCAGGTAGACGATGTAGTCCTCCTTCTTTGGGTAATC SEQ ID NO: Probe ID Capture Probe Sequence

93 AATGAA

1122 NM 002691.2:2 TCTCAAACTCCAGCCGGATGGGCGACGGGAAGTGACCTGACACC

392 CAG

1123 NM 002736.2:1 TTCCAAACAGGGCAACTAACTGTTCTTCATAGGTAGCGATGTTC

350 CTTTTC

1124 NM 002737.2:6 AATGTAAAGGACTCATTCCACTGCGGATTTAGTGTGGAGCGGAT

80 GGTTTT

1125 NM 002800.4 : 4 TGGCAAAAGGCTGTCGAGTCAGCATTCCTCCCAGG

55

1126 NM 002801.2:2 GTATCGGCGCCCAGAATGACCCCGTCTTGGAACACCAGG

21

1127 NM 002834.3:1 GCATGACGCCATATTCTTTTAGAGCATACTCATCAGGCCAGTAT

480 TTGACA

1128 NM 002838.4 : 2 GGGGAAGGTGTTGGGCTTTGCCCTGTCACAAATACTTCTGTGTC

58 CAGAAA

1129 NM 002852.3:1 TCCTCCGGTCTCTCTTATCTCTTCATTGCTAAGAACACTATCCC

152 AGATAT

1130 NM 002856.2:1 TGGTGACTGTGCAGACGAAGGTGGTATTGAACAGACTGTCCACT

337 GCGTGG

1131 NM 002876.2:3 AAGGTGATTATGAAGCCCTGGGTATGCTCCTGCTCAAGAAGTTC

00 C

1132 NM 002964.3:1 AATTTCTTCAGGTCATCCCTGTAGACGGCATGGAAATTCCCCTT

15 TATCAG

1133 NM 002965.2:7 CCCAGCTTCACAGAGTATTGGTGGAAGGTGTTGATGATGGTCTC

5 TATGTT

1134 NM 002982.3:1 AGGTGACTGGGGCATTGATTGCATCTGGCTGAGCGAG

23

1135 NM 002983.2 : 1 CTGAAGCAGCAGGCGGTCGGCGTGTCAGCAGCAAGTGATG

59

1136 NM 002984.2 : 3 CTTCATGGTATTGGTGGCAAAGAGGTTTTCTCAGAGGTGAGGCT

5 GCAGAA

1137 NM 002985.2:2 AAGAGTTGATGTACTCCCGAACCCATTTCTTCTCTGGGTTGGCA

80 CACACT

1138 NM 002988.2 : 5 ACACTGATTGATCCATGCATTGAATGTACGAAGAGTTGAAGGGA

85 AAGGGG

1139 NM 002989.2 : 1 CGGTAGCTGCGGACAACCTTGGCGGGAATCTTCCTTTGGCTGTA

80 CTTGAG

1140 NM 002990.3:7 GCCAGGGGACATCTAATACATGAAATGGAATTACCAGCTGCTTG

97 GGCGAG

1141 NM 002993.3:5 GCTCCGCTGAAGACTGGGCAATTTTATGATGCATGGTCTTTTTT

39 GTTACT

1142 NM 002994.3:2 TTGGGATGAACTCCTTGCGTGGTCTGTAAACAAACGCAACGCAG

50 CTCTCT

1143 NM 002996.3:1 TGATGTCATCTTGCTGCACGTGATGTTGCATTTCGTCACACCGT

40 GGTGCT

1144 NM 003005.2:1 GCACAGCGGAAGCTACAGTTGGTGTCATACTGAAACGCTCTCAA

295 GGATGG

1145 NM 003012.3:3 TCTGTGGTAACTACTAATGTTCCAGGTAAACCCCTCCACTAAGG

320 ACTCTG

1146 NM 003014.2:1 CAGCCTCTCTTCCCACTGTATGGATCTTTTACTAAGCTGATCTC

060 TCCATT

1147 NM 003051.3:6 TGTTACAGAAAGAAGCTGCAATCAAGCCACAGCCTGACAAGCAG

35 CCACCA

1148 NM 003068.3:7 CCCGTGTGAGTTCTAATGTGTCCTTGAAGCAACCAGGGTCTGGA SEQ ID NO: Probe ID Capture Probe Sequence

40 AAACGC

1149 NM 003106.2:1 ATCCTGCCGCCGCCGATGATTGTTATTATTATTTTTTGGAAAGG

51 CTTAAG

1150 NM 003108.3:5 CCACCCGCCACCCCCAGGTTACCATTTTAAGATATTCTGTCAAT

650 GCTTAG

1151 NM 003121.3:1 GTCCTGTCACCCAAAACATGAGGATCCCAGGGAGTCTGTACATG

029 ACAAAG

1152 NM 003151.2:7 AACTTCCTGATTCACCATGGCACTATTCTTGTCACTCTGATCCA

89 TTGTCT

1153 NM 003155.2:2 GATTGACTCATTCCTGATTGATTTAATGGAAAGTCTCCCACCCC

265 ATCATC

1154 NM 003161.2:3 ATTTTTTCTGGCCCTCTGTTCACACTAGTTTCTGAGATTTCAAA

10 TTTCTC

1155 NM 003175.3:3 AAAGTGAAATGAGCTGGCTGGCTGGAGACGGACAGGGTGCCAGA

77 GACTAC

1156 NM 003177.3:1 TCTGGGCCTTGTAGTAGTTTTCATCAGCACGCAGTGCTTTGGAG

685 AGTCCG

1157 NM 003190.4 : 1 CGCTGTCCTCAAGGGAGGGCCCTGAAAGACCTGCTAC

536

1158 NM 003200.3:8 CCATGCAGCTGGTAGCCCATACGCTCGTGCTGGTG

58

1159 NM 003205.3:1 TCCAATTGGTGCATTATGGGATGGTCCCAATAAACTATGTATAT

579 CACTGT

1160 NM 003236.2:7 CACAAAAGGCTGCACAGGTGATTACAGGCCAAGTAGGAAGGTCT

80 GTGGCA

1161 NM 003238.2:1 GGACTTGAGAATCTGATATAGCTCAATCCGTTGTTCAGGCACTC

125 TGG

1162 NM 003239.2:1 AGTGAATGCTGATTTCTAGACCTAAGTTGGACTCTCTTCTCAAC

485 AGCCAC

1163 NM 003246.2:3 GAGACGCCATCTGTAGGCGGTGAAATCTTTCCAGCCTATGTGAC

465 GAGG

1164 NM 003263.3:5 CTTCACCAACTTGTTGTGGGACAAATCCAAGTATTCCAATTCCT

45 GGTTGA

1165 NM 003264.3:1 GTATGTGGCATTGTCCAGTGCTTCAACCCACAACTACCAGTTGA

80 AAGCAG

1166 NM 003265.2:2 TGGGTAAGGTTCAACACTGTTATGTTTGTGGGTAGATCATCGGG

30 TACCTG

1167 NM 003268.3:2 CACGTTGTCAGTAGCATCAGGAGTATGAATCTTGTAGTAGTGCC

15 AGGAAC

1168 NM 003294.3:5 GGTATTTTGCGTCACAAATGTGGTTTTCCATTATGGGGACCTTC

79 ACCTGC

1169 NM 003326.2:5 CTTTGTAAGTCAGAGAGGCCACCATCAAGGAGTTGACAGACCTG

45 ACCTTC

1170 NM 003327.2:2 TTGCACGGCTTGGAGCTGACCACGTCGTTGTAGAAGCCCGG

00

1171 NM 003377.3:6 TCACCCTGCTGAGTCTGAAAAGCCATGTGTCACCTTCGCAG

87

1172 NM 003391.2:2 ATACAACACACCATAGTACCAAAGGACACACGTCCCCACCTTGT

014 TACATC

1173 NM 003392.3:4 GCAGAGAGGCTGTGCTCCTATAATATATACTTCTGACATCTGAA

75 CAGGGT

1174 NM 003442.5:9 TTTTTAATCCATAACCTGTTGCAAATGCCTTCCCACAGCCTGCA

25 TGCTCA

1175 NM 003465.2:4 AGTTGACAAAGGTCTGACGGTTGTTGGCCGTGGCTACCATATCT SEQ ID NO: Probe ID Capture Probe Sequence

10 GTGAAC

1176 NM 003467.2:1 ATACAGCAACTAAGAACTTGGCCACAGGTCCTGCCTAGACACAC

335 ATCAAT

1177 NM 003474.5:6 CTGGCAATGAGACCTTCATTTCTTTCCAGATTTATGATCAGTTC

38 TTTGCT

1178 NM 003486.5:7 CATAGGCAAAGAGGCCGCTGTATAATGCCAGCACAATGTTCCCC

85 ACAT

1179 NM 003508.2:1 CCGCCACCTTGCGCAGGGTCAGGATGACGATGGTC

320

1180 NM 003629.3:5 TCAAAGCTTCTTCAAAGCACATGAGGCCTAAATAAGTGGAGGTC

016 CCATCA

1181 NM 003639.2:4 CCTCTGGCTGGCTTGGAAATGCAGAAGCTCCTCGC

70

1182 NM 003641.3:4 TCTGTAACATAATATGGTAGACTGTCACAGAGCCGAATACCAGT

82 AACAGG

1183 NM 003686.3:2 TTTCTCTTCTGGATGCTTGCCGGCTTCTTGCTCAGCCCACTG

715

1184 NM 003747.2:1 GTGGAGTAAACTGCCAGAGATCCATGGCATTAACACAAGCTCCA

270 TGCTTT

1185 NM 003749.2:7 GTTCAGGCAGCAGTCGAGAGCGATCACCCGTTTCG

64

1186 NM 003808.3:8 CTGCCCCCCAACTCAACCAGAGGGCAACTGAGAGTGCCGG

10

1187 NM 003809.2 : 3 CCTTTAGGTGCACTTCTGCGAGGCCGAACTAGTCGGTTCAGGAA

39 AGG

1188 NM 003810.2 : 1 CTGTGAAGATCACGATCAGCACGCAGGTCTGTCCC

15

1189 NM 003811.3 : 3 TTGGCCACCACCAGCTCCTTCGTGTCCTCTTTGTA

98

1190 NM 003820.2 : 9 TGATTAGGCCAACTGTGGAGCAAACAATGACGATGACGAGGCTC

16 CCTGAG

1191 NM 003830.2:2 ATCCCCAGCCTTGAGAGAACTTGCCAGCAGGACCTTTCTATTCA

145 AGGAAG

1192 NM 003839.2:4 TGTCCGTGGAGGAAAAGGCATCAGAGAAGTAGCCTGCAAGGCAA

90 GGTTTG

1193 NM 003840.3:2 CCATGACTGTCCCAGCACGACAAACCAGACACATGGCTTCCCAA

380 AGATAC

1194 NM 003841.3 : 6 TACAATTACTGACTTGGACTTCCCCACTAGGGCACCTGCTACAC

82

1195 NM 003842.3:5 GAGGTCATTCCAGTGAGTGCTATAGTCCTGTCCATATTTGCAG

65

1196 NM 003855.2:2 CCACTGGTCCCTAGAAAATGCCTCTTCAGACACTTAAAATCCCC

025 TCATTC

1197 NM 003862.1:8 ATCGGGCTTCCCCACGAGCTTGCCTTTGCGGTTCATGCACAGGT

50 AGAATT

1198 NM 003883.2 : 1 AGCAGGTAGATGGTTCGAGAACCAAATGTGGTCTCCAGACTCTT

455 TCCCAG

1199 NM 003884.3:1 ATATCATCATTGGGAGATCGCAGTCTTCGTTGAGATGGTGCCTC

220 CAGATG

1200 NM 003897.3:5 TCTCGCGCACCAGGTACGCCTGGTGTTTCTTTGTG

27

1201 NM 003914.3:1 ATGGGGTATATCAAGGTACGCTTTATGAAGCTCACTCAGGCAAG

605 GCACAA

1202 NM 003998.2:1 AAGTAATCCCACCATAAGTAGGAAATCCATAGTGTGGGAAGCTA SEQ ID NO: Probe ID Capture Probe Sequence

675 TACCCT

1203 NM 004048.2 : 2 CACGGAGCGAGACATCTCGGCCCGAATGCTGTCAGCTT

5

1204 NM 004052.2:5 GCAGAGATGGAAGGAAAACTTTCAGAAATTCTGCAGAGAATATG

84 CCCCCT

1205 NM 004072.1:7 AGTGGTAGTCCATGGCGGCATAGGTGATATGGATTGGGAGGAAG

70 ACGTTG

1206 NM 004079.3 : 6 TCTGAGTCGATGCCCTTGTTATCAATGATGTACTGGAAAGCCGT

85 TGTCAT

1207 NM 004095.3:3 AACTGTGACTCTTCACCGCCCGCCCGCTTATCTTCTGG

63

1208 NM 004107.3:1 AACTGAGGCAGACCACAGGACGGGGCTCCAGAGGGAGGACAACT

366 AG

1209 NM 004131.3:5 GATTCGCACTTTCGATCTTCCTGCACTGTCATCTTCACCTCTTG

40 TAGTGT

1210 NM 004152.2:3 AATAAGTTAGCTGAAAGATTGTGATCCCTCTGACTATTCCCTCG

13 CCCACC

1211 NM 004165.1:9 CGAAAGGCCATCTTGCGGCTGTTACGAGCTACGATGCGGCCCAA

60 GAAGCG

1212 NM 004168.1:2 TAAACCCTGCCTCAGAAAGGCCAAATGCAGCTCGCAAGCCTGC

30

1213 NM 004195.2:4 GGTCCCCGAGGCACAGTCGATACACTGGAAGCCAAAACTGAATT

45 TCCCCT

1214 NM 004203.3:7 GGAGCGCACCTTGAAGACCTCTCCGTAGGAGCCAT

80

1215 NM 004221.4:3 TGCTGCTCCTCATAATAAGCCGCCACTGTCTCCAG

58

1216 NM 004244.4:1 CCCTGCATAGAACGCTGGCAGCTTCCAGAGAGAAGTCCGAATCA

630 CAGATG

1217 NM 004322.3:6 CACAAACTCGTCACTCATCCTCCGGAGCTCGCGGCCATAGCG

52

1218 NM 004350.1:2 CTATCTATCTGGCCCTCCTGTTCTCTCCACAAATGGAATTATGA

085 GACCAC

1219 NM 004360.2:5 CTCTTCTGTCTTCTGAGGCCAGGAGAGGAGTTGGGAAATGTGAG

35 CAATTC

1220 NM 004369.3:2 CACAAGATTGGCTGAGCCGTCAAAGAGGAACAGAATGTCTCGCT

782 TGCTCT

1221 NM 004385.3 : 9 CAAACATTTGTTCTTCGTGAGACAGGATGCTTGTGAGATGGGCA

915 CCCTGC

1222 NM 004416.2:2 GGCCTGGAGATGGGAAGGGAGAAGGAGATCAGAGTCCAGAGAGA

855 TGAAGA

1223 NM 004417.2:9 GGAAATGCCTGCCTGGCAGTGGACAAACACCCTTCCTC

87

1224 NM 004418.3:1 GAGGGAAAGAGCAGACACACCCTTGGTTCCCGACCCCGAATGAG

235 GG

1225 NM 004419.3 : 6 AGGGCTCTCTCACTCTCAATCTTCTCTTGTGAAATGGGTTTTAC

75 ATCCAC

1226 NM 004456.3:1 CGCATGTACTCTGATTTTACACGCTTCCGCCAACAAACTGGTCC

90 CTTCTC

1227 NM 004460.2:1 CCTTAGATGGCAAGTAACACACTTCTTGCTTGGAGGATAGCTTC

490 CAATGC

1228 NM 004485.2:2 TGGCTTGGGAGATGCTAGTGGTGCTGTTATTAGACATGCCCTCT

15 TTCATT

1229 NM 004513.4:1 CAGAACCATTTGCAGCTGAGTCTTCGTTGGATGATGATGTTGGA SEQ ID NO: Probe ID Capture Probe Sequence

262 GATGCC

1230 NM 004525.2:1 AGCACCAAACCTAGAGCCCTCCCCTCGCACAGTGTAATACACAA

2505 C

1231 NM 004556.2:1 CTGAAGGGTGGCAATGTGGAGACAAGCCAGACCTTGCCAGTTTT

115 GCAGCT

1232 NM 004560.2:7 GCGAGTCCACATAAATGGTCCGGTTGCCAATGAAGCGTGCACAG

35 GCAATT

1233 NM 004563.2:7 CCAATCAGGGTTTTCTCTGGGTTGCACGGCCACTGGCT

95

1234 NM 004566.3:7 CATCGAAAACCGCAATTTGTCCCCCTTCTTTCGCCAGGTAGCTT

10 TTGACA

1235 NM 004591.1:3 CAGGAGCAAACTCTTGGTACAGCACATGGTTTTTAGCTCAAAGA

5 ACAGAT

1236 NM 004599.3 : 1 TTGATGTAATCAATGGCCTTCCTCAGAACGCCAGACTTGTGCAT

275 CTTGGC

1237 NM 004612.2:1 TCCCAGAATACTAAGCCCATTGCATAGATGTCAGCACGTTTGAA

255 GGATTC

1238 NM 004626.2:9 TCTTGTGTCCCGTGGGAGCCCACCTTCTCATTCTT

60

1239 NM 004654.3:8 ATACACAAGGGTCAGTTTCACCTCTGAGCCCAGAAAAGTCTTTC

5 CACAC

1240 NM 004658.1:2 TATCCACTCCAGTCTGAATCAAGCCAGAGGGCAAGTTTCACTCA

900 G

1241 NM 004756.3:5 GAGAAAGCCTTGTCCAGGTTGCGGTCAGGAGCACAAAAGGAGAC

91 CTTTTC

1242 NM 004829.5 : 6 GGCTCACTGGGGAAAGACCAGGCATGGTTGTTATAGGAGCCAAA

02 ACATCG

1243 NM 004850.3 : 3 TGGGCAGCCAAAGAGTCCCGTTCATCCTGTAATTCCTGTTTCTT

140 CTGCTG

1244 NM 004887.4:1 CATTGTTCCTCCCGGGCGCTTATAAAGCTCAGATGTATAGTGAC

125 GTATGG

1245 NM 004931.3:4 TTCTTGGTGGGCTGGGCAGTGGTGGGAAGGAAATCAACCACACT

40 CAG

1246 NM 004936.3:1 ACTCCTCAGCAGACATTGGAGTGAACGCATCGACTGCCGTCA

175

1247 NM 004958.3:1 AGAGTGGCCTTCAAATTCAAAGCTGCCAAGCGTTCGGAGGGCAA

865 GAGTGA

1248 NM 004972.2:4 GCCATTCCCATGCAGAGTCTTTTTCAGAACATTTGCCGTCGCGG

55 GAGGAG

1249 NM 004985.3 : 3 CACTGTACTCCTCTTGACCTGCTGTGTCGAGAATATCCAAGAGA

27 CAGGTT

1250 NM 004994.2:1 AGATGTTCACGTTGCAGGCATCGTCCACCGGACTCAAAGGCACA

530 G

1251 NM 005018.1:1 TGAAGGTGGCGTTGTCCCCTTCGGTCACCACGAGC

75

1252 NM 005026.3:2 ATGGACAAAGTCGTAGGTGAGGATGAATGGGACACGCTCGCGGT

978 TGATTC

1253 NM 005027.2:3 CCTGCCCTGACCCCAGGTCTATGGCTTAAAAATCAGGGTG

100

1254 NM 005041.3:2 GGGTGAATCGGGATTAGCGTGTAAACCCAGCCACCTCCCTGAAA

120 AACAGT

1255 NM 005044.1:2 TCCCAAAGTCCCAGGGTTACAGGAGTGCACCACCG

590

1256 NM 005045.2:3 GAAATTGTCACATGGTATTCTTGTCCCGGAACGTAGTAGGTGGG SEQ ID NO: Probe ID Capture Probe Sequence

45 GTTGCC

1257 NM 005084.3:2 GAGGCAGAAAAGCACATGCAATTTGGGTGGCACCATCTTGGGAG

55 CTGAG

1258 NM 005092.2:1 ATTTTGAGGGTAATGGTCCAAACTTAGCCATACAGGGCTCCTTA

75 GCAGTC

1259 NM 005101.3:3 CTCAGAGGTTCGTCGCATTTGTCCACCACCAGCAGGAC

05

1260 NM 005103.4:4 TCTTGGCGTTGTAGTTCCGAAAGCAGACATTGAGCTTCTCATCA

26 AATTCA

1261 NM 005191.3:1 AGTTCCCAGAAGAGGTCAATTGCAAATGGAGGTGGGACCTTCAG

288 ATCTTT

1262 NM 005194.2:1 TCTTCTTTAAATAACACCACGGGCGGGAGCCCCATCTGCATGTG

420 CGGTTG

1263 NM 005204.2:2 TCAGCCATATTCAAGCGTTGGTGGTCCCCGAACAAGATTGAAGT

050 AGCCAG

1264 NM 005211.2:3 CACCCCCAACTTTTAGCTGCCACTTGGCTCATTACAGCAGTACC

775 AGTATG

1265 NM 005214.3:4 CATCTAGGAAGGTCAACTCATTCCCCATCATGTAGGTTGCCGC

05

1266 NM 005238.3:4 GATGGTGTATTTCTCACCATGAAGGTTAGGCAGGTTAATGCTGT

625 AAAACC

1267 NM 005242.3:9 TCTGAGTTTTCATCCATGGCAGAAGATCGCAGCATTCTGATCAT

40 CAGCAC

1268 NM 005269.1:2 CAAAGCCAGGTCCATATGTGTTCACTGGAGCTTTAGCACGG

885

1269 NM 005317.2:6 AAGGACAGGACTCCGGCCAACACCCGGCCTTTGCC

69

1270 NM 005342.3:2 CCATCTCCCCTCACCCCAACCTGGATAAAATGTTACACTACCCA

332 CTAATA

1271 NM 005343.2:3 GTTGTTGATGGCAAACACACACAGGAAGCCCTCCCCGGTGCG

96

1272 NM 005356.2:1 TTGATGGTGAATGTCCCGTAGTTAATGGCTTCTGGCGCTGTCCA

260 CTTAAT

1273 NM 005384.2:1 AATGGACTGCTCTATTGCAAATGACATCTTTCTAAATGCCCAGC

795 TCTTAC

1274 NM 005406.1:2 ACTGCTCAGACTCAGCTTTTGTTTCTGCTAGATCCAACTGAGTA

660 GCAAGA

1275 NM 005408.2:3 AAGTCTTCAGGGTGTGAGCTTTCCGGCCCAGGTGTTTCATATAA

20 T

1276 NM 005409.4:2 TTCACTGCTTTTACCCCAGGGCCTATGCAAAGACAGCGTC

82

1277 NM 005419.2:1 CGGATGATTTCAGTCAGCGGGAGTGACTGCAGCACCTCCTT

965

1278 NM 005429.2:5 GACCGTAACTGCTCCTCCAGATCTTTGCTTGCATAAGCCGTGG

65

1279 NM 005438.3:1 AGTCTCATTAGAGGGATGGAGAAGAAGTTGCTGGAGTTGGATGT

086 GGGATA

1280 NM 005442.2:1 CTGCCATTGCAGGAAAGGTTGGGTCTGGGTAATACCCCAGG

670

1281 NM 005445.3:3 TCCAGAGCCTGGTCAATTTCATCAAACAAGTAAAATGGAGCCGG

525 GTCACA

1282 NM 005474.4:3 AGACTAGGACCACATCAGGTGAGAACTCGTGGGCAATGGGCATC

160 AC

1283 NM 005508.4:3 CTGTGAGGCAATGCCAGGCTTGCTCAGGAAGCACGATGCTAAGA SEQ ID NO: Probe ID Capture Probe Sequence

5 AGGAC

1284 NM 005514.6:9 AATGCCCACGATGGGGACGGTGGACTGGGAAGACGGCTCCCATC

37 T

1285 NM 005516.4:1 GACAGATTCAGAGGCCCTTGCAAAAAGAGAAGCCAGAGTCCCCT

204 AAGACA

1286 NM 005524.2:8 GGAGCCGGTACCACCTGGAAGCCTCCAAACACCTTAG

60

1287 NM 005531.1:2 TGGTGAGTTTCAGTTTATCTCCTTCCTCACAGTTGATTGTGTTC

255 AGTCGT

1288 NM 005532.3:3 GAGCCCAGGATGAACTTGGTCAATCCGGAGAGTCCAGTTGC

90

1289 NM 005533.3:4 ACTTTGGGGTCATCAAAGGTGATCAGAGCAGAGCCCGCAAGCAG

15 AG

1290 NM 005559.2:5 AATAAATCTTCAGCAGCCTTGAGTTCAAGGGTGGCATTTTGGTG

230 CAACTG

1291 NM 005562.2:4 TGTGCCGGTAAAAGCCATTCTTGCACTTCTCGCAGTGAATGCCA

90 TCAGTG

1292 NM 005591.3:5 CACTGGAATTGAAATGTTGAGGTTGCCATCTTGATAGTTCACCC

05 ATGGAA

1293 NM 005601.3:6 CTCTTGCCTTCTGCTCACAAGGTTTCATAGCCAGGACGG

33

1294 NM 005611.3:1 AGGGCTATTCTCCTTAATGTACCTAACACCAGTTAGTGGTGTGG

310 AG

1295 NM 005618.3:2 TGCTATGACGCACTCATCCTTCTCCTCGGATATGACGTACACCG

580 ACTG

1296 NM 005621.1:2 CGCAATGGCTACCAGGGATATGAATTCTTGAAAGTCGACCTGTT

60 CATCTTG

1297 NM 005623.2:6 TGAAATATTTGGTCCAGATGCTTCATGGAATCCCTGACCCATCT

89 CTCCTT

1298 NM 005627.2:1 ACAAAATCCATCTGTGATCAGGCATACCACACTCACACGACGGT

790 TCACAC

1299 NM 005631.3:1 AAGCCAAAGGCCAGGAAGCCAAAAATGCCCAGGCGCAGCATGGT

615

1300 NM 005651.1:0 GTCTGAGAAGCACGGAGGTTTGACTCTAGGCAGATGCTATCATT

GACCTT

1301 NM 005732.2:5 GGCACAAAACCATGCCATGTGACTGAATCAAGACCCGGTATGGT

397 CCTGGC

1302 NM 005764.3:2 CAGGAACACGGCCACCGCGATAAGGCCCTGCATCCAG

40

1303 NM 005816.4 : 1 TTTGGCCTCAAGGCACTCACATCTACAAGGGTCACTGAAGATGT

355 AGCTGG

1304 NM 005860.2:2 AAGAAGCCGAGGAGGTTGATCTTGTTCCCCGGGTGGGTGAGGTT

45 G

1305 NM 005903.5:1 TTGCTTGTATCCATAGGCTGGGAATTATCTTGACCCATCTGATC

044 ATCAGG

1306 NM 005905.2:1 CAGGCACCAAAGTCCTGCTTTTCCAATTGCACTGTACTGGCATC

595 AGGTTA

1307 NM 005923.3:1 CCCCAGAAAAAATCCAACTTCCCAGTAGCTCTGGAGTTTTTCCA

760 AGTTTC

1308 NM 005931.3:1 CTCTCTACGTGGCAGAGCAGCAAACACCTCATACCTACTAACAC

387 TTTGCA

1309 NM 005944.5:6 CATTTGGGTGAGACAGAGTCACTGTACTATTTTCAATCCCTGAC

65 CGAGGG

1310 NM 005985.2 : 6 GATTGGGGTCGGAGGGCTTCCTGACGAGGAAAGAGCGCGGCATA SEQ ID NO: Probe ID Capture Probe Sequence

3 G

1311 NM 006015.4:5 CAGGCATCGTCGGAAATATTCTACAAGGAGCTCTAGCAACCCTG

495 GGAGCT

1312 NM 006017.1:9 CTTGATGGATGCACCAAGCACAGAGGGTCATTGAGAGATGACCG

25 CAGGCT

1313 NM 006037.3:6 TACACAGTAATGCTCTCAGCACATTTGTGAAGCTGGAGTGAGCT

965 GACAGA

1314 NM 006039.3:3 CCCTCTGCGAGGCATGGAGGCCAATCCAAAGGTCAAAGGT

482

1315 NM 006084.4:3 ATGCGGCCCCTCTCAGGAACCTCCTTAAATTCAGAACTCTTGTT

85 GAGTGC

1316 NM 006120.3:3 TTTGGCCCTATTTGCTGGATCATCCACTCGCAGAACTCTTTGTC

80 AAATAA

1317 NM 006137.6:4 GGTGCCGGAGCCGTAGACATTGACCTCCGTGATGG

40

1318 NM 006142.3:5 GCTGTTGGCGATCTCGTAGTGGAAGACGGAAAAGTTCAGGGCCA

79 GGC

1319 NM 006144.2:1 CCAGCACAGATGGTTTTTCTGTCAAGACTAAGTAGGACCATGTA

55 GGGTCT

1320 NM 006158.3:3 AGCCTTCATAGTTCCAATCCATTACCATCATGGCAAGGAAGCAC

300 TTTACC

1321 NM 006187.2:4 AGGTAAGTTTTAACAGTGGTTTGTGGAGAGTCAGGCTGTCTAAG

980 GCACTC

1322 NM 006218.2:2 ACAGTGGCCTTTTTGCAGAGGACATAATTCGACACTCTTCAAGC

445 CTGAGG

1323 NM 006252.2:9 AATGATAAGATGATAAGCCACTGCAAGCTGGTCTTGAGGGTCAC

75 CACTAT

1324 NM 006254.3:2 CTGAAAGGTGGCTCCAACCTCCGCTTTTCCAGCAGAGTCCAGTT

165 TATGGT

1325 NM 006274.2:4 TCTGCACGGTCATAGGTTAACTGCTGCGGCGCTTCATCTTG

01

1326 NM 006288.2 : 1 GGTATTCTCATGGCGGCAGTCCAGACGAAGGCTCT

35

1327 NM 006290.2:2 TCTTCTGGCTTTCCAGGGTGGCCTGGATGTTTCTGTCGATGAG

60

1328 NM 006291.2:3 TGTGATCATAAGCGTCCTTAAAAGCGGTAGAGCAGGCCGGGTAC

525 AGTGAC

1329 NM 006301.2:8 TTCACCACATCGTCGTAGGTGATTAGCATGTTGGGTGACTTGAG

00 ATCCCT

1330 NM 006343.2:6 TGAGGAAGTCCTTGTACTTCGATGTAGATGGGATCAGACACGAT

65 CTCTTC

1331 NM 006350.2:5 CAGGCTCTGGGCAAATCCGATTACAGGTCACACAGTAGGCATTA

75 TTGG

1332 NM 006419.2:2 GGACAACCATTCCCACGGGGCAAGATTTGAATTCGATCAATGAA

10 GCGTCT

1333 NM 006433.2:3 AGTTTTTGGACTATCGTCAGACAGGTCCTGTAGTCACGGCCCAG

05

1334 NM 006435.2:3 AATGGTCATGAAGATGCCCAAAATCAGGGCCCAGATGTTCAGGC

90 ACTTGG

1335 NM 006437.3:1 GGGATGGTGGGTTGGGTTTGGACAAATTAGTTTCACAGACATTA

170 ACCATG

1336 NM 006500.2:1 GAGGATGCTGGTGTTTTTGCCCAGGTCGTTGGAGGCCGTGCATT

515 CAACAC

1337 NM 006505.3:6 CTTCATCCTCTACGCGCAACCCGAACATCCTCAGCGAGGCATTC SEQ ID NO: Probe ID Capture Probe Sequence

04 CG

1338 NM 006509.2:2 GTCGATGATCTCCAATTCATCTGTGCTCCTGGAAACGGCGAGCG

50 AGAGTG

1339 NM 006516.2:2 TGAGTGGTTGGGTAGGAAGAGATGGGAAGGGGCAAATCCTAATG

500 GAGCCT

1340 NM 006564.1:9 CCTCCTGGCTGCTGTCATTGAAACTGCTGAACCCATAGTCTTCA

5 TGGTAA

1341 NM 006573.4:1 ACGTTTTACAAAATCCTTACTGCCCCTTTGAATTGTGTCCTTCC

430 TCCAAG

1342 NM 006623.2:5 CCCATGAACTTCTTCCGCTCCCATTTGCCGTCCTTCATCGAAGC

05 CG

1343 NM 006705.3:2 CGGAGAGCGCGGAGGGGACGCGGGCGAACACACTGACAGCCAGA

7 G

1344 NM 006725.3:1 CAGATTGTGCAAACTCCGGGAAGCTGAGCAGAGGACCCTGGCTG

280 C

1345 NM 006737.2:8 GAAAGAGCCGAAGCATCTGTAGGTCCCTCCGTGGGTGG

84

1346 NM 006770.3 : 1 CACTCGTCATCGCAAATTGTCCCCCAGGTACCACTGTAGTAAAC

434 TTCAGC

1347 NM 006845.3 : 1 CTCCTCTTCCTTGGATAAATTGCCTGGAATCAGCGCCCCGTTAG

940 AGCAGG

1348 NM 006846.3:2 TTCTCTGCATGCTTCGAAATTCACGACACAGATCCTCTTTGTCA

595 TTGCTC

1349 NM 007108.2:8 CTCCAGCTTGTGTTTCTGCTCTTGGCCATCGTCTG

00

1350 NM 007115.2:2 CTGGCTGCCTCTAGCTGCTTGTAAGTTGCGAGATGG

50

1351 NM 007129.2 : 1 GGAGATTAGCAGGGAGGTTTGGTTCAACATTTTTGTGGGTTTTT

849 ATTTTT

1352 NM 007199.1 : 1 GCTCCTGCAAGAATGCCCTGGAGCTTCTGAAGAAGGATCTATAT

735 TTACCT

1353 NM 007305.2:1 ATTCTGAAGACTCCCAGAGCAACTGTGCATGTACCACCTATCAT

275 CTAATG

1354 NM 007315.2:2 CAGAGTGCGAACGTTAACCTAGACAGCTCTCGAGGATGGCATAC

05 AGCAAA

1355 NM 007360.3:5 GCATTTTGAGACATACAAGAAGCCTGGCTCTCATACCAGTTTTT

22 ACTCTC

1356 NM 007361.3:1 CCGTTCTCAGAGCCAGGTTTTTCTAAAGCAAAGAGCCAGCCAAA

995 CAGGC

1357 NM 007371.3:2 AAAGGGATTCCACAAGGTTCTTCGGTACGAATCTCACACGGTTT

645 TCTGGG

1358 NM 012092.2:6 TCAAGTTGAGGAAAACTGGCCAACGTGCTTCATGCCTGGGTGCC

40 AGAGTT

1359 NM 012242.2:7 GAGAAAATGACCGTCACTTTGCAAGCCTGGGTCCCCACGAAACC

5 GTGCCG

1360 NM 012252.3:7 TTCCAGCGCATATCAGGATCATTAGACTTTGGAATAAGAGTGCC

33 AAGCTC

1361 NM 012258.3:5 ATCTAGTCCTTCAATGATGCTCAGATAACGCGCAACTTCTGCCA

85 GGCATT

1362 NM 012340.3:1 GAACTCGGAAAACCAGTCTCACCCGCGTGTTCTTTCTTCCAATG

815 TCCGTC

1363 NM 012342.2:1 GACCGGCACCATGCATTCCAAGTCTAACTTTGCAACCTGCCCCT

010 TTTTGG

1364 NM 012435.2:6 TGGACGGCATGTGGTGGTTGGCGATGACCTGGCGCG SEQ ID NO: Probe ID Capture Probe Sequence

98

1365 NM 013252.2:6 ATTCTGATTGGTAACATTGCCATTGAACACAGAGTTGTTGATCC

15 AACGCC

1366 NM 013261.3:1 CTGCTTCGTCGTCAAAAACAGCTTGACTGGGATGACCGAAGTGC

505 TTGTTC

1367 NM 013289.2 : 1 GTATGTTTGGAATTGTGAGTTCCTCAGTGTGATTGCAGCC

691

1368 NM 013351.1:8 CTTTAGTTTCCCAAATGAAACTTCCTGGCGCATCCAGTGCGCTC

90 CTGTGT

1369 NM 014009.3 : 1 GTAGATCTCATTGAGTGTCCGCTGCTTCTCTGGAG

230

1370 NM 014143.3:1 GAGCAATGGATGATTTGCTTGGAGGCTCCTTGTTCAGAAGTATC

245 C

1371 NM 014176.3:5 CCAGCCTCTGGTAGATTATCAAGCATCTCTTCCTCATCAGCCTT

95 TTGTTT

1372 NM 014207.2:1 TGTTTTGGTTCATTCCCGTTGGGCCAATCCACTGGCGCTGCTTC

295 TTCTGG

1373 NM 014261.1:5 GAGCAGGGGTTTTTGACCGGCTCCAGAATAGGCAAGGGGAGAGA

18 CTGGGG

1374 NM 014299.2:7 AGGTTTTGCTGTCCCTGTTTCTTTCCTCCCACGTCCTCTTCCTT

45 TTGCCT

1375 NM 014358.2:5 CATTGCCACTGACCCTCGACAACCTGGTCTGACAGTCCAATAAA

70 AAACTC

1376 NM 014417.4:1 CTCCAGGAGGCTAGTGGTCACGTTTGGCTCATTTG

310

1377 NM 014442.2:4 TTGTAACTCCATTTCATGCTTCCTCTCTCTAGCCGAAAGAAATA

24 TGACCC

1378 NM 014511.3:5 CTTGTTCATCAGAGTCCTCCCTGTTCACTGTTCTG

92

1379 NM 014729.2:5 TGGAATTAGAAAGCAGTGTTCCATCCTGGCCCAGCATATTGGAG

74 ACTGTG

1380 NM 014791.2:8 GAATGCTACTGGGAGAGAGCCACTTGGGAACATCATATTTTCCT

00 CTCATA

1381 NM 014805.2:1 AGGGCTTGGAGATGCTCATCTGTTAATGGCTGACTCAAAGTGTG

925 TTGGTT

1382 NM 014905.3:9 ACTGAATTTGGCCAGTTGAGGAATATAATCTGCAACCTTTCCTC

85 CAGACT

1383 NM 014963.2:2 AGGAACACGCCTTCAGCGGCCGAGACGAAGCAGTTGAGGTG

002

1384 NM 015091.2:2 GGAACAGGCTTTGTCCCATTTAGACCTCGTCGGGAAGATGGCGA

900 T

1385 NM 015177.1:4 CAGAGCAGAGCTTCTAGTGGGAAAACACTCTGTGTCAAGGTAGT

820 AGATGC

1386 NM 015259.4:1 ATGACGCTTTTGAAAGGGCCTCATTCCAGGATCACAGCCAACGC

190 CAGCAG

1387 NM 015364.2:3 GAGCTCTGCAAAAAGAGTAATCGTCATCAGATCCTCGGCAAATA

60 ACTTCT

1388 NM 015366.3:1 CGGGACGGGACGCAGTAAAAAAGTCTCACTCACACACACGCCAC

635 ATGGAC

1389 NM 015441.1:2 ACTTGGAGCTGGAGGGGCTGAAGGCTTGAAGGAAGGTGGTTACT

920 G

1390 NM 015527.3:2 AGAACCAAAGGACAGAAGACAAAGCGAGCACCCCCACCCCAGGC

915 CAACGC

1391 NM 015714.3:7 GTGGTAGGTCAGTTCTAGATGTCAGCGGTTTCTCTGAAGTTAAG SEQ ID NO: Probe ID Capture Probe Sequence

07 TCCAAA

1392 NM 015850.3:1 CATTCACCTCGATGTGCTTTAGCCACTGGATGTGCGGCTG

775

1393 NM 015869.3:1 CGGAGCGAAACTGGCAGCCCTGAAAGATGCGGATGGCCACCTCT

035 TTG

1394 NM 015900.2:1 TGCAGAACTTCCCAATAATGGTAGTCCGGTCTTTTTTCCAAACT

250 CGGTTG

1395 NM 015991.2:7 TGGTAAATGTGACCCTTTTTGGGGTCTTTTTCAACCCAGACCTG

18 GTCACC

1396 NM 016270.2:1 CGTGTGCTTTCGGTAGTGGCGCGTGAGCTCGTCTG

015

1397 NM 016343.3:5 CATCAAGAAATCTCTCCTTCCAGCTGTCATTCACCTTGGCCACA

822 TTATCT

1398 NM 016382.2:1 CCAATCACTTCATAGATAGTGCTATTGAAGGAAGGGCTGTGGTT

150 CCTCTT

1399 NM 016388.2:7 ACAAATGATCAGGTCATCACCCTGCTGCCAAGTCCTTCTG

70

1400 NM 016524.2:1 ATGACACAGTGGCGGGAGAACTTATCAAAATCCACCACGGTCAG

150 GAGCAG

1401 NM 016562.3:4 GAAAAAGAGCAGGAAGCACTGAAGCAGCAACCACCTGTGTGGTG

120 CCCACA

1402 NM 016610.2:2 GCAGCAGTGTCCGAAGGGAAGATGTAAAGTCAGATAGGCTATCA

310 GTTAAA

1403 NM 016817.2:4 CTGGATGGTGAACCCATCAAGGGACTTCTGGATCTCGAAATTGT

80 TTTTCA

1404 NM 017412.3:7 GGAAGTGTGACACGTCCATATTCCATACAAATAGGAGCGTAGAG

72 TGCACA

1405 NM 017617.3:7 GGACAATCGTCGATATTTTCCTCACAGTTCTGGCCGGTGAAGCC

35 TGGCAG

1406 NM 017712.2:6 TATGTGGAATCTCCTTGAGACAAAGTGTCACGACACAAAACCCC

600 CAGGCC

1407 NM 017778.2:4 GAGAAAGAGAAATCCATTGTTCTGCTCCAGCATCCTTAACTTTC

85 CCTTTC

1408 NM 017970.3 : 3 GTTTTGCTGGCACTGTGGGACTTATTCTGAATCTGTACATAGGA

233 CCTCCA

1409 NM 018063.3:2 TTGAAGCTGTGCATGTTTTTTTCTCTCTCTGAGTAAGACATGGA

040 CCCATC

1410 NM 018131.3:5 TTCTCCTTCTCTCGTTGTCTCTTCCAGCTGTTCAAGCAATGCGG

70 TAGTAC

1411 NM 018245.2:3 CAGGAATGCCCCATAAAACAGAGCGCAAACAAATCACCCAGCAG

615 GTTCGC

1412 NM 018326.2:3 GCACCTCTGTGTCGAAAATGCCTGGTGTGTCAACTACGACAAGT

15 TCTGTT

1413 NM 018404.2:4 CTGATGTCAGGGAAGTTACGGTGGACGCCGCAGCAGTTGAGACA

05 GATGAA

1414 NM 018643.3:3 CCTTGGGAGGCTGGTAGATCACACACTGATACAGTCCAGAATCT

75 T

1415 NM 018664.2:7 CCATGCTGGATCTGCACAAGGGCTCTGTGAGTTTGG

70

1416 NM 018685.2:1 CTTCTCCATATCTAGTTCACCTTCCTCTAGGACATCACTGAAGA

900 GGTCAT

1417 NM 018955.2:7 ATGCCATGACTGAAGAATTAACAGCCACCCCTCAGGCGCAGGAC

95 CAGGTG

1418 NM 018965.3 : 6 AGATGCAGGCCAGGAGGAGAAGGATGGAAGTGGGTGGGAA SEQ ID NO: Probe ID Capture Probe Sequence

11

1419 NM 019074.2:8 CAGGACAAGTTGCCATCTGGCTGGCACACATAGTGGCCGAAGTG

93 G

1420 NM 019111.3:3 AGCGCTTTGTCATGATTTCCAGGTTGGCTTTGTCCACAGCTATG

35 TTGGCC

1421 NM 020056.4:2 GTGCACTCTGCGGGTCAAAACTTATAAATTTGCTAAACATAGGC

64 AACTGC

1422 NM 020529.1:9 CCTCTGTGAACTCCGTGAACTCTGACTCTGTGTCATAGC

45

1423 NM 020761.2:6 GCCGGTTAACGTCGTGATTGAATTTTCACATCAGACCTGTGAAG

665 ACAGCC

1424 NM 020980.3 : 1 AGATGCCGAGTTATTAGTGCTTACCTAGCAAGAATTCCCATCGA

502 GGATGA

1425 NM 021147.4:1 ATGGCCACCAGCAGCTGCAACTTGCCCATACAGTC

121

1426 NM 021155.2:1 AGGTGGTAGGTGGAAGTTGAACAGATGGTAGGTTTGCATGTATG

532 AGATAA

1427 NM 021181.3:2 GGAAGTCTACTCTCTCCCTATTACGATTTTGGGTCACTATGATA

15 GTGCCC

1428 NM 021258.2:2 GCAGAGCTTGCAAAGTTGTGACATCAGTACAGTGTGTTATTGTA

524 CCCGTC

1429 NM 021602.2:2 TCTGTCCCCGACCCCAAACCCGTGACAACGTCCGAGG

4

1430 NM 021642.3:6 AAGCAGCCACAGGTTTCTGGGACATACATTCTGAGACATTTGGG

0 TCTC

1431 NM 021798.2:2 AAGACCCTAGGAGGGAGGACGGCTGTTGTCATCTGTTGACCACA

080 AACACG

1432 NM 021913.2:2 ATGGTCAAATTCCTTCATGCAGACCGCTTCACTCAGGAAATCCT

190 CCAGCT

1433 NM 021940.3:1 GAGTACTTTGCTGTTGAATGGTTCCTGTGCCATACAGAGATAAG

075 ATGGAG

1434 NM 022136.3:5 TGGCGTGAAATCCGTATGCACTCTGGCACGGCCACAGAATGGTC

60 CTGAAT

1435 NM 022153.1:1 CCCCATGTAGTTTTTAATAGCATCCCGCTTCATACTCAGAAGTG

955 TC

1436 NM 022162.1:4 TTCACAGGCATCAACCAGAAGCCTAGTGAGGCCGTTTGAAATTC

080 TGGCCC

1437 NM 022168.2:1 ACCCATTCGACATCTTTCTTTCTCAGAGAAGGGAGAGGGTTCTC

85 CCAAGC

1438 NM 022754.6:1 GAAATGATTGGCTCGTCCAATGAAAGTGCTTTGATCCCATCGAG

85 GTTCCT

1439 NM 022783.3:1 ATGTGCGGAGAAGACTCGTATGTCCAAAACCATCCATTTGCATG

497 GCAATC

1440 NM 023068.3:5 CAACACTGCCTCATTCACATTCATAGGCTGGAGTCATCACAGAT

165 TCTG

1441 NM 024013.1:5 ATTCCTTCCTCCTTAATCTTTCTTGCAAGTTTGTTGATAAAGAG

85 AGGGAT

1442 NM 024070.3:1 CCTGGCCAGACACCTATGGGACACTTATTGGAGGCCCAAGAATT

390 AAAGTA

1443 NM 024107.2:1 TCCCGCCAGTGTGATTTCAGTCTCAAAAGATGAGTATTTGGCTG

485 AGAAAT

1444 NM 024408.3:2 CCAGCCAGGAGCACACAAGCAAGTATAACTCTCAAAATTTGGTG

842 ACTCTT

1445 NM 024494.1:1 AAAAGAAGCTCTCTACAGGTACCCTTCCTCTTGCACACCAAGAA SEQ ID NO: Probe ID Capture Probe Sequence

530 GTGTCG

1446 NM 024608.2:1 GGCAAGACAATAAGAAAGGGTGAGTGCAAGCAAGGAGAGCCTCC

675 TGCTAA

1447 NM 024626.2:1 GTGGCAGTCAATTAGCAGCGTCTTAGGGTACATACTACAGCTTA

375 ATTTGT

1448 NM 024689.2:3 AAGAAAGCAAGGAATCGGGAGGCAGTCCAAGGTGGGAAGCCAGC

14 CAGTTG

1449 NM 024756.2:3 TTTCCAGGGAAGAGACAGACCAACTGAATGACCTCCAGCCCATC

040 C

1450 NM 024827.3:2 CAGAGACCAACGGCAAGGGTAGGGATCTCAGAGTGCATTGTTAG

601 AG

1451 NM 024829.5 : 8 AATCCAGGAAGAACCTTGATAAGAGCGGAGCAATGTCCCATGTC

24 CCATCT

1452 NM 024908.3 : 1 GTGCATGGCATTGATGGAACACACAGAGACAAGGTATTCTCCAC

875 CAAACG

1453 NM 025107.2:1 GTCCTCCCAAAAGTTTTCTGGCCATGGACTCCCTAAACTTGTTG

59 TGTTAT

1454 NM 025216.2:2 TTGTGTCTCGCTTACTCACATCTGTGGCCTCAGTG

255

1455 NM 025217.2:9 TCATCATGATCTGCTGGAGGCCACTGGACATACACCGTAGGTCG

05 TGG

1456 NM 025239.3:2 GAGGAAGATCATGTTCTGTATTTGATATGAGGACTTGCCACAGC

35 TCCACA

1457 NM 030761.3:6 GGCGATGTTGTCAGAGCATCCTGACCACTGGAAGC

25

1458 NM 030955.2:6 CAGTCCATGGCAGGCACTGAGGGCTGCCGTCCCAACTCTGG

02

1459 NM 030964.3:1 TGTGGTGAGCAGAACACCCCCGAGAGTTAGTTGATGCAGTTGGA

900 AGGGAG

1460 NM 031866.1: 8 GGCCGCTCCGGGTACTTGAAGCGCTCCATGTCGATAAGGAAG

90

1461 NM 031966.2:7 TTCCCGACCCAGTAGGTATTTTGGTCTGACTGCTTGCTCTTCCT

15 CAAGTT

1462 NM 032043.1:1 GTTTCTTCCCCAGGCTGACAAGTTCTTCTATATCCCAGGCTTTG

130 CACATC

1463 NM 032364.5:1 AGAGGGCCAGAGCCAGGAGCAGCAAAGCACCCAGCAGCTTAAGA

166 AAACGA

1464 NM 032427.2:1 GGCCACCTTGTCCTGCAGAGAGATTCTCCCCAACACGAATTCTT

890 TTGATA

1465 NM 032514.2:4 CTCGTAGATGTCCGCGATGGGCGTGGACACACTCACCATG

04

1466 NM 032642.2:1 AACTGCAGATGCCGCACAAGTGCACGTGGATGAAAGAGTAAGAG

745 AGCACC

1467 NM 032782.3:9 CCTGCTGCTGACATAGCAATAATACTCATTGGGCTCCTCCACTT

55 CATATA

1468 NM 032963.3:2 CACTTGTCACTGGGGTTGGTACAGACGGAATGGCCCCTTTTGGT

74 GATGAA

1469 NM 033035.4:8 GAGCAATGCTTATGCAACTACAGCCGAGAATTACTGCCATGAAG

99 CCAGTC

1470 NM 033119.3:2 GAGAGGGATGGTCTCAGGGATAGTCCTTAAATACGTGTGTGTAT

325 CACTGT

1471 NM 033381.1:5 GTCAGCATGTTATCTTGATCATATATAGTAGCACCATTGACGGC

360 AGCAGT

1472 NM 033388.1 : 1 ACGCAGGTCGATGACCTTGAGTGTGTTGTCTCGGGAACAG SEQ ID NO: Probe ID Capture Probe Sequence

586

1473 NM 033423.3:7 GGCAGGAAGTGTGAGACCTTGATGTAGACTCCTGGAGGTGTCCC

05 r^ir^ir^ir^ir^ir^i

1474 NM 033439.2:1 TGTTAATTCGGTGTCTCATCTAGGCTCTGGTAGGTTAGAAGATT

725 TCTGG

1475 NM 033554.2:8 AAGAAAAGCTGAGATGGAGTTTGTAGGGCAGCTGGAGTTCAGAT

57 CTCTCC

1476 NM 033642.1:6 TCACTGGCTACGTTGATTCATTGTGGCTCATGGATTTGCCTCCG

20 TTCAGC

1477 NM 033666.2:2 GGACCGGCTGGGGTAATTTGTCCCGACTTTCTACCTTGGTAATG

000 TTAAAA

1478 NM 052902.2:5 CTGTCTAAGGCGGTCAGTGCATTGTAGCTGAAGTTGGCAGAAAG

65 CAGAGC

1479 NM 052966.2:3 ACACCTTCCACCCTCCATTTCCGCTTAGCTTCTCTTGAATCTAT

526 TGGGCA

1480 NM 053056.2:6 GATCTGTTTGTTCTCCTCCGCCTCTGGCATTTTGGAGAGGAAGT

90 GTTCAA

1481 NM 057179.2:4 GAAGTCTATGTACCTGGCGGCCAGCTTGAGCGTCTG

82

1482 NM 058238.1:1 CAGCCTGGGAACTGGTCTGGAGAGGCCAGCCGGCGTAGCTTTTC

535 TGTGTC

1483 NM 080792.2 : 3 GTTATAGTGAAGACTGAATAAATAGGGCTTGCGACATCTGCTTG

115 CCCTGG

1484 NM 080921.2 : 9 TGCGTCCTTTCTCCACTGTTGTCTTATCAGACGAGGAACAATTT

0 CCTCCT

1485 NM 080921.3:2 GGGGAAGGTGTTGGGCTTTGCCCTGTCACAAATACTTCTGTGTC

58 CAGAAA

1486 NM 130386.2:9 CTGCAGATTTTGAAAGTCGTTCTTGATTCGCTGGATAGCCTGGC

00 TTGTG

1487 NM 133487.2:5 ATTCTACCATCATGGCTGATGCTTGATAAAGGAGCTGGGTCTGG

66 TGG

1488 NM 138554.2:2 CTGTTCCTTCTGGATTCCATGATTTACCATCCAGCAGGGCTTTT

570 CTGAGT

1489 NM 138761.3:3 CCCCAGTTGAAGTTGCCGTCAGAAAACATGTCAGCTGCCACTCG

42 GAAAAA

1490 NM 138981.2:4 CGCTCATGGTCTAATTCCATCTGAATCACTTGACATAAGTTGGC

50 ATCCAT

1491 NM 144728.2:1 TGGTGTAAGGATTCTCGGTGTCACACCGTTGTTTAGGTC

176

1492 NM 145159.1:4 GCTCTCTCCTTTCATACAGCGAGTGCCACGCACGGAAACTTTAC

225 AAAAAT

1493 NM 145259.2:5 ACAACCCTGAGTTTTCTCTGCCCCAATAAGTCACATGGTGGCAA

168 AATTCC

1494 NM 145333.1:6 GGGAACACTGTAAACACCAACTCATTGCGTGGGCAGCAGTATAA

70 TATGGC

1495 NM 145902.2:9 CGGCTGGTGTGCTGTGTAGTGTGGTGGTGAGGGCACAGGTGGAA

06 GATGGG

1496 NM 145912.5:5 GCCCACCTCTCCTGCATAAGCTGTCTGCCAAGAAAACTATTGAA

290 CTACAT

1497 NM 147162.1:4 AGAAGTTCTCATAGTCGGCTGCTTGGCAGGAGACAACAGGGCGG

00 G

1498 NM 147164.1:7 TGCTGACACTTATGGAGACCTTGTACTTGATGGTGGAGAACAGG

84 TGCATG

1499 NM 147780.2:1 CAGGAAGTCCGAATACACAGAGAAAGCTCCCTCCACGGGGCCGT SEQ ID NO: Probe ID Capture Probe Sequence

054 TTTTGT

1500 NM 152275.3:2 GAAGTGATGCAGCTTACACTGCATAGTCCCTACCCTTCTGGATT

408 AAATGA

1501 NM 152456.1:8 TACAGCAGCTCCATGACCCGGAAGCAGTTGTCCAGCAG

60

1502 NM 152756.3:3 TGGCACAGATTCACTTTCACTATTATGTCTAGAGCTGGTTGACT

097 CCGAGT

1503 NM 152852.2:1 AATTGCCACTTCGAGACATACAAGTTTCCTGTTGTTAGGCAAGT

46 CTGTTC

1504 NM 152866.2:6 CACACAGTCACACAGATGGGTGCATAGATCCCTGC

20

1505 NM 152899.1: 1 CGGCCATAAGGGACCGTCCAGTCATCCTTTTCGGTTTG

452

1506 NM 152942.2:2 TCGCAAGGCCACGGCTTCTCCAACTTTCCCCAAAACATCTGAGC

030 GGTTTC

1507 NM 153603.3:1 GTTTGCACTTCTTTCGTATGGACTGGAGAGTGCTGGTGAAATCA

492 GACACA

1508 NM 156038.2:9 CAAGTTACTTCACCTTTCCGAGCCGAGCCTCAGTTTCCCCATGT

0 TGGCAC

1509 NM 172174.1:1 CTGCAGCATTGGTACCCAGCCCCACCAATACATAATTTGACTAT

685 CACCCT

1510 NM 172195.3:1 CACACGCTCACAGAACTTGTATGTTTCACAGCAAACCAGCACTG

390 GTACAT

1511 NM 173343.1:9 ACACGGGATTGTCAGTCTTGACCCCAGAGAAGCTGATATGG

05

1512 NM 173799.2 : 1 CTCATTCCTCTGAGAGAGATGGTGGAAGGATAAAAGTCTTCTAA

968 GATCCA

1513 NM 175060.1: 1 GAGTGTGCAGTTCTGATTTAGCTCCTCAGTGGAGTAAAGGGAAT

930 TTAGAG

1514 NM 175862.3:1 GAAGCAGTAAGAGAATTAAAGTCTCCTCTTGGCATACGGAGCAG

265 AGCTGG

1515 NM 176894.1:2 ATGGAAGAAAACGTGGGCTTCACCCTACGATGGTCGTGTTGGAG

300 CTCGTG

1516 NM 178502.2:1 CCAAGGGCAATGGAGGGGCAGGGAAACCGGGAGTATATGTACAC

620 GGGGAG

1517 NM 181501.1: 1 CACCTGATGGAATACGTTGTGCATACTCTTTCCTTATAGTCTTG

875 CCACTT

1518 NM 181504.2:1 CAGCTTTGTTTCGGTTGCTGCTTCCAACATTCCATGTCTTCTCA

105 TCATGA

1519 NM 181755.1: 1 TGGAGCATCTCTGGTCTGAATTCCTCGTTTGCAGAATAGTAGTA

55 GTAGGC

1520 NM 181780.2:3 ATTTCACAGGGCATTCTAGTTCAAAGGGATCTCCTGCTAAGATG

05 GAGTGT

1521 NM 181803.1:2 CTGGCTGGTGACCTGCTTTGAGTAGGTTTCTTGCAGGTACTTCT

69 TAAAAG

1522 NM 181879.2:5 TCACGTTCTCTCCTGAGGTCACCACAGGACTGGGC

45

1523 NM 182398.1:1 CAACATTTGTCACTCCAGGACGTTCAACTCCCATGTGAAACTGA

390 AGAGGG

1524 NM 182471.1:2 GGAACTGGACAGAGTACACACAGGAAAGGAAGCTGTCACCCTCT

105 TGCCAT

1525 NM 182795.1:7 TTCTTCTTTTTCCAGCTTTTTTTTCTTAGCCACGCTCGCC

45

1526 NM 182797.2:9 GTAGTGAGCCAGAGGATGGTCCATTTCTTGGTAAAGTTCTAAAC SEQ ID NO: Probe ID Capture Probe Sequence

94 GATCTA

1527 NM 182906.2:4 TCCAACCACACAGATGATGACCAGCAGCAGGAGGCCGAGG

30

1528 NM 182948.2 : 8 AGCCAAATACTCTGGAGTTCCACATAATGTCCAAGTTCTGCCTT

05 TAACTC

1529 NM 182962.2:2 CAGTTCACATGACAAGTCGTATTTCAGTTCAAACGTGTTGGCGC

75 TTTTCA

1530 NM 184041.2:1 CACCACACACCACTGTCACGAGGGAAGAAAGAGCGCGGGCAAGC

455 CAG

1531 NM 197954.2:5 AGAATCTCTGAGTCAAATCATGTGGGCTAGGTACTTACCGGAGT

5 TTAACA

1532 NM 198053.1: 1 AATGACGCAGCAGTATCCTAGTACATTGACGGGTTTTTCCTGTC

490 CTGCCA

1533 NM 198282.1:7 AGCTCTGGCAGGATCAGCCGCAGATATCCGATGTAATATGACCA

25 TG

1534 NR 001434.3:2 GCCTTGCAGATCTGTGTGTTCCGGTCCCAATACTC

20

1535 NR 003085.2 : 8 CTGTCTGTTGAACTCCTTCCAACTCCATGCGTGCATTGTGAAAT

92 GAAACC

1536 NR 024115.1:2 CCTTCCAGGAAAACATCATGGGCTTCAGAGTTCTCCCATAAACC

175 AGGCAG

1537 NR 026800.2:9 GTCACAGAGGGAAAGAGAAACAGGACATCAGCCTTTGACTTCAG

125 AACTGT

1538 NR 029467.1:1 AATAGGACTCTTTCAACTTGAGCAGGACCCCATTACTTCACTGG

585 AGTTAG

1539 NR 049726.1:5 GGGTAGAGCTGCCACATGATAGGCAGCAGGCTTGG

43

1540 NR 104213.1:4 CTTGAGTTGTGTCTGCAGGCTGTGAAGGACCTCAG

75

[062] The compositions of the present disclosure can comprise at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700 or 770 (or any integer within said ranges) first probes. In some preferred aspects, compositions of the present disclosure can comprise at least 174 or at least 37 first probes.

[063] The compositions of the present disclosure can comprise at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700 or 770 (or any integer within said ranges) first probes and second probes. In some preferred aspects, compositions of the present disclosure can comprise at least 174 or at least 37 first probes and at least 174 or at least 37 second probes.

[064] The compositions of the present disclosure can comprise at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700 or 770 (or any integer within said ranges) first probes, second probes, third probes and fourth probes. In some preferred aspects, compositions of the present disclosure can comprise at least 174 or at least 37 first probes, at least 174 or at least 37 second probes, at least 174, at least 37 third probes and at least 174 or at least 37 fourth probes.

[065] In some aspects, when a first probe is hybridized to a target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule.

[066] In some aspects, when a first probe and a second probe are bound to the target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule. In some aspects, when a first probe, a second probes, a third probe and a fourth probe are bound to a target molecule, the identity of the first and second signals emitted from the second probe and their locations relative to each other constitute at least part of a code that identifies the target molecule.

[067] In some aspects, a plurality of first RNA molecules can be hybridized to a first label attachment region, wherein the first RNA molecules are attached to said one or more label monomers that emit light constituting said first signal; and a plurality of second RNA molecules can hybridized to a second label attachment region, wherein the second RNA molecules are attached to one or more label monomers that emit light constituting a second signal.

[068] In some aspects, a second region of a first probe can further comprise a third, fourth, fifth and at least sixth label attachment region, wherein: (i) the third label attachment region is hybridized to at least one third RNA molecule, wherein the at least one third RNA molecule is attached to one or more label monomers that emit light constituting a third signal; (ii) the fourth label attachment region is hybridized to at least one fourth RNA molecule, wherein the at least one fourth RNA molecule is attached to one or more label monomers that emit light constituting a fourth signal; (iii) the fifth label attachment region is hybridized to at least one fifth RNA molecule, wherein the at least one fifth RNA molecule is attached to one or more label monomers that emit light constituting a fifth signal; (iv) the at least sixth label attachment region is hybridized to at least one sixth RNA molecule, wherein the at least one sixth RNA molecule is attached to one or more label monomers that emit light constituting a sixth signal; and wherein none of the label attachment regions overlap.

[069] In some aspects, when a first probe, or a first and a second probe, are bound to a target molecule, the identity of the first, second, third, fourth, fifth and sixth signals emitted from the first probe and their locations relative to each other constitute at least part of a code that identifies the target molecule.

[070] In some aspects, a second region of a second probe can further comprise a third, fourth, fifth and at least sixth label attachment region, wherein: (i) the third label attachment region is hybridized to at least one third RNA molecule, wherein the at least one third RNA molecule is attached to one or more label monomers that emit light constituting a third signal; (ii) the fourth label attachment region is hybridized to at least one fourth RNA molecule, wherein the at least one fourth RNA molecule is attached to one or more label monomers that emit light constituting a fourth signal; (iii) the fifth label attachment region is hybridized to at least one fifth RNA molecule, wherein the at least one fifth RNA molecule is attached to one or more label monomers that emit light constituting a fifth signal; (iv) the at least sixth label attachment region is hybridized to at least one sixth RNA molecule, wherein the at least one sixth RNA molecule is attached to one or more label monomers that emit light constituting a sixth signal; and wherein none of the label attachment regions overlap.

[071] In some aspects, when a first probe, a second probe, a third probe and a fourth probe are bound to a target molecule, the identity of the first, second, third, fourth, fifth and sixth signals emitted from the second probe and their locations relative to each other constitute at least part of a code that identifies the target molecule.

[072] In some aspects, a plurality of first RNA molecules are hybridized to the first label attachment region, wherein the first RNA molecules are attached to said one or more label monomers that emit light constituting said first signal; wherein a plurality of second RNA molecules are hybridized to the second label attachment region, wherein the second RNA molecules are attached to one or more label monomers that emit light constituting a second signal; wherein a plurality of third RNA molecules are hybridized to the third label attachment region, wherein the third RNA molecules are attached to one or more label monomers that emit light constituting a third signal; wherein a plurality of fourth RNA molecules are hybridized to the fourth label attachment region, wherein the fourth RNA molecules are attached to one or more label monomers that emit light constituting a fourth signal; wherein a plurality of fifth RNA molecules are hybridized to the fifth label attachment region, wherein the fifth RNA molecules are attached to one or more label monomers that emit light constituting a fifth signal; and wherein a plurality of sixth RNA molecules are hybridized to the sixth label attachment region, wherein the sixth RNA molecules are attached to one or more label monomers that emit light constituting a sixth signal.

[073] In some aspects, a first probe can comprise an affinity moiety. In some aspects, any of the first probe, second probe, third probe or fourth probe can comprise an affinity moiety.

[074] Various methods of the present disclosure are described in full detail herein.

[075] The present disclosure also provides a method of detecting a target molecule in a biological sample comprising: (i) contacting said sample with a composition of the present disclosure under conditions that allow hybridization of a first target-specific sequence of a first probe to a target molecule, wherein when a first target-specific sequence of a first probe is bound to a target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule; and (ii) detecting the code that identifies the target molecule.

[076] The present disclosure also provides a method of detecting a target molecule in a biological sample comprising: (i) contacting said sample with a composition of the present disclosure under conditions that allow hybridization of the first target-specific sequence of a first probe and the second target-specific sequence of a second probe to a target molecule, wherein when the first target-specific sequence of a first probe and the second target-specific sequence of a second probe are bound to the target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule; and (ii) detecting the code that identifies the target molecule.

[077] The method of detecting a target molecule in a biomolecular sample can comprise contacting a sample with a composition of the disclosure under conditions that allow (i) binding of a first target-specific sequence of a first probe to a target molecule; (ii) binding of the first probe to a second probe; wherein when said first and second probes are bound to the target molecule, the identity of the first and second signals emitted from the second probe and their locations relative to each other constitute at least part of a code that identifies the target molecule; and (iii) detecting the code that identifies the target molecule.

[078] The method of detecting a target molecule in a biomolecular sample can comprise (a) contacting said sample with the composition pair of the disclosure under conditions that allow (i) binding of a first target-specific sequence of a first probe and the second target-specific sequence of a third probe to a target molecule, (ii) binding of the first probe to a second probe; and (iii) binding of the third probe to a fourth probe, wherein when said first, second, third and fourth probes are bound to the target molecule, the identity of the first and second signals and their locations relative to each other constitute at least part of a code that identifies the target molecule.

[079] In certain aspects, the methods of detection are performed in multiplex assays, whereby a plurality of target molecules are detected in the same assay (a single reaction mixture). In a preferred aspect, the assay is a hybridization assay in which the plurality of target molecules are detected simultaneously. In certain aspects, the plurality of target molecules detected in the same assay is at least 5 different target molecules, at least 10 different target molecules, at least 20 different target molecules, at least 50 different target molecules, at least 75 different target molecules, at least 100 different target molecules, at least 200 different target molecules, at least 500 different target molecules, or at least 750 different target molecules, or at least 1000 different target molecules. In other aspects, the plurality of target molecules detected in the same assay is up to 50 different target molecules, up to 100 different target molecules, up to 150 different target molecules, up to 200 different target molecules, up to 300 different target molecules, up to 500 different target molecules, up to 750 different target molecules, up to 1000 different target molecules, up to 2000 different target molecules, or up to 5000 different target molecules. In yet other aspects, the plurality of target molecules detected is any range in between the foregoing numbers of different target molecules, such as, but not limited to, from 20 to 50 different target molecules, from 50 to 200 different target molecules, from 100 to 1000 different target molecules, from 500 to 5000 different target molecules, and so on and so forth.

[080] Preferably, the target molecule is DNA (including cDNA) or RNA (including mRNA and cRNA).

[081] The present disclosure may be particularly useful for multiplex assays to detect a plurality of target molecules in a sample, for example, a set of genes. Each target molecule, or gene of interest, in a multiplex assay is assigned a unique or distinct tag sequence in the reporter oligo, thereby associating each gene with a unique reporter code as designated by the unique linear arrangement of label monomers associated with the reporter probe. A single non-labeled capture probe can be utilized for all genes wherein the region of each target-specific capture oligo that binds to the capture probe is the same for all target genes. In such a system, the specificity for each individual target gene is directed by the target-specific sequence of each capture oligo; therefore, each target gene has a unique capture oligo comprising a unique target- specific sequence plus a universal capture tag sequence.

[082] Nanoreporter Nomenclature

[083] STANDARD NANOREPORTER SYSTEM: The term "standard nanoreporter system" refers to the existing non-tag-based nanoreporter systems that utilize capture and reporter probes that contain target-specific sequences for binding directly to the target molecule. This system allows for efficient detection and quantification of a plurality of target molecules, however has some drawbacks.

[084] TAG-BASED NANOREPORTER SYSTEM: The term "tag-based nanoreporter system" refers to reporter systems utilizing four probes for each target molecule. Two of the probes (e.g., reporter and capture oligo) bind specifically to the target molecule, and each also binds to another probe containing either a detection label (e.g., reporter probe) or an affinity moiety (e.g., capture probe) via a tag sequence. This system allows for more reliable and reproducible methods for manufacturing the probes and reduces the variability and false positives of previous non-tag-based nanoreporter systems.

[085] NANOREPORTER: The term "nanoreporter", when not referring to the standard nanoreporter system, refers to tag-based nanoreporter s, or compositions that include a first probe that has a target specific region and a region that hybridizes to a second probe, wherein the second probe comprises an affinity moiety, and a third probe that has a target specific region and a region that hybridizes to a fourth probe, and where the fourth probe has a label attachment region or an affinity moiety. For example, the nanoreporters of the present disclosure refer to a composition that includes a reporter oligo and reporter probe pair, and a capture oligo and capture probe pair, wherein the target-specific sequences of the reporter oligo and capture oligo recognize or bind to different sequences of the same target molecule. Nanoreporters are preferably synthetic, i.e., non-naturally-occurring, nucleic acid molecules.

[086] PROBE: This refers to a molecule that can specifically hybridize to another molecule through a sequence-specific interaction. In some aspects, the probes may contain target-specific sequences. In some aspects, the probes may contain sequences that can hybridize to other probes. In some aspects, the probes may contain label attachment regions and attached label monomers suitable for detection. In some aspects, the probes may contain at least one affinity moiety, such as biotin or repeat nucleotide sequences.

[087] REPORTER PROBE: A molecule that is labeled with at least one label monomer that emits a signal that contributes to the nanoreporter code and may or may not also contain a target- specific sequence. A reporter probe without a target-specific sequence contains instead a tag- specific sequence, which is complementary to a tag sequence present on a second probe (referred to herein as "reporter oligo"). The reporter probe binds or hybridizes to the second probe, which binds to the target molecule through a target-specific sequence.

[088] CAPTURE PROBE: A molecule that has at least one affinity tag for purification and immobilization, and may or may not also contain a target specific sequence. Preferably the affinity moiety is biotin. The capture probe may also contain additional affinity moieties, such as repeat nucleotide sequences, for affinity purification. In some aspects, the capture probe contains at least one label monomer that emits a signal that contributes to the nanoreporter code. A capture probe without a target-specific sequence contains instead a tag-specific sequence which is complementary to a tag sequence present on a second probe (referred to herein as "capture oligo"). The capture probe binds or hybridizes to the second probe, which binds to the target molecule through a target-specific sequence.

[089] REPORTER OLIGO: The reporter oligo is a probe that comprises a target-specific sequence in a first region, and a second region that does not overlap with the first region and does not bind to the target molecule. The second region binds to a reporter probe.

[090] CAPTURE OLIGO: The capture oligo is a probe that comprises a target-specific sequence in a first region, and a second region that does not overlap with the first region and does not bind to the target molecule. The second region binds to a capture probe.

[091] TAG: The region of the reporter or capture oligo that binds to the reporter probe or capture probe, and/or its complementary sequence that is present in the reporter or capture probe that binds to the reporter oligo or the capture oligo. This sequence preferably consists of "alien" sequences which have no significant similarity to known biological genomes or sequences derived from these genomes. These tags are also typically selected due to structural properties, such as melting temperature and secondary structure.

[092] TARGET-SPECIFIC SEQUENCE: The term "target-specific sequence" refers to a molecular entity that is capable of binding a target molecule. In the context of the tag-based nanoreporter system of the present disclosure, the target-specific sequence is covalently attached to a tag sequence in a reporter or capture probe. The target molecule is preferably (but not necessarily) a naturally occurring or synthetic DNA or RNA molecule or a cDNA of a naturally occurring RNA molecule or the complement of said cDNA.

[093] SEGMENT: The term "segment" refers to a molecular entity attached to the label attachment region of the nanoreporter, generally for the purpose of labeling the nanoreporter. The segment can have one or more label monomers either directly (covalently or noncovalently) or indirectly attached to it.

[094] NANOREPORTER CODE: The order and nature (e.g., primary emission wavelength(s), optionally also size) of spots of light from a nanoreporter serve as a nanoreporter code that identifies the target molecule capable of being bound by the nanoreporter through the

nanoreporter's target-specific sequence. When the nanoreporter is bound to a target molecule, the nanoreporter code also identifies the target molecule. Optionally, the size of a spot can be a component of the nanoreporter code. Nanoreporter codes are also known as reporter codes, barcodes, or codes.

[095] SPOT: A spot, in the context of nanoreporter detection, is the aggregate signal detected from the label monomers attached to a single label attachment site on a nanoreporter, and which, depending on the size of the label attachment region and the nature (e.g. primary emission wavelength) of the label monomer, may appear as a single point source of light when visualized under a microscope. Spots from a nanoreporter may be overlapping or non-overlapping. The nanoreporter code that identifies that target molecule can comprise any permutation of the size of a spot, its position relative to other spots, and/or the nature (e.g., primary emission

wavelength(s)) of its signal. Generally, for each probe, probe pair, composition or composition pair of the disclosure, adjacent label attachment regions are non-overlapping, and/or the spots from adjacent label attachment regions are spatially and/or spectrally distinguishable.

[096] Tags

[097] The "tags" referred to herein are the sequences of the reporter or capture oligos that hybridize to a reporter probe or a capture probe, and their complementary sequences, or complements, present in the reporter or capture probe that hybridize to the corresponding reporter or capture oligo. In a reporter or capture oligo, the tag sequence is adjacent to, but not overlapping with, the target-specific sequence. In a multiplexed reaction, a given tag must only hybridize to its complement to form a reporter probe and reporter oligo pair, or a capture probe and capture oligo pair. This given tag must not cross hybridize to any other tag of a different oligo, reporter probe or capture probe, or any other biological or synthetic nucleic acid sequence present in the reaction under the conditions of hybridization at which the experiment is performed.

[098] Preferably, a set of tags are "alien" sequences which have no significant similarity to known biological genomes or sequences derived from these genomes. In some aspects, the tags may be 10 bases, 15 bases, 20 bases, 25 bases, 30 bases, 35 bases, 40 bases, 45 bases, 50 bases, 55 bases, or 60 bases long. Preferably, the tags are 25 or 35 bases long. The tags must also have similar melting temperatures (Tm's) under the same hybridization conditions so that the hybridization of each tag retains its specificity when mixed in the same reaction. In addition, the tags should be substantially free of any secondary structure which could impact the kinetics of hybridization to the complementary target. Exemplary sample tags described in U.S. Patent Application No. 2014/0371088 are "alien tags" which have been matched for Tm and screened for minimal secondary structure and cross-hybridization with known biological sequences. Each tag can be synthesized adjoined to a target-specific sequence and can be utilized as the tag region of a reporter oligo or a capture oligo in a multiplex reaction.

[099] Target-Specific Sequences

[0100] The term "target-specific sequence" refers to a molecular entity that is capable of binding a target molecule. In the context of the tag-based nanoreporter system, the target-specific sequence of a capture or reporter oligo is in a first region that does not overlap with the second region, does not bind to the target, and binds or hybridizes to a capture or reporter probe.

[0101] The target specific sequence is generally an amino acid sequence (i.e., a polypeptide or peptide sequence) or a nucleic acid sequence.

[0102] In specific aspects, where the target-specific sequence is an amino acid sequence, the target-specific sequence is an antibody fragment, such as an antibody Fab' fragment, a single chain Fv antibody.

[0103] The target-specific sequence is preferably a nucleic acid sequence, and is most preferably within an oligonucleotide that is covalently attached to a tag sequence, resulting in a

oligonucleotide that is hybridizes or binds to a capture or reporter probe, i.e. a capture oligo or a reporter oligo. A target-specific nucleic acid sequence is preferably at least 15 nucleotides in length, and more preferably is at least 20 nucleotides in length. In specific aspects, the target- specific sequence is approximately 10 to 500, 20 to 400, 30 to 300, 40 to 200, or 50 to 100 nucleotides in length. In other aspects, the target-specific sequence is approximately 30 to 70, 40 to 80, 50 to 90, or 60 to 100, 30 to 120, 40 to 140, or 50 to 150 nucleotides in length.

[0104] A target-specific nucleotide sequence preferably has a Tm of about 65-90°C for each probe in 825 mM Na⁺ (5xSSC), most preferably about 78-83°C.

[0105] Target Molecules

[0106] The term "target molecule" is the molecule detected or measured by binding of a labeled nanoreporter (i.e., a reporter probe/oligo pair and a capture probe/oligo pair) whose target- specific sequence(s) recognize (are specific binding partners thereto). Preferably, a target molecule can be, but is not limited to, any of the following: DNA, cDNA, RNA, or mRNA. Generally, a target molecule is a naturally occurring molecule or a cDNA of a naturally occurring molecule or the complement of said cDNA.

[0107] A target molecule can be part of a biomolecular sample that contains other components or can be the sole or major component of the sample. A target molecule can be a component of a whole cell or tissue, a cell or tissue extract, a fractionated lysate thereof or a substantially purified molecule. The target molecule can be attached in solution or solid-phase, including, for example, to a solid surface such as a chip, microarray or bead. Also, the target molecule can have either a known or unknown structure or sequence.

[0108] In certain specific aspects, that target molecule is not a chromosome. In other specific aspects, the target molecule is no greater than 1,000 kb (or 1 mb) in size, no greater than 500 kb in size, no greater than 250 kb in size, no greater than 175 kb in size, no greater than 100 kb in size, no greater than 50 kb in size, no greater than 20 kb in size, or no greater than 10 kb in size. In yet other specific aspects, the target molecule is isolated from its cellular milieu.

[0109] Design of Label Attachment Regions

[0110] The present disclosure provides reporter and/or capture probes that are artificial nucleic acid molecules (DNA, RNA, or DNA/RNA hybrids) designed to have features that optimize labeling and detection of the tag-based nanoreporter.

[0111] A reporter probe or a capture probe can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-100 label attachment regions or more.

[0112] The label attachment regions of a reporter or capture probe will vary in size depending on the method of labeling. In various aspects, a label attachment region can have a length anywhere from 10 nm to 10,000 nm, but is more preferably from 50 nm to 5,000 nm, and is more preferably from 100 nm to 1,000 nm. In various aspects, the label attachment region is from about 100 nm to about 500 nm, from about 150 nm to about 450 mm, from about 200 nm to about 400 nm, or from 250 to about 350 nm. In a preferred aspect, the label attachment region corresponds closely to the size of a diffraction-limited spot, i.e., the smallest spot that can be detected with standard optics, which is about 300 nm.

[0113] Where the probe is a nucleic acid, 1 nm corresponds to approximately 3 nucleotides; thus, an approximately 300 nm-label attachment region corresponds to approximately 900 bases. In other preferred aspects, the label attachment region is from about 300 nucleotides to about 1.5 kb, from about 450 nucleotides to about 1.35 kb, from about 0.6 kb to about 1.2 kb, or from 0.75 kb to about 1.05 kb.

[0114] In these aspects of the disclosure, a reporter or capture probe is designed to have one or more regions, useful as label attachment regions, comprising a regular pattern of a particular base (the "regularly-repeated base"). In such regions, the regularly-repeated base occurs with a periodicity of every nth plus or minus 1 residue, where n is any number, and preferably from 4 to 25.

[0115] Preferably, not more than 25% of the regularly-repeated base in a region appears at other than said regular intervals. For example, if in a region of 100 nucleotides there are 12 thymidine bases, and thymidine is the regularly-repeated base, in this aspect of the disclosure not more than 25% of these, i.e., 3 thymidine bases, appear outside the regular pattern of thymidines. In specific aspects, not more than 20%, not more than 15%, not more than 10%, not more than 9%, not more than 8%, not more than 7%, not more than 6%, not more than 5%, not more than 4%, not more than 3%, not more than 2% or not more than 1% of said base appears at other than said regular intervals in said region

[0116] The regularly-repeated base in the regions in a reporter or capture probe, or its complementary regularly-repeated base in an annealed segment can be used to attach label monomers, preferably light emitting label monomers, to the nanoreporter in a regular, evenly spaced pattern for better distribution of the nanoreporter signal. Preferably, where a region is labeled, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%), at least 80%, at least 90%, at least 95% or at least 98% of occurrences of the regularly- repeated base is attached to at least one light-emitting label monomer, either by covalent attachment of a label monomer to a base, or by hybridization to a nucleic acid in which the complements of the regularly-repeated base are so-labeled.

[0117] This percentage of occurrences can be measured by any means known in the art. In one method, the amount of nucleic acid produced in a labeling reaction is purified (for example,

RNA can be purified using a Qiagen RNeasy kit) and subjected to UV spectrophotometry. The absorbance ("A") at the appropriate wavelengths is measured for each of the nucleic acid (260 nm) and the label monomer whose occurrence is to be measured (e.g., 495 nm for Alexa Fluor

488; 590 nm for Alexa Fluor 594; 650 for Alexa Fluor 647; and 550 nm for Cy3). The absorbance of the nucleic acid is corrected by adjusting the value of the absorbance at 260 nm

("A260") to remove the "noise" contribution from the label monomer by subtracting the absorbance at the peak wavelength for the label monomer (ALM) minus the correction factor for that label monomer. Where the nucleic acid is RNA, the number of label monomers per one thousand nucleotides is calculated according to the formula:

no. of label monomers A260 9010

= x x 1000

1000 nucleotides A_LM EC_LM

where ECLM is the extinction coefficient for the label monomer. From this formula, the percentage of occurrences of the regularly-repeated base that are attached to a light-emitting label monomer can be calculated.

[0118] Generally, the preferred regularly-repeating base in a label attachment region is thymidine, so that the region can be labeled by hybridization to one or more complementary RNA segments in which the regularly-repeated base is uridine. This permits the use of amino- allyl-modified UTPs, which are readily commercially available, as label monomer attachment sites, in an otherwise random sequence. Preferably, in addition to the regular periodicity of the regions, the regions (and the nucleic acid comprising them) contain minimal secondary structure. The overall GC-content is preferably maintained close to 50%, and is preferably consistent over relatively short stretches to make local Tm's similar.

[0119] The artificial nucleic acids of the disclosure, or at least the regions therein, preferably do not have direct or inverted repeats that are greater than 12 bases in length. In other aspects, the artificial nucleic acids and/or regions do not have direct or inverted repeats that are greater than about 11, about 10 or about 9 bases in length.

[0120] In an exemplary region in which the regularly-repeated nucleotide is a thymidine and a GC content of approximately 50%, excess adenines would make up the loss in abundance of T's. To generate the selected sequence, random sequences with fixed patterns of T's ranging from every 4th base to every 25th base are created and screened to minimize the presence of inverted and direct repeats.

[0121] Sequences are also screened preferably to avoid common six-base-cutter restriction enzyme recognition sites to aid in the ease of manipulation for conventional molecular cloning techniques. Selected sequences are additionally subjected to predicted secondary structure analysis, and those with the least secondary structure are chosen for further evaluation. Any program known in the art can be used to predict secondary structure, such as the MFOLD program (Zuker, 2003, Nucleic Acids Res. 31 (13):3406-15; Mathews et al., 1999, J. Mol. Biol. 288:911-940).

[0122] An appropriate sequence is divided into label attachment regions ranging from 50 bases to 2 kilobases long (could be longer). Each label attachment region is a unique sequence, but contains a consistent number and spacing of T's in relation to the other label attachment regions in a given reporter sequence. These label attachment regions can interspersed with other regions whose sequence does not matter. The synthetic label attachment regions in a nanoreporter scaffold can be of different lengths and/or have different regularly-repeated bases. An optimized start sequence for transcription by RNA polymerase T7, T3, or SP6 (beginning at position +1 of the transcript) can be added to the 5' end of each label attachment region. Restriction sites are optionally added at the boundaries of each label attachment region to allow specific addition or deletion of individual label attachment regions to the sequence using conventional cloning techniques. The number of synthetic label attachment regions in a nanoreporter preferably ranges from 1 to 50. In yet other aspects, the number of synthetic label attachment regions in a nanoreporter ranges from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 synthetic label attachment regions to 15, 20, 30, 40, or 50 synthetic label attachment regions, or any range in between.

[0123] The synthetic nucleic acids of the present disclosure can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the label attachment region and the annealed segments, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the synthetic nucleic acid include 5-fluorouracil, 5-bromouracil, 5- chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, S- (carboxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5- carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6- isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5- methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'- methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5- oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, (acp3)w, and 2,6- diaminopurine.

[0124] Alternatively, the synthetic nucleic acid (i.e., the reporter and/or capture probe) can be produced biologically using a vector into which the nucleic acid has been subcloned.

[0125] In various aspects, the synthetic nucleic acid molecules of the disclosure can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al., 1996, Bioorganic & Medicinal Chemistry 4(l):5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al., 1996, Bioorganic & Medicinal Chemistry 4(1): 5-23; Peny-O'Keefe et al., 1996, Proc. Natl. Acad. Sci. USA 93 : 14670-675.

[0126] To make the RNA molecules ("segments") for each label attachment region, polymerase chain reaction ("PCR") primers are designed to generate a double-stranded template beginning with an RNA polymerase promoter (T7, T3, or SP6) directly upstream (5') of the transcription start site and ending following the 3' restriction enzyme site. Using this template, in vitro transcription of RNA molecules is performed in the presence of amino-allyl modified regularly- repeated base in the RNA (e.g., UTP') and unmodified other bases (e.g., ATP, CTP and GTP). This leads to an RNA product in which every regularly-repeated base (e.g., U) is modified to allow covalent coupling of a label monomer at that position in the RNA molecule.

[0127] Coupling of light-emitting label monomers to the RNA molecules and annealing of the labeled RNA molecules to the scaffold are carried out as described below.

[0128] Some design considerations for the synthetic sequence are listed in U.S. Patent

Application No. 2014/0371088.

[0129] Label Monomers

[0130] The tag-based nanoreporters of the present disclosure can be labeled with any of a variety of label monomers, such as a fluorochrome, dye, enzyme, nanoparticle, chemiluminescent marker, biotin, or other monomer known in the art that can be detected directly (e.g., by light emission) or indirectly (e.g., by binding of a fluorescently-labeled antibody). Generally, one or more of the label attachments regions in the reporter and/or capture probe is labeled with one or more label monomers, and the signals emitted by the label monomers attached to the label attachment regions of a reporter and/or capture probe constitute a code that identifies the target to which the target-specific oligos bind. In certain aspects, the lack of a given signal from the label attachment region (i.e., a "dark" spot) can also constitute part of the nanoreporter code. In certain preferred aspects, the label monomers are fluorophores or quantum dots.

[0131] A preferred example of label monomers that can be utilized by the disclosure are fluorophores. Several fluorophores can be used as label monomers for labeling nucleotides including, for example, fluorescein, tetramethylrhodamine, and Texas Red. Several different fluorophores are known, and more continue to be produced, that span the entire spectrum. Also, different formulations of the same fluorophore have been produced for different applications. For example, fluorescein can be used in its isothiocynanate form (FITC), as mixed isomer or single isomer forms of carboxyfluorescein succinimidyl ester (FAM), or as isomeric dichlorotriazine forms of fluorescein (DTAF). These monomers are chemically distinct, but all emit light with a peak between 515-520 nm, thereby generating a similar signal. In addition to the chemical modifications of fluorescein, completely different fluorophores have been synthesized that have the same or very similar emission peaks as fluorescein. For example, the Oregon Green dye has virtually superimposable excitation and emission spectra compared to fluorescein. Other fluorophores such as Rhodol Green and Rhodamine Green are only slightly shifted in their emission peaks and so also serve functionally as substitutes for fluorescein. In addition, different formulations or related dyes have been developed around other fluorophores that emit light in other parts of the spectrum.

[0132] Very small particles, termed nanoparticles, also can be used as label monomers to label nucleic acids. These particles range from 1-1000 nm in size and include diverse chemical structures such as gold and silver particles and quantum dots. In a preferred aspect, only one oligonucleotide molecule is coupled to each nanoparticle. To synthesize an oligonucleotide- nanoparticle complex in a 1 : 1 ratio by conventional batch chemistry, both the oligonucleotide and the nanoparticle require a single reactive group of different kinds that can be reacted with each other. For example, if an oligonucleotide has an amino group and a nanoparticle has an aldehyde group, these groups can react to form a Schiff base. An oligonucleotide can be derivatized to attach a single amino or other functional group using chemistry well known in the art. However, when a nanoparticle is derivatized, it is covered with a chemical reagent which results in coating the entire surface of the nanoparticle with several functional groups.

[0133] When irradiated with angled incident white light, silver or gold nanoparticles ranging from 40-120 nm will scatter monochromatic light with high intensity. The wavelength of the scattered light is dependent on the size of the particle. Four to five different particles in close proximity will each scatter monochromatic light which when superimposed will give a specific, unique color. The particles are being manufactured by companies such as Genicon Sciences. Derivatized silver or gold particles can be attached to a broad array of molecules including nucleic acids.

[0134] Another type of nanoparticle that can be used as a label monomer are quantum dots. Quantum dots are fluorescing crystals 1-5 nm in diameter that are excitable by a large range of wavelengths of light. These crystals emit light, such as monochromatic light, with a wavelength dependent on their chemical composition and size. Quantum dots such as CdSe, ZnSe, InP, or InAs possess unique optical properties. Due to their very small size the quantum dots can be coupled into oligonucleotides directly without affecting the solubility or use of the

oligonucleotide.

[0135] Many dozens of classes of particles can be created according to the number of size classes of the quantum dot crystals. The size classes of the crystals are created either 1) by tight control of crystal formation parameters to create each desired size class of particle, or 2) by creation of batches of crystals under loosely controlled crystal formation parameters, followed by sorting according to desired size and/or emission wavelengths. Use of quantum dots for labeling particles, in the context of the present disclosure, is new, but is old in the art of semiconductors. Two examples of earlier references in which quantum dots are embedded within intrinsic silicon epitaxial layers of semiconductor light emitting/detecting devices are U.S. Pat. Nos. 5,293,050 and 5,354,707 to Chappie Sokol, et al.

[0136] In specific aspects, one or more of the label attachments regions in the nanoreporter is labeled with one or more light-emitting dyes, each label attachment region containing, directly or indirectly, one or more label monomers. The light emitted by the dyes can be visible light or invisible light, such as ultraviolet or infrared light. In exemplary aspects, the dye is a

fluorescence resonance energy transfer (FRET) dye; a xanthene dye, such as fluorescein and rhodamine; a dye that has an amino group in the alpha or beta position (such as a naphthylamine dye, l-dimethylaminonaphthyl-5-sulfonate, l-anilino-8-naphthalende sulfonate and 2-p- touidinyl-6-naphthalene sulfonate); a dye that has 3-phenyl-7-isocyanatocoumarin; an acridine, such as 9-isothiocyanatoacridine and acridine orange; a pyrene, a bensoxadiazole and a stilbene; a dye that has 3-(s-carboxypentyl)-3'-ethyl-5,5'-dimethyloxacarbocyanine (CYA); 6-carboxy fluorescein (FAM); 5&6-carboxyrhodamine-l 10 (R110); 6-carboxyrhodamine-6G (R6G);

N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA); 6-carboxy-X-rhodamine (ROX); 6- carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE); ALEXA Fluor.TM.; Cy2; Texas Red and Rhodamine Red; 6-carboxy-2',4,7,7'-tetrachlorofluorescein (TET); 6-carboxy-2',4,4',5',7,7'- hexachlorofluorescein (HEX); 5-carboxy-2',4',5',7'-tetrachlorofluorescein (ZOE); NAN; NED; Cy3; Cy3.5; Cy5; Cy5.5; Cy7; and Cy7.5; Alexa Fluor 350; Alexa Fluor 488; Alexa Fluor 532; Alexa Fluor 546; Alexa Fluor 568; Alexa Fluor 594; or Alexa Fluor 647.

[0137] A label monomer can be directly attached to a nucleotide using methods well known in the art. Nucleotides can also be chemically modified or derivatized in order to attach a label monomer.

[0138] A nucleotide can be attached to a label monomer first and then be incorporated into a nucleic acid. Alternatively, an existing nucleic acid can be labeled by attaching a label monomer to a nucleotide within the nucleic acid. For example aminoallyl- (" AA-") modified UTP nucleotides can be incorporated into the RNA product during transcription. In various aspects, 20% or more of UTP nucleotides in a transcription reaction to generate RNA patches are AA modified. In various aspects, about 20% to 100%, 20% to 80%, 30 to 80%, 40 to 60% or 50% to 75% of UTPs in a transcription reaction are AA-modified, in a preferred aspect, approximately 50% of UTPs in a transcription reaction are AA-modified.

[0139] In addition, for example, different types of label monomennucleotide complexes can be incorporated into a single acid nucleic acid, where one component of the nanoreporter code comprises more than one type of signal.

[0140] Fluorescent dyes that can be bound directly to nucleotides can also be utilized as label monomers. For example, FAM, JOE, TAMRA, and ROX are amine reactive fluorescent dyes that have been attached to nucleotides and are used in automated DNA sequencing. These fluorescently labeled nucleotides, for example, ROX-ddATP, ROX-ddCTP, ROX-ddGTP and ROX-ddUTP, are commercially available.

[0141] Affinity Moieties

[0142] A variety of affinity moieties known in the art may be used to purify and/or immobilize the tag-based nanoreporters described herein.

[0143] Where an affinity moiety is used to immobilize a tag-based nanoreporter for the purpose of detection or imaging, it may be referred to herein as an "anchor." In a preferred aspect, a biotin anchor is attached to the nanoreporter (i.e., the capture probe of the tag-based

nanoreporter), allowing immobilization of the nanoreporter on a streptavidin coated slide.

[0144] An affinity moiety that can be used for attachment to beads or other matrices for a variety of useful applications including but not limited to purification.

[0145] Non-limiting examples of suitable affinity moieties are provided below. It should be understood that most affinity moieties could serve dual purposes: both as anchors for immobilization of the nanoreporters and moieties for purification of the nanoreporters (whether fully or only partially assembled).

[0146] In certain aspects, the affinity moiety is a protein monomer. Examples of protein monomers include, but are not limited to, the immunoglobulin constant regions (see Petty, 1996, Metal -chelate affinity chromatography, in Current Protocols in Molecular Biology, Vol. 2, Ed. Ausubel et al., Greene Publish. Assoc. & Wiley Interscience), glutathione S-transferase (GST; Smith, 1993, Methods Mol. Cell. Bio. 4:220-229), the E. coli maltose binding protein (Guan et al., 1987, Gene 67:21-30), and various cellulose binding domains (U.S. Pat. Nos. 5,496,934; 5,202,247; 5, 137,819; Tomme et al., 1994, Protein Eng. 7: 117-123), etc. Other affinity tags are recognized by specific binding partners and thus facilitate isolation and immobilization by affinity binding to the binding partner, which can be immobilized onto a solid support. For example, the affinity moiety can be an epitope, and the binding partner an antibody. Examples of such epitopes include, but are not limited to, the FLAG epitope, the myc epitope at amino acids 408-439, the influenza virus hemagglutinin (HA) epitope, or digoxigenin ("DIG"). In other aspects, the affinity moiety is a protein or amino acid sequence that is recognized by another protein or amino acid, for example the avidin/streptavidin and biotin.

[0147] In certain aspects of the disclosure, the affinity moiety is a nucleotide sequence. A large variety of sequences of about 8 to about 30 bases, more preferably of about 10 to about 20 bases, can be used for purification and immobilization of nanoreporters, and the sequence can be tandemly repeated (e.g., from 1 to 10 tandem repeats). Such a sequence is preferably not widely represented (that is, present in fewer than 5% of the genes, more preferably, present in fewer than 3% of the genes, and, most preferably, present in fewer than 1% of the genes) in the sample being assayed (for example, where the nanoreporter is used for detection of human cellular RNA, the sequence is preferably not widely represented in the human genome); have little or no secondary structure or self-complementarity either internally or with copies of itself when multimerized (that is, all secondary structures of the multimerized tag preferably have a Tm less than 25°C. at 1 M NaCl); have no significant identity or complementarity with segment or tag sequences (that is, the Tm of complementary sequences is preferably less than 25°C. at 0.2 M NaCl); and have a Tm of about 35-65°C, more preferably about 40-50°C, in 50 mM Na+.

[0148] In certain aspects, different sequences are used as purification and immobilization moieties. In this case, for example, the purification moiety can be as described above, but the immobilization moiety can be in the range of 10 to 100 bases, with a Tm up to 95° C. in 50 mM Na⁺. An alternative aspect would be to have the purification moiety nested within the

immobilization moiety (e.g., the affinity moiety would comprise a 25-base sequence of which 15 bases are used as a purification moiety and the entire 25 bases are used as the immobilization moiety).

[0149] In certain instances, the affinity moiety can be used for labeling a nanoreporter in addition to purifying or immobilizing the nanoreporter.

[0150] As will be appreciated by those skilled in the art, many methods can be used to obtain the coding region of the affinity moieties, including but not limited to, DNA cloning, DNA amplification, and synthetic methods. Some of the affinity moieties and reagents for their detection and isolation are available commercially.

[0151] Tag-Based Nanoreporter Populations

[0152] The present disclosure provides tag-based nanoreporter (e.g., compositions comprising reporter probe/oligo and capture probe/oligo pairs) populations, that contain at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 75, at least 100, at least 200, at least 300, at least 400, at least 500, at least 750, or at least 1,000 unique tag-based

nanoreporters. As used herein, "unique" when used in reference to a nanoreporter within a population is intended to mean a tag-based nanoreporter that has a code that distinguishes it from other tag-based nanoreporters in the same population.

[0153] In specific aspects, the present disclosure provides nanoreporter populations with at least 5,000, at least 10,000, at least 20,000 or at least 50,000 unique nanoreporters.

[0154] The size of a tag-based nanoreporter population and the nature of the target-specific sequences of the reporter and capture oligos within it will depend on the intended use of the nanoreporter. Nanoreporter populations can be made in which the target-specific sequences correspond to markers of a given cell type, including a diseased cell type. In certain aspects, tag- based nanoreporters populations are generated in which the target-specific sequences of the reporter and/or capture oligos represent at least 0.1%, at least 0.25%, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70% of the different type of transcripts in a cell. In certain aspects, tag-based nanoreporters populations are generated in which the target-specific sequences of the reporter and/or capture oligos represent at least 0.1%, at least 0.25%, at least 0.5%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%), or at least 70% of the different genes in a cell. In yet other aspects, tag-based nanoreporter populations are generated in which at least some of the target-specific sequences of the reporter and/or capture oligos represent rare transcripts in a cell or tissue. Such tag-based nanoreporter populations preferably represent at least 5 rare transcripts. In specific aspects, such tag-based nanoreporter populations represent at least 10, at least 20, at least 30, at least 40 or at least 50 rare transcripts.

[0155] In a specific aspect, the cell or tissue is a mammalian cell or tissue, and more preferably is a human cell or tissue. [0156] In certain aspects, the tag-based nanoreporter population is a diagnostic or prognostic nanoreporter populations. For example, a diagnostic nanoreporter population can be generated that is useful for screening blood products, in which the target-specific sequences bind to the nucleic acids of contaminating viruses such the hepatitis B, hepatitis C, and the human immunodeficiency virus. Alternatively, the diagnostic nanoreporter population may contain reporter and capture oligos with target-specific sequences corresponding to cellular disease markers, such as tumor antigens. Prognostic nanoreporter populations generally include reporter and capture oligos with target-specific sequences that recognize markers that represent different stages of a given disease such as cancer. By selecting appropriate target-specific sequences, a tag-based nanoreporter population can be used both to diagnose and prognose disease.

[0157] Biomolecular Samples

[0158] The tag-based nanoreporter systems of the disclosure can be used to detect target molecule in any biomolecular sample. As will be appreciated by those in the art, the sample may comprise any number of things, including, but not limited to: cells (including both primary cells and cultured cell lines), cell lysates or extracts (including but not limited to RNA extracts;

purified mRNA), tissues and tissue extracts (including but not limited to RNA extracts; purified mRNA); bodily fluids (including, but not limited to, blood, urine, serum, lymph, bile, cerebrospinal fluid, interstitial fluid, aqueous or vitreous humor, colostrum, sputum, amniotic fluid, saliva, anal and vaginal secretions, perspiration and semen, a transudate, an exudate (e.g., fluid obtained from an abscess or any other site of infection or inflammation) or fluid obtained from a joint (e.g., a normal joint or a joint affected by disease such as rheumatoid arthritis, osteoarthritis, gout or septic arthritis) of virtually any organism, with mammalian samples being preferred and human samples being particularly preferred; environmental samples (including, but not limited to, air, agricultural, water and soil samples); biological warfare agent samples;

research samples including extracellular fluids, extracellular supernatants from cell cultures, inclusion bodies in bacteria, cellular compartments, cellular periplasm, mitochondria

compartment, etc.

[0159] The biomolecular samples can be indirectly derived from biological specimens. For example, where the target molecule of interest is a cellular transcript, e.g., a messenger RNA, the biomolecular sample of the disclosure can be a sample containing cDNA produced by a reverse transcription of messenger RNA. In another example, the biomolecular sample of the disclosure is generated by subjecting a biological specimen to fractionation, e.g., size fractionation or membrane fractionation.

[0160] The biomolecular samples of the disclosure may be either "native," i.e., not subject to manipulation or treatment, or "treated," which can include any number of treatments, including exposure to candidate agents including drugs, genetic engineering (e.g. the addition or deletion of a gene), etc.

[0161] The label monomers of the nanoreporter, or reporter probe, can detected by any means known in the art. Specific methods for separating and detecting label monomers, as well as immobilizing reporter and capture probes are described in U.S. Patent No. 8,986,926 and PCT Publication No. WO2007/076132, incorporated by reference in their entirety, and described in more detail herein. These methods apply to both direct binding (non-tag-based) nanoreporter systems utilizing a reporter probe and capture probe and indirect binding (tag-based)

nanoreporter systems utilizing a reporter oligo (Oligo A) and a capture oligo (Oligo B) as intermediate probes that bind to the reporter or capture probe.

[0162] Separation of Label Monomers

[0163] In addition to detecting an overall signal generated from a non-tag or tag-based nanoreporter, the disclosure provides for the determination of the spatial location of signals emanating from the label monomers (i.e., spots) on a nanoreporter, each spot representing the aggregate signal from label monomers attached to a given label attachment region. A spot may contain signals of the same wavelength or of different wavelengths. Thus, the nature of the spots on a nanoreporter and their location constitutes the nanoreporter code.

[0164] Any of a variety of means can be used to "stretch" the nanoreporter to separate the individual spots. For example, a nanoreporter can be stretched using a flowstretch technique (Henegariu et al., 2001, Biotechniques 31 :246-250), a receding meniscus technique (Yokota et al., 1997, Nuc. Acids Res. 25: 1064-1070) or an electrostretching technique (Matsuura et al., 2001, Nuc. Acids Res. 29: E79).

[0165] The use of flow- stretching, receding meniscus, or electro-stretching techniques allows for the separation of the label attachment regions within a nanoreporter so that one can determine spatially where a particular signal is positioned in the nanoreporter. Therefore, unique nanoreporters that have the same combination of label monomers and the same overall signal can be differentiated from one another based on the location of those label monomers within the nanoreporter.

[0166] This ability to locate the position of a label attachment region or spot within a nanoreporter allows for the position of the signal(s) emitted by the label monomers in each label attachment region to be used as a distinguishing characteristic when generating a set of unique nanoreporters. Hence, a complex set of nanoreporters can be generated using the same combination of starting label monomers by varying the positions of the label monomers within a nanoreporter.

[0167] Prior to stretching a nanoreporter, it is preferable to immobilize the nanoreporter to a solid surface using an affinity tag, as described above.

[0168] In certain aspects of the disclosure, one end of a nanoreporter is immobilized, either through specific or non-specific binding to a solid surface, the nanoreporter is stretched, and then the other end of the reporter is immobilized, also either through specific or non-specific binding to a solid surface. Accordingly, the nanoreporter is "frozen" in its stretched, or extended, state, to facilitate resolution of the nanoreporters code by detecting and/or imaging the signals emitted by the label monomers attached to a nanoreporter and their locations relative to one another. These aspects of the disclosure are described below.

[0169] Immobilization of Stretched Nanoreporters

[0170] The present disclosure provides methods and compositions that facilitate the

identification of primary structures of the tag-based nanoreporters described herein. In certain aspects, the present disclosure provides methods for the selective immobilization of

nanoreporters in an extended state. According to the disclosure, a nanoreporter can be selectively immobilized while fully extended under whatever force is used for the extension. In addition, the methods of the disclosure facilitate the selective immobilization of extended nanoreporters that are oriented with respect to each other. In other words, according to the methods of the disclosure, a plurality of nanoreporters can readily be immobilized in the same orientation with respect to each other.

[0171] In one aspect, the present disclosure provides methods for selectively immobilizing a nanoreporter in an extended state. For the methods of this aspect of the disclosure, generally, a first portion of the nanoreporter, or capture probe hybridized to the target-specific capture oligo, is immobilized by any technique known to those of skill in the art. In certain aspects, the first portion of the nanoreporter, or capture probe hybridized to the target-specific capture oligo, can be immobilized selectively or non- selectively. In certain aspects the first portion is immobilized by one or more covalent bonds. In certain aspects, the first portion is immobilized by one or more non-covalent bonds. Exemplary immobilized first portions are described in the sections below.

[0172] With an immobilized first portion, the nanoreporter can be extended by any technique for extending a nanoreporter apparent to those of skill in the art. In certain aspects, the technique for extending the nanoreporter is not critical for the methods of the disclosure. In certain aspects, the technique for extending the nanoreporter appropriate for the class of nanoreporter according to the judgment of one of skill in the art. In certain aspects, the nanoreporter is extended by application of a force capable of extending the nanoreporter. The force can be any force apparent to one of skill in the art for extending the nanoreporter. Exemplary forces include gravity, hydrodynamic force, electromagnetic force and combinations thereof. Specific techniques for extending the nanoreporter are described in the sections below.

[0173] The nanoreporter is in an extended state if it would be recognized as extended by one of skill in the art. In certain aspects, the nanoreporter is in an extended state when it is in the field of a force capable of extending the nanoreporter. In certain aspects, the nanoreporter is in an extended state when its average hydrodynamic radius is more than double the average hydrodynamic radius of the nanoreporter in its native state as recognized by those of skill in the art.

[0174] In this aspect of the disclosure, the methods generally comprise the step of selectively immobilizing a second portion of the nanoreporter while it is in an extended state. This can result in an immobilized nanoreporter that is extended between the first and the second portion.

Remarkably, since the nanoreporter is selectively immobilized while extended, that extension can be preserved in the immobilized nanoreporter. The selective immobilization can be according to any technique for selective immobilization of a portion of a nanoreporter apparent to those of skill in the art. The selective immobilization can be through, for example, the formation of one or more covalent bonds or one or more non-covalent bonds, or both. Particular examples of selective immobilization techniques are described in the sections below. In particular aspects, one or more binding pairs are used to immobilize the second portion of the nanoreporter, which is the reporter probe hybridized to the target-specific reporter oligo.

[0175] The second portion can be immobilized onto any substrate apparent to those of skill in the art. The substrate can be any substrate judged to be useful for immobilization known to those of skill in the art. In certain aspects, the second portion can be immobilized to another molecule. Further useful substrates include surfaces, membranes, beads, porous materials, electrodes, arrays and any other substrate apparent to those of skill in the art.

[0176] In another aspect, the present disclosure provides a composition comprising a selectively immobilized, extended nanoreporter. The compositions generally comprise a substrate and an extended nanoreporter selectively immobilized onto the substrate. The substrate can be any substrate known to those of skill in the art. Exemplary substrates include those described in the sections below. At least two portions of the nanoreporter are immobilized onto the substrate, and the nanoreporter is in an extended state between the two portions. In certain aspects, at least one portion of the nanoreporter is selectively immobilized onto the substrate. In certain aspects, two or more portions of the nanoreporter are selectively immobilized onto the substrate. The nanoreporter can be extended and/or immobilized by any technique apparent to those of skill, including particularly the methods of the present disclosure.

[0177] In another aspect, the present disclosure provides methods for selectively immobilizing a nanoreporter in an oriented state. The nanoreporter can be any nanoreporter described above. In certain aspects, the nanoreporter can be flexible, or in certain aspects the nanoreporter can be rigid or semi-rigid. For the methods of this aspect of the disclosure, generally, a first portion of the nanoreporter is immobilized as described above. With an immobilized first portion, the nanoreporter can be oriented by any technique for extending a nanoreporter apparent to those of skill in the art. In certain aspects, the technique for orienting the nanoreporter is not critical for the methods of the disclosure. In certain aspects, the technique for orienting the nanoreporter appropriate for the class of nanoreporter according to the judgment of one of skill in the art. In certain aspects, the nanoreporter is oriented by application of a force capable of orienting the nanoreporter. The force can be any force apparent to one of skill in the art for orienting the nanoreporter. Exemplary forces include gravity, hydrodynamic force, electromagnetic force and combinations thereof. Specific techniques for extending the nanoreporter are described in the subsections below.

[0178] The nanoreporter is in an oriented state if it would be recognized as oriented by one of skill in the art. In certain aspects, the nanoreporter is in an oriented state when it is in the field of a force capable of orienting the nanoreporter. In certain aspects, the nanoreporter is in an oriented state when its termini are arranged in parallel, as recognized by those of skill in the art, with the field of a force capable of orienting the nanoreporter. In certain aspects, a plurality of nanoreporters is in an oriented state when the termini of the nanoreporters are arranged in parallel, as recognized by those of skill in the art.

[0179] In this aspect of the disclosure, the methods generally comprise the step of selectively immobilizing a second portion of the nanoreporter while it is in an oriented state. This can result in an immobilized nanoreporter that is oriented between the first and the second portion.

Remarkably, since the nanoreporter is selectively immobilized while extended, that orientation can be preserved in the immobilized nanoreporter. The selective immobilization can according to the methods described above.

[0180] In another aspect, the present disclosure provides a composition comprising a selectively immobilized, oriented nanoreporter. The compositions generally comprise a substrate and an oriented nanoreporter selectively immobilized onto the substrate. The substrate can be any substrate known to those of skill in the art. Exemplary substrates include those described in the sections below. At least two portions of the nanoreporter are immobilized onto the substrate, and the nanoreporter is in an oriented state between the two portions. In certain aspects, at least one portion of the nanoreporter is selectively immobilized onto the substrate. In certain aspects, both portions of the nanoreporter are selectively immobilized onto the substrate. The nanoreporter can be oriented and/or immobilized by any technique apparent to those of skill, including particularly the methods of the present disclosure.

[0181] The methods and compositions of the present disclosure can be used for any purpose apparent to those of skill in the art. For instance, the immobilized and extended and/or oriented nanoreporter can be used as a label for a substrate on which the nanoreporter is immobilized. The primary sequence of the immobilized and extended and/or oriented nanoreporter can be identified by any technique apparent to those of skill. Advantageously, immobilization of the extended and/or oriented nanoreporter can facilitate such techniques. In certain aspects, the immobilized and extended and/or oriented nanoreporter can be used to guide the manufacture of nanopaths, for example to create nanowires or nanocircuits. Further uses for the immobilized and extended and/or oriented nanoreporters are described in the sections below.

[0182] All terms used herein have their ordinary meanings to those of skill in the art unless indicated otherwise. The following terms shall have the following meanings. [0183] As used herein, the term "binding pair" refers to first and second molecules or moieties that are capable of selectively binding to each other, i.e. binding to each other with greater affinity than to other components in a composition. The binding between the members of the binding pair can be covalent or non-covalent. In certain aspects, the binding is noncovalent. Exemplary binding pairs include immunological binding pairs (e.g., any haptenic or antigenic compound in combination with a corresponding antibody or binding portion or fragment thereof, for example digoxigenin and anti-digoxigenin, fluorescein and anti-fluorescein, dinitrophenol and anti-dinitrophenol, bromodeoxyuridine and anti-bromodeoxyuridine, mouse immunoglobulin and goat anti-mouse immunoglobulin) and nonimmunological binding pairs (e.g., biotin-avidin, biotin-streptavidin, hormone-hormone binding protein, receptor-receptor ligand (e.g., acetylcholine receptor-acetylcholine or an analog thereof), IgG-protein A, lectin-carbohydrate, enzyme-enzyme cofactor, enzyme-enzyme inhibitor, complementary polynucleotide pairs capable of forming nucleic acid duplexes, and the like). For instance, immunoreactive binding members may include antigens, haptens, aptamers, antibodies (primary or secondary), and complexes thereof, including those formed by recombinant DNA methods or peptide synthesis. An antibody may be a monoclonal or polyclonal antibody, a recombinant protein or a mixture(s) or fragment(s) thereof, as well as a mixture of an antibody and other binding members. Other common binding pairs include but are not limited to, biotin and avidin (or derivatives thereof), biotin and streptavidin, carbohydrates and lectins, complementary nucleotide sequences

(including probe and capture nucleic acid sequences), complementary peptide sequences including those formed by recombinant methods, effector and receptor molecules, hormone and hormone binding protein, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, and so forth.

[0184] "Selective binding" refers to the any preferential binding of a pair of molecules or moieties for each other with respect to other molecules or moieties in a composition that would be recognized by one of skill in the art. In certain aspects, a pair of molecules or moieties selectively binds when they preferentially bind each other compared to other molecules or moieties. Selective binding can include affinity or avidity, or both, of one molecule or moiety for another molecule or moiety. In particular aspects, selective binding requires a dissociation constant (KD) of less than about lxlO^"5 M or less than about lxlO^"6 M, lxlO^"7 M, lxlO^"8 M, lxlO^"9 M, or lxlO^"10 M. In contrast, in certain aspects, non-selective binding has significantly less affinity, for example, a KD greater than 1x10 M

[0185] "Extended state" refers to a nanoreporter in a state that would be recognized as extended by one of skill in the art. In certain aspects, a nanoreporter is in an extended state when it is extended relative to its native conformation in solution. In certain aspects, a nanoreporter is in an extended state when it is in the field of a force capable of extending the nanoreporter. In certain aspects, an extended state of a nanoreporter can be determined quantitatively. In such aspects, those of skill in the art will recognize R as the end-to-end vector of the nanoreporter, i.e. the distance between two termini of the nanoreporter, and <R> as the average end-to-end vector such that 95% of R will be within 2<R> in a solution deemed appropriate to one of skill in the art. Exemplary solutions include, for example, a dilute solution of the nanoreporter in water or in a pH buffer. In particular aspects, a nanoreporter is in an extended state when R is greater than 2.0<R>.

[0186] "Oriented state" refers to a nanoreporter in a state that would be recognized as oriented by one of skill in the art. In certain aspects, a nanoreporter is in an oriented state when it is oriented relative to its native conformation in solution. In certain aspects, the nanoreporter is oriented when it is arranged in parallel with the field of a force capable of orienting the nanoreporter. In certain aspects, the nanoreporter is oriented when it is one of a plurality of nanoreporters that are arranged in parallel, as recognized by those of skill in the art.

[0187] Methods of Selective Immobilization

[0188] As described above, the present disclosure provides methods for the selective

immobilization of a nanoreporter in an extended state. The nanoreporter, once selectively immobilized, can be used for any purpose apparent to those of skill in the art.

[0189] In the methods of the disclosure, a first portion of the nanoreporter is immobilized. For example, the first portion of the nanoreporter is the capture probe hybridized to a target-specific capture oligo. Generally, the first portion is immobilized if it would be recognized as

immobilized by one of skill in the art. The first portion can be immobilized by any technique apparent to those of skill in the art. In certain aspects, the technique for immobilization of the first portion of the nanoreporter is not critical for the methods of the disclosure.

[0190] The nanoreporter can be immobilized onto any substrate apparent to those of skill in the art. The substrate can be any moiety to which the nanoreporter can be immobilized without limitation. In certain aspects, the substrate is a surface, membrane, bead, porous material, electrode or array.

[0191] In certain aspects, the first portion of the nanoreporter can be immobilized non- selectively. In further aspects, the first portion of the nanoreporter can be immobilized selectively. In advantageous aspects, after the first portion of the nanoreporter is immobilized, some portion of the nanoreporter should be free to move sufficiently so that the nanoreporter can be extended in the following steps of the method. In particular, in certain aspects, when the first portion of the nanoreporter is immobilized non-selectively, it is important that the entire nanoreporter not be immobilized non-selectively to an extent that prevents extension of any portion of the nanoreporter

[0192] The immobilization can be by any interaction with the substrate apparent to those of skill in the art. The immobilization can be via electrostatic or ionic interaction, via one or more covalent bonds, via one or more non-covalent bonds or combinations thereof. In certain aspects, the immobilization can be via electrostatic interaction with an electrode. In further aspects, the immobilization is via electrostatic interaction with a substrate other than the electrode

[0193] In certain aspects, the capture probe of the first portion of the nanoreporter comprises a first member of a binding pair (i.e. an affinity moiety). The first member of the binding pair can be covalently bound to the first portion of the nanoreporter, or they can be non-covalently bound. Useful covalent bonds and non-covalent bonds will be apparent to those of skill in the art. In useful aspects, the substrate onto which the first portion of the nanoreporter is bound will comprise a second member of the binding pair. The substrate can be covalently bound to the second member, or they can be non-covalently bound.

[0194] In certain aspects, the first portion of the nanoreporter (i.e., the capture probe) can comprise a member of a binding pair that is capable of binding with a member of a binding pair on the substrate to form one or more non-covalent bonds. Exemplary useful substrates include those that comprise a binding moiety selected from the group consisting of ligands, antigens, carbohydrates, nucleic acids, receptors, lectins, and antibodies. The first portion of the nanoreporter would comprise a binding moiety capable of binding with the binding moiety of the substrate. Exemplary useful substrates comprising reactive moieties include, but are not limited to, surfaces comprising epoxy, aldehyde, gold, hydrazide, sulfhydryl, HS-ester, amine, thiol, carboxylate, maleimide, hydroxymethyl phosphine, imidoester, isocyanate, hydroxyl, pentafluorophenyl-ester, psoralen, pyridyl disulfide or vinyl sulfone, or mixtures thereof. Such surfaces can be obtained from commercial sources or prepared according to standard techniques.

[0195] In advantageous aspects, the first portion of the nanoreporter can be immobilized to the substrate via an avidin-biotin binding pair. In certain aspects, the nanoreporter can comprise a biotin moiety in its first portion. For instance, a polynucleotide nanoreporter can comprise a biotinylated nucleotide residue. Similarly, a polypeptide nanoreporter can comprise a

biotinylated amino acid residue. The substrate comprising avidin can be any substrate comprising avidin known to those of skill in the art. Useful substrates comprising avidin are commercially available including TB0200 (Accelr8), SAD6, SAD20, SAD 100, SAD500, SAD2000 (Xantec), SuperAvidin (Array-It), streptavidin slide (catalog #MPC 000, Xenopore) and STREPTAVIDINnslide (catalog #439003, Greiner Bio-one).

[0196] In certain aspects, the first portion of the nanoreporter (i.e., the capture probe) can comprise a nucleotide sequence that is capable of selectively binding a nucleotide sequence on the substrate.

[0197] In further aspects, the first portion of the nanoreporter (i.e., the capture probe) can comprise avidin, and the substrate can comprise biotin. Useful substrates comprising biotin are commercially available including Optiarray -biotin (Accler8), BD6, BD20, BD100, BD500 and BD2000 (Xantec).

[0198] In further aspects, the first portion of the nanoreporter (i.e., the capture probe) is capable of forming a complex with one or more other molecules that, in turn, are capable of binding, covalently or non-covalently, a binding moiety of the substrate. For instance, a first portion of the nanoreporter can be capable of selectively binding another molecule that comprises, for instance, a biotin moiety that is capable of selectively binding, for instance, an avidin moiety of the substrate.

[0199] In further aspects, the first portion of the nanoreporter (i.e., the capture probe) can comprise a member of a binding pair that is capable of reacting with a member of a binding pair on the substrate to form one or more covalent bonds. Exemplary useful substrates comprising reactive groups include those that comprise a reactive moiety selected from the group consisting of succinimides, amines, aldehydes, epoxies and thiols. The first portion of the nanoreporter would comprise a reactive moiety capable of reacting with the reactive moiety of the substrate. Exemplary useful substrates comprising reactive moieties include, but are not limited to, OptArray-DNA NHS group (Accler8), Nexterion Slide AL (Schott) and Nexterion Slide E (Schott).

[0200] In certain aspects, the first portion of the nanoreporter (i.e., the capture probe) can comprise a reactive moiety that is capable of being bound to the substrate by photoactivation. The substrate could comprise the photoreactive moiety, or the first portion of the nanoreporter could comprise the photoreactive moiety. Some examples of photoreactive moieties include aryl azides, such as N-((2-pyridyldithio)ethyl)-4-azidosalicylamide; fluorinated aryl azides, such as 4- azido-2,3,5,6-tetrafluorobenzoic acid; benzophenone-based reagents, such as the succinimidyl ester of 4-benzoylbenzoic acid; and 5-Bromo-deoxyuridine.

[0201] In further aspects, the first portion of the nanoreporter (i.e., the capture probe) can be immobilized to the substrate via other binding pairs apparent to those of skill in the art.

[0202] Extension of the Nanoreporter

[0203] In certain methods of the disclosure, the nanoreporter is in an extended state. Generally, any nanoreporter is in an extended state if it would be recognized as such by one of skill in the art.

[0204] In certain aspects, the nanoreporter is in an extended state when it is in the field of a force capable of extending the nanoreporter under conditions suitable for extending the nanoreporter. Such forces and conditions should be apparent to those of skill in the art. For instance, many nanoreporters can be extended by hydrodynamic force or by gravity, and many charged nanoreporters can be extended by electromagnetic force. In certain aspects, the force can be applied to the nanoreporter indirectly. For instance, the nanoreporter can comprise or can be linked, covalently or noncovalently, to a moiety capable of being moved by a force. In certain aspects, the nanoreporter can be linked to a moiety.

[0205] In certain aspects, the force is an electromagnetic force. For instance, when the nanoreporter is charged, such as a polynucleotide, the nanoreporter can be extended in an electric or magnetic field. The field should be strong enough to extend the nanoreporter according to the judgment of one of skill in the art. Exemplary techniques for extending a nanoreporter in an electric or magnetic field are described in Matsuura et al., 2002, J Biomol Struct Dyn. 20(3):429- 36; Ferree & Blanch, 2003, Biophys J. 85(4):2539-46; Stigter & Bustamante, 1998, Biophys J. 1998 75(3): 1197-210; Matsuura et al., 2001, Nucleic Acids Res. 29(16); Ferree & Blanch, 2004, Biophys J. 87(l):468-75; the contents of which are hereby incorporated by reference in their entirety. [0206] In certain aspects, the force is a hydrodynamic force. For instance, many nanoreporters, including polysaccharides, polypeptides, and polynucleotides, can be extended in the field of a moving fluid. The hydrodynamic force should be strong enough to extend the nanoreporter according to the judgment of one of skill in the art. Exemplary techniques for extending a nanoreporter in hydrodynamic field are described in Bensimon et al., 1994, Science 265:2096- 2098; Henegariu et al., 2001, BioTechniques 31 : 246-250; Kraus et al., 1997, Human Genetics 99:374-380; Michalet et al., 1997, Science 277: 1518-1523; Yokota et al., 1997, Nucleic Acids Res. 25(5): 1064-70; Otobe et al., 2001, Nucleic Acids Research 29: 109; Zimmerman & Cox, 1994, Nucleic Acids Res. 22(3):492-7, and U.S. Pat. Nos. 6,548,255; 6,344,319; 6,303,296; 6,265,153; 6,225,055; 6,054,327; and 5,840,862, the contents of which are hereby incorporated by reference in their entirety.

[0207] In certain aspects, the force is gravity. In advantageous aspects, the force of gravity can be combined with, for example, hydrodynamic force to extend the nanoreporter. In certain aspects, the force should be strong enough to extend the nanoreporter according to the judgment of one of skill in the art. Exemplary techniques for extending a nanoreporter with gravity are described in Michalet et al, 1997, Science 277: 1518-1523; Yokota et al., 1997, Nucleic Acids Res. 25(5): 1064-70; Kraus et al., 1997, Human Genetics 99:374-380, the contents of which are hereby incorporated by reference in their entirety.

[0208] In particular aspects, the force is applied through a moving meniscus. Those of skill in the art will recognize that a moving meniscus can apply various forces to a nanoreporter including hydrodynamic force, surface tension and any other force recognized by those of skill in the art. The meniscus can be moved by any technique apparent to those of skill in the art including evaporation and gravity. Exemplary techniques for extending a nanoreporter with a moving meniscus are described in, for example, U.S. Pat. Nos. 6,548,255; 6,344,319; 6,303,296; 6,265,153; 6,225,055; 6,054,327; and 5,840,862, the contents of which are hereby incorporated by reference in their entireties.

[0209] In particular aspects, the nanoreporter can be extended by an optical trap or optical tweezers. For instance, the nanoreporter can comprise or can be linked, covalently or

noncovalently, to a particle capable of being trapped or moved by an appropriate source of optical force. Useful techniques for moving particles with optical traps or optical tweezers are described in Ashkin et al, 1986, Optics Letters 11 :288-290; Ashkin et al., 1987, Science 235: 1517-1520; Ashkin et al., Nature 330:769-771; Perkins et al., 1994, Science 264:822-826; Simmons et al., 1996, Biophysical Journal 70: 1813-1822; Block et al., 1990, Nature 348:348- 352; and Grier, 2003, Nature 424: 810-816; the contents of which are hereby incorporated by reference in their entireties.

[0210] In certain aspects, the nanoreporter can be extended by combinations of the above forces that are apparent to those of skill in the art. In the examples, below, certain nanoreporters are extended by a combination of an electric field and hydrodynamic force.

[0211] The nanoreporter is extended when it would be recognized as extended by one of skill in the art according to standard criteria for extension of a nanoreporter. In certain aspects, the nanoreporter is extended when it loses most of its tertiary structural features as recognized by those of skill in the art. In certain aspects, the nanoreporter is extended when it loses most of its secondary structural features as recognized by those of skill in the art. In certain aspects, the nanoreporter is extended when its primary structural features are detectable in sequence when imaged according to standard techniques. Exemplary imaging techniques are described in the examples below.

[0212] In certain aspects, an extended state of a nanoreporter can be recognized by comparing its hydrodynamic radius to its average hydrodynamic radius when free in dilute solution. For instance, in certain aspects, a nanoreporter, or portion thereof, is extended when its

hydrodynamic radius is more than about double its average hydrodynamic radius in dilute solution. More quantitatively, R represents the hydrodynamic radius of the nanoreporter, or portion thereof, and <R> represents the average hydrodynamic radius of the nanoreporter, or portion thereof, in dilute solution. The average <R> should be calculated such that R for the nanoreporter, or portion thereof, when unbound in dilute solution is less than 2<R>95% of the time. In certain aspects, a nanoreporter, or portion thereof, is in an extended state when R is greater than 1.5<R>, greater than 1.6<R>, greater than 1.7<R>, greater than 1.8<R>, greater than 1.9<R>, greater than 2.0<R>, greater than 2.1<R>, greater than 2.2<R>, greater than 2.3<R>, greater than 2.4<R>, greater than 2.5<R> or greater than 3.0<R>. In particular aspects, a nanoreporter, or portion thereof, is in an extended state when R is greater than 2.0<R>.

[0213] Orientation of the Nanoreporter

[0214] In certain methods of the disclosure, the nanoreporter is in an oriented state. Generally, any nanoreporter is in an oriented state if it would be recognized as such by one of skill in the art.

[0215] In certain aspects, the nanoreporter is in an oriented state when it is in the field of a force capable of orienting the nanoreporter under conditions suitable for orienting the nanoreporter. Such forces and conditions should be apparent to those of skill in the art.

[0216] In certain aspects, the force is an electromagnetic force. For instance, when the nanoreporter is charged, such as a polynucleotide, the nanoreporter can be oriented in an electric or magnetic field. The field should be strong enough to orient the nanoreporter according to the judgment of one of skill in the art. Exemplary techniques for orienting a nanoreporter in an electric or magnetic field are described above.

[0217] In certain aspects, the force is a hydrodynamic force. For instance, many nanoreporters, including polysaccharides, polypeptides, and polynucleotides, can be oriented in the field of a moving fluid. The hydrodynamic force should be strong enough to orient the nanoreporter according to the judgment of one of skill in the art. Exemplary techniques for orienting a nanoreporter in hydrodynamic field are described above.

[0218] In certain aspects, the force is gravity. In advantageous aspects, the force of gravity can be combined with, for example, hydrodynamic force to orient the nanoreporter. In certain aspects, the force should be strong enough to orient the nanoreporter according to the judgment of one of skill in the art. Exemplary techniques for orienting a nanoreporter with gravity are described above.

[0219] In certain aspects, the nanoreporter can be oriented by combinations of the above forces that are apparent to those of skill in the art. In the examples, below, certain nanoreporters are oriented by a combination of an electric field and hydrodynamic force.

[0220] The nanoreporter is oriented when it would be recognized as oriented by one of skill in the art according to standard criteria for orientation of a nanoreporter. In certain aspects, the nanoreporter is oriented when it is arranged in parallel, as recognized by those of skill in the art, with the field of a force capable of orienting the nanoreporter. In certain aspects, the

nanoreporter is oriented when it is one of a plurality of nanoreporters that are arranged in parallel, as recognized by those of skill in the art. For instance, a plurality of nanoreporters can be oriented when the vector from a first terminus to a second terminus of a nanoreporter is parallel, as recognized by those of skill in the art, to the vectors between corresponding termini of other nanoreporters in the plurality. [0221] Selective Immobilization of Second Portion of Nanoreporter

[0222] As discussed above, in the methods of the disclosure, a second portion of the tag-based nanoreporter is selectively immobilized. The second portion of the nanoreporter is the reporter probe hybridized to the target-specific reporter oligo. The reporter probe optionally comprises a moiety for immobilization.

[0223] In certain aspects, the present disclosure provides methods that comprise the single step of selectively immobilizing a second portion of a nanoreporter (i.e., via the reporter probe) while the nanoreporter is in an extended or oriented state, and while a first portion (i.e. via the capture probe) of the nanoreporter is immobilized. Exemplary methods for immobilization of the first portion of the nanoreporter, and for extension or orientation of the nanoreporter are described in detail in the sections above.

[0224] In certain aspects, the present disclosure provides methods that comprise the step of extending a nanoreporter, while a first portion of the nanoreporter is immobilized, and the step of selectively immobilizing a second portion of a nanoreporter while the nanoreporter is in an extended state. Exemplary methods for immobilization of the first portion of the nanoreporter, and for extension of the nanoreporter are described in detail in the sections above.

[0225] In certain aspects, the present disclosure provides methods that comprise the step of immobilizing a first portion of a nanoreporter, the step of extending the nanoreporter while the first portion is immobilized and the step of selectively immobilizing a second portion of a nanoreporter while the nanoreporter is in an extended state. Exemplary methods for

immobilization of the first portion of the nanoreporter, and for extension of the nanoreporter are described in detail above.

[0226] In certain aspects, the present disclosure provides methods that comprise the step of orienting a nanoreporter, while a first portion of the nanoreporter is immobilized, and the step of selectively immobilizing a second portion of a nanoreporter while the nanoreporter is in an oriented state. Exemplary methods for immobilization of the first portion of the nanoreporter, and for orienting the nanoreporter are described in detail in the sections above.

[0227] In certain aspects, the present disclosure provides methods that comprise the step of immobilizing a first portion of a nanoreporter, the step of orienting the nanoreporter while the first portion is immobilized and the step of selectively immobilizing a second portion of a nanoreporter while the nanoreporter is in an oriented state. Exemplary methods for immobilization of the first portion of the nanoreporter, and for orienting the nanoreporter are described in detail above.

[0228] The selective immobilization of the second portion of the nanoreporter can follow any technique for selective immobilization of a nanoreporter apparent to those of skill in the art. Significantly, in advantageous aspects of the disclosure, the second portion of the nanoreporter is not immobilized non-selectively. Selective immobilization can allow the nanoreporter to be immobilized while in a fully extended state or nearly fully extended state. Selective

immobilization can also allow the nanoreporter to be immobilized in an oriented manner. In other words, the first portion and second portion of the nanoreporter can be immobilized along the direction of the field or fields used to extend the nanoreporter, with the first portion preceding the second portion in the field. When a plurality of nanoreporters are immobilized, the can be uniformly oriented along the field.

[0229] As discussed above, the second portion of the nanoreporter, or the reporter probe hybridized to the target-specific reporter oligo, is immobilized selectively. The immobilization can be by any selective interaction with the substrate apparent to those of skill in the art. The immobilization can be via electrostatic or ionic interaction, via one or more covalent bonds, via one or more non-covalent bonds or combinations thereof. In certain aspects, the immobilization can be via electrostatic interaction with an electrode. In further aspects, the immobilization is via electrostatic interaction with a substrate other than the electrode.

[0230] If the first portion and the second portion of the nanoreporter are selectively immobilized to the same substrate, the techniques of selective immobilization should of course be compatible with the substrate. In particular aspects, the techniques of immobilization are the same. For instance, on a substrate coated with avidin, both the first and second portion of the nanoreporter can be immobilized selectively via biotin-avidin interactions. However, as will be apparent to those of skill in the art, the same interaction need not be used at both the first and second portions for immobilization on the same substrate. For instance, the substrate can comprise multiple moieties capable of selective binding, or the first portion can be immobilized non- selectively, or other techniques apparent to those of skill in the art.

[0231] In certain aspects, the second portion of the nanoreporter comprises a first member of a binding pair. The second member of the binding pair can be covalently bound to the second portion of the nanoreporter, or they can be non-covalently bound. Useful covalent bonds and non-covalent bonds will be apparent to those of skill in the art. In useful aspects, the substrate onto which the second portion of the nanoreporter is bound will comprise a second member of the binding pair. The substrate can be covalently bound to the second member, or they can be non-covalently bound.

[0232] In certain aspects, the second portion of the nanoreporter can comprise a member of a binding pair that is capable of binding with a member of a binding pair on the substrate to form one or more non-covalent bonds. Exemplary useful substrates include those that comprise a binding moiety selected from the group consisting of ligands, antigens, carbohydrates, nucleic acids, receptors, lectins, and antibodies such as those described in the sections above.

[0233] In advantageous aspects, the second portion of the nanoreporter can be immobilized to the substrate via an avidin-biotin binding pair. In certain aspects, the nanoreporter can comprise a biotin moiety in its first portion. For instance, a polynucleotide nanoreporter can comprise a biotinylated nucleotide residue. Similarly, a polypeptide nanoreporter can comprise a

biotinylated amino acid residue. Useful substrates comprising avidin are described in the sections above.

[0234] In further aspects, the second portion of the nanoreporter can comprise avidin, and the substrate can comprise biotin. Useful substrates comprising biotin are described in the sections above.

[0235] In further aspects, the second portion of the nanoreporter can comprise a member of a binding pair that is capable of reacting with a member of a binding pair on the substrate to form one or more covalent bonds. Exemplary useful substrates comprising reactive groups are described in the sections above.

[0236] In certain aspects, the second portion of the nanoreporter can comprise a reactive moiety that is capable of being bound to the substrate by photoactivation. The substrate could comprise the photoreactive moiety, or the second portion of the nanoreporter could comprise the photoreactive moiety. Some examples of photoreactive moieties include aryl azides, such as N- ((2-pyridyldithio)ethyl)-4-azidosalicylamide; fluorinated aryl azides, such as 4-azido-2,3,5,6- tetrafluorobenzoic acid; benzophenone-based reagents, such as the succinimidyl ester of 4- benzoylbenzoic acid; and 5-Bromo-deoxyuridine.

[0237] In further aspects, the second portion of the nanoreporter can be immobilized to the substrate via other binding pairs described in the sections above. [0238] In further aspects, the second portion of the nanoreporter is capable of forming a complex with one or more other molecules that, in turn, are capable of binding, covalently or non- covalently, a binding moiety of the substrate. For instance, the second portion of the

nanoreporter can be capable of selectively binding another molecule that comprises, for instance, a biotin moiety that is capable of selectively binding, for instance, an avidin moiety of the substrate.

[0239] Immobilization of Two Portions of an Extended or Oriented Nanoreporter

[0240] In certain aspects, the present disclosure provides methods for selective immobilization of a first portion and a second portion of a nanoreporter that is in an extended or oriented state. Significantly, according to these methods of the disclosure, the nanoreporter need not be immobilized prior to application of a force capable of extending or orienting the nanoreporter.

[0241] In these methods, the nanoreporter is extended or oriented, or both, by a force capable of extending or orienting the nanoreporter. Such forces are described in detail in the sections above. In particular aspects, the force is a force capable of extending or orienting the nanoreporter while maintaining the nanoreporter in one location, i.e. a force capable of extending or orienting without substantially moving the nanoreporter. Exemplary forces include oscillating

electromagnetic fields and oscillating hydrodynamic fields. In a particular aspect, the force is an oscillating electrical field. Exemplary techniques for extending or orienting a nanoreporter in an oscillating electric field are described in Asbury et al., 2002, Electrophoresis 23(16):2658-66; Kabata et al., 1993, Science 262(5139): 1561-3; and Asbury and van den Engh, 1998, Biophys J. 74: 1024-30, the contents of which are hereby incorporated by reference in their entirety.

[0242] In the methods, the nanoreporter is immobilized at a first portion and at a second portion while extended or oriented. Both the first portion and the second portion can be immobilized non-selectively, both can be immobilized selectively, or one can be immobilized selectively and the other non-selectively. Techniques for immobilization of the first portion and second portion are described in detail in the sections above.

[0243] Substrate for Immobilization

[0244] In the methods of the disclosure, the substrate for immobilization can be any substrate capable of selectively binding the nanoreporter apparent to those of skill in the art. Further, in certain aspects, the present disclosure provides compositions comprising a selectively

immobilized nanoreporter in an extended state. The compositions comprise a substrate, as i l l described herein, having immobilized thereto a nanoreporter in an extended state. The nanoreporter can be, of course, immobilized according to a method of the disclosure.

[0245] The only requirement of the substrate is that it be capable of selectively binding the second portion of the nanoreporter as described above. Thus, the substrate can be a filter or a membrane, such as a nitrocellulose or nylon, glass, a polymer such as polyacrylamide, a gel such as agarose, dextran, cellulose, polystyrene, latex, or any other material known to those of skill in the art to which capture compounds can be immobilized. The substrate can be composed of a porous material such as acrylic, styrene methyl methacrylate copolymer and ethylene/acrylic acid.

[0246] The substrate can take on any form so long as the form does not prevent selective immobilization of the second portion of the nanoreporter. For instance, the substrate can have the form of a disk, slab, strip, bead, submicron particle, coated magnetic bead, gel pad, microtiter well, slide, membrane, frit or other form known to those of skill in the art. The substrate is optionally disposed within a housing, such as a chromatography column, spin column, syringe barrel, pipette, pipette tip, 96 or 384 well plate, microchannel, capillary, etc., that aids the flow of liquid over or through the substrate.

[0247] The nanoreporter can be immobilized on a single substrate or on a plurality of substrates. For instance, in certain aspects, the first and second portions of nanoreporter are immobilized on the same substrate, as recognized by those of skill in the art. In certain aspects, the first portion of the nanoreporter can be immobilized on a first substrate while the second portion of the nanoreporter can be immobilized on a second substrate, distinct from the first.

[0248] The substrate can be prepared according to any method apparent to those of skill in the art. For a review of the myriad techniques that can be used to activate exemplary substrates of the disclosure with a sufficient density of reactive groups, see, the Wiley Encyclopedia of Packaging Technology, 2d Ed., Brody & Marsh, Ed., "Surface Treatment," pp. 867 874, John Wiley & Sons (1997), and the references cited therein. Chemical methods suitable for generating amino groups on silicon oxide substrates are described in Atkinson & Smith, "Solid Phase Synthesis of Oligodeoxyribonucleotides by the Phosphite Triester Method," In: Oligonucleotide Synthesis: A Practical Approach, M J Gait, Ed., 1984, IRL Press, Oxford, particularly at pp. 45 49 (and the references cited therein); chemical methods suitable for generating hydroxyl groups on silicon oxide substrates are described in Pease et al., 1994, Proc. Natl. Acad. Sci. USA 91 :5022 5026 (and the references cited therein); chemical methods for generating functional groups on polymers such as polystyrene, polyamides and grafted polystyrenes are described in Lloyd Williams et al., 1997, Chemical Approaches to the Synthesis of Peptides and Proteins, Chapter 2, CRC Press, Boca Raton, Fla. (and the references cited therein).

[0249] Exemplary useful substrates include surfaces coated with streptavidin, e.g. Accelr8 TB0200. Further useful substrates include surfaces coated with N-hydroxysuccinamide that are capable of reacting with a portion of a nanoreporter that comprises an amine. One such surface is OptArray-DNA (Accelr8). Additional useful surfaces are coated with aldehyde (e.g. Nexterion Slide AL, Schott) and surfaces coated with epoxy (e.g. Nexterion Slide E, Schott). Another useful surface is a biotinylated BSA coated surface useful for selective immobilization of a portion of a nanoreporter that comprises avidin or streptavidin.

[0250] Methods of Using Selectively Immobilized, Extended or Oriented Nanoreporters

[0251] In certain aspects, the selectively immobilized, elongated nanoreporters can be used to create macromolecular barcodes for the purposes of separation and sequential detection of labels. These labels spaced along the molecule provide a unique code that can be read when the nanoreporter is extended and immobilized. Extension and selective immobilization can facilitate the decoding of the macromolecular barcode.

[0252] The selectively immobilized, elongated nanoreporters can further be used for can be used in any context where detection or imaging of a nanoreporter might be useful. They can be used for diagnostic, prognostic therapeutic and screening purposes. For instance, they can be applied to the analysis of biomolecular samples obtained or derived from a patient so as to determine whether a diseased cell type is present in the sample and/or to stage the disease. They can be used to diagnose pathogen infections, for example infections by intracellular bacteria and viruses, by determining the presence and/or quantity of markers of bacterium or virus, respectively, in the sample. The compositions and methods of the disclosure can be used to quantitate target molecules whose abundance is indicative of a biological state or disease condition, for example, blood markers that are upregulated or downregulated as a result of a disease state. In addition, the compositions and methods of the disclosure can be used to provide prognostic information that assists in determining a course of treatment for a patient.

[0253] Detection of Nanoreporters

[0254] The no tag or tag-based nanoreporters of the present disclosure are detected by any means available in the art that is capable of detecting the specific signals on a given nanoreporter.

Where the nanoreporter is fluorescently labeled, suitable consideration of appropriate excitation sources may be investigated. Possible sources may include but are not limited to arc lamp, xenon lamp, lasers, light emitting diodes or some combination thereof. The appropriate excitation source is used in conjunction with an appropriate optical detection system, for example an inverted fluorescent microscope, an epi-fluorescent microscope or a confocal microscope.

Preferably, a microscope is used that can allow for detection with enough spatial resolution to determine the sequence of the spots on the nanoreporter.

[0255] Microscope and Objective Lens Selection

[0256] The major consideration regarding the microscope objective lens is with the optical resolution, which is determined by its numerical aperture (NA). Generally, the larger the NA, the better the optical resolution. The required NA is preferably at least 1.07 based on the relationship of 6=0.6 Ιλ/NA (6=optical resolution and =wavelength). The amount of light that is collected by an objective is determined by NA⁴/Mag² (Mag=magnifi cation of the objective). Therefore, in order to collect as much light as possible, objectives with high NA and low magnifications should be selected.

[0257] CCD Camera Selection and Image Capture Techniques.

[0258] When selecting a CCD camera, the first consideration is the pixel size, which partially determines the final resolution of the imaging system. Optimally the optical resolution should not be compromised by the CCD camera. For example, if the optical resolution is 210-300 nm, which corresponds to 12.6-18 μπι on a CCD chip after a 60x magnification, in order to resolve and maintain the optical resolution there should be at least two pixels to sample each spot. Or the pixel size of the CCD chip should be at most 6.3-9 μπι.

[0259] The second consideration is detection sensitivity which can be determined by many factors that include but are not limited to pixel size, quantum efficiency, readout noise and dark noise. To achieve high sensitivity, select a qualitative camera with big pixel size (which can give big collection area), high quantum efficiency and low noise. An exemplary camera with these criteria is the Orca-Ag camera from Hamamatsu Inc. The chip size is 1344x1024 pixels; when using the 60x objective, the field of view is 144x110 μπι².

[0260] Computer Systems

[0261] The disclosure provides computer systems that may be used to computerize nanoreporter image collection, nanoreporter identification and/or decoding of the nanoreporter code.

Specifically, the disclosure provides various computer systems comprising a processor and a memory coupled to the processor and encoding one or more programs. The computer systems can be connected to the microscopes employed in imaging the nanoreporter, allowing imaging, identification and decoding the nanoreporter, as well as storing the nanoreporter image and associated information, by a single apparatus. The one or more programs encoded by the memory cause the processor to perform the methods of the disclosure.

[0262] In still other aspects, the disclosure provides computer program products for use in conjunction with a computer system (e.g., one of the above-described computer systems of the disclosure) having a processor and a memory connected to the processor. The computer program products of the disclosure comprise a computer readable storage medium having a computer program mechanism encoded or embedded thereon. The computer program mechanism can be loaded into the memory of the computer and cause the processor to execute the steps of the methods of the disclosure.

[0263] The methods described in the previous subsections can preferably be implemented by use of the following computer systems, and according to the following methods. An exemplary computer system suitable for implementation of the methods of this disclosure comprises internal components and being linked to external components. The internal components of this computer system include a processor element interconnected with main memory. For example, the computer system can be an Intel Pentium-based processor of 200 MHz or greater clock rate and with 32 MB or more of main memory.

[0264] The external components include mass storage. This mass storage can be one or more hard disks which are typically packaged together with the processor and memory.

[0265] Such hard disks are typically of 1 GB or greater storage capacity. Other external components include user interface device, which can be a monitor and a keyboard, together with pointing device, which can be a "mouse", or other graphical input devices (not illustrated).

Typically, the computer system is also linked to a network link, which can be part of an Ethernet link to other local computer systems, remote computer systems, or wide area communication networks, such as the Internet. This network link allows the computer system to share data and processing tasks with other computer systems.

[0266] Loaded into memory during operation of this system are several software components, which are both standard in the art and special to the instant disclosure. These software components collectively cause the computer system to function according to the methods of the disclosure. The software components are typically stored on mass storage. A first software component is an operating system, which is responsible for managing the computer system and its network interconnections. This operating system can be, for example, of the Microsoft Windows family, such as Windows 95, Windows 2000, or Windows XP, or, alternatively, a Macintosh operating system, a Linux operating system or a Unix operating system. A second software component may include common languages and functions conveniently present in the system to assist programs implementing the methods specific to this disclosure. Languages that can be used to program the analytic methods of the disclosure include, for example, C, C++, JAVA, and, less preferably, FORTRAN, PASCAL, and BASIC. Another software component of the present disclosure comprises the analytic methods of this disclosure as programmed in a procedural language or symbolic package.

[0267] In an exemplary implementation, to practice the methods of the present disclosure, a nanoreporter code (i.e., a correlation between the order and nature of spots on a nanoreporter and the identity of a target molecule to which such a nanoreporter binds) is first loaded in the computer system. Next the user causes execution of analysis software which performs the steps of determining the presence and, optionally, quantity of nanoreporters with a given nanoreporter code.

[0268] The analytical systems of the disclosure also include computer program products that contain one or more of the above-described software components such that the software components may be loaded into the memory of a computer system. Specifically, a computer program product of the disclosure includes a computer readable storage medium having one or more computer program mechanisms embedded or encoded thereon in a computer readable format. The computer program mechanisms encoded, e.g., one or more of the analytical software components described above which can be loaded into the memory of a computer system and cause the processor of the computer system to execute the analytical methods of the present disclosure.

[0269] The computer program mechanisms or mechanisms are preferably stored or encoded on a computer readable storage medium. Exemplary computer readable storage media are discussed above and include, but are not limited to: a hard drive, which may be, e.g., an external or an internal hard drive of a computer system of the disclosure, or a removable hard drive; a floppy disk; a CD-ROM; or a tape such as a DAT tape. Other computer readable storage media will also be apparent to those skilled in the art that can be used in the computer program mechanisms of the present disclosure

[0270] The present disclosure also provides databases useful for practicing the methods of the present disclosure. The databases may include reference nanoreporter codes for a large variety of target molecules. Preferably, such a database will be in an electronic form that can be loaded into a computer system. Such electronic forms include databases loaded into the main memory of a computer system used to implement the methods of this disclosure, or in the main memory of other computers linked by network connection, or embedded or encoded on mass storage media, or on removable storage media such as a CD-ROM or floppy disk.

[0271] Alternative systems and methods for implementing the methods of this disclosure are intended to be comprehended within the accompanying claims. In particular, the accompanying claims are intended to include the alternative program structures for implementing the methods of this disclosure that will be readily apparent to one of skill in the art.

[0272] Applications of Nanoreporter Technology

[0273] The compositions and methods of the disclosure can be used for diagnostic, prognostic therapeutic and screening purposes. The present disclosure provides the advantage that many different target molecules can be analyzed at one time from a single biomolecular sample using the methods of the disclosure. This allows, for example, for several diagnostic tests to be performed on one sample

[0274] Diagnostic/Prognostic Methods

[0275] The present methods can be applied to the analysis of biomolecular samples obtained or derived from a patient so as to determine whether a diseased cell type is present in the sample and/or to stage the disease.

[0276] For example, a blood sample can be assayed according to any of the methods described herein to determine the presence and/or quantity of markers of a cancerous cell type in the sample, thereby diagnosing or staging the cancer.

[0277] Alternatively, the methods described herein can be used to diagnose pathogen infections, for example infections by intracellular bacteria and viruses, by determining the presence and/or quantity of markers of bacterium or virus, respectively, in the sample. [0278] Thus, the target molecules detected using the compositions and methods of the disclosure can be either patient markers (such as a cancer marker) or markers of infection with a foreign agent, such as bacterial or viral markers.

[0279] Because of the quantitative nature of nanoreporters, the compositions and methods of the disclosure can be used to quantitate target molecules whose abundance is indicative of a biological state or disease condition, for example, blood markers that are upregulated or downregulated as a result of a disease state.

[0280] In addition, the compositions and methods of the disclosure can be used to provide prognostic information that assists in determining a course of treatment for a patient. For example, the amount of a particular marker for a tumor can be accurately quantified from even a small sample from a patient. For certain diseases like breast cancer, overexpression of certain genes, such as Her2-neu, indicate a more aggressive course of treatment will be needed.

[0281] Analysis of Pathology Samples

[0282] RNA extracted from formaldehyde- or paraformaldehyde-fixed paraffin-embedded tissue samples is typically poor in quality (fragmented) and low in yield. This makes gene expression analysis of low-expressing genes in histology samples or archival pathology tissues extremely difficult and often completely infeasible. The nanoreporter technology can fill this unmet need by allowing the analysis of very small quantities of low-quality total RNA.

[0283] To use nanoreporter technology in such an application, total RNA can be extracted from formaldehyde- or paraformaldehyde-fixed paraffin-embedded tissue samples (or similar) using commercially available kits such as RecoverAll Total Nucleic Acid Isolation Kit (Ambion) following manufacturer's protocols. RNA in such samples is frequently degraded to small fragments (200 to 500 nucleotides in length), and many paraffin-embedded histology samples only yield tens of nanograms of total RNA. Small amounts (5 to 100 ng) of this fragmented total RNA can be used directly as target material in a nanoreporter hybridization following the assay conditions described herein.

[0284] Screening Methods

[0285] The methods of the present disclosure can be used, inter alia, for determining the effect of a perturbation, including chemical compounds, mutations, temperature changes, growth hormones, growth factors, disease, or a change in culture conditions, on various target molecules, thereby identifying target molecules whose presence, absence or levels are indicative of a particular biological states. In a preferred aspect, the present disclosure is used to elucidate and discover components and pathways of disease states. For example, the comparison of quantities of target molecules present in a disease tissue with "normal" tissue allows the elucidation of important target molecules involved in the disease, thereby identifying targets for the

discovery/screening of new drug candidates that can be used to treat disease.

[0286] Kits

[0287] The disclosure further provides kits comprising one or more components of the disclosure. The kits can contain pre-labeled reporter or capture probes, or unlabeled reporter or capture probes with one or more components for labeling the nanoreporters. The kits also contain probes that contain target-specific sequences and tag sequences that bind to the reporter or capture probes.

[0288] The kit can include other reagents as well, for example, buffers for performing hybridization reactions, linkers, restriction endonucleases, and DNA ligases.

[0289] The kit also will include instructions for using the components of the kit, and/or for making and/or using the labeled nanoreporters.

Claims

What is claimed is:

1. A composition comprising a plurality of first probes, wherein a first probe comprises:

i. a first region comprising a first target-specific sequence that independently base-pair hybridizes to a target molecule comprising at least five of the genes listed in Table 1A; and

ii. a second region comprising: a first label attachment region hybridized to at least one first RNA molecule, wherein the at least one first RNA molecule is attached to one or more label monomers that emit light constituting a first signal, and an at least second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to at least one second RNA molecule, wherein the at least one second RNA molecule is attached to one or more label monomers that emit light constituting a second signal; and

wherein the second region does not overlap with the first region and does not

independently base-pair hybridize with the target nucleic acid.

2. The composition of claim 1, further comprising a plurality of second probes, wherein each second probe comprises:

i. a first region comprising a second target-specific sequence that independently base- pair hybridizes to a target molecule comprising at least five of the genes listed in Table 1A; and

ii. a second region comprising an affinity moiety; and

wherein the first target-specific sequence and the second target-specific sequence base-pair hybridize to non-overlapping regions of the same target molecule.

3. A method of detecting a target molecule in a biological sample comprising:

(i) contacting said sample with a composition according to claim 1 under conditions that allow hybridization of a first target-specific sequence of a first probe to a target molecule, wherein when a first target-specific sequence of a first probe is bound to a target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule; and

(ii) detecting the code that identifies the target molecule.

4. A method of detecting a target molecule in a biological sample comprising:

(i) contacting said sample with a composition according to claim 2 under conditions that allow hybridization of the first target-specific sequence of a first probe and the second target-specific sequence of a second probe to a target molecule,

wherein when the first target-specific sequence of a first probe and the second target- specific sequence of a second probe are bound to the target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule; and

(ii) detecting the code that identifies the target molecule.

5. A composition of claim 1 comprising at least 50 first probes.

6. A composition of claim 1 comprising at least 100 first probes.

7. A composition of claim 1 comprising 770 first probes.

8. A composition of claim 1, wherein when a first probe is hybridized to a target molecule, the identity of the first and second signals emitted from the first probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule.

9. A composition of claim 1, wherein the plurality of first probes further comprise a third, fourth, fifth and at least sixth label attachment region, wherein

i. the third label attachment region is hybridized to at least one third RNA molecule,

wherein the at least one third RNA molecule is attached to one or more label monomers that emit light constituting a third signal; ii. the fourth label attachment region is hybridized to at least one fourth RNA molecule, wherein the at least one fourth RNA molecule is attached to one or more label monomers that emit light constituting a fourth signal;

iii. the fifth label attachment region is hybridized to at least one fifth RNA molecule,

wherein the at least one fifth RNA molecule is attached to one or more label monomers that emit light constituting a fifth signal;

iv. the at least sixth label attachment region is hybridized to at least one sixth RNA

molecule, wherein the at least one sixth RNA molecule is attached to one or more label monomers that emit light constituting a sixth signal; and

wherein none of the label attachment regions overlap.

10. A composition of claim 9, wherein when a first probe is bound to a target molecule, the identity of the first, second, third, fourth, fifth and sixth signals emitted from the first probe and the locations of the signals relative to each other constitute at least part of a code that identifies the target molecule.

11. A kit comprising the composition of claim 1 and instructions for use.

12. A composition pair comprising a first composition and a second composition,

wherein the first composition comprises a first probe and a second probe,

wherein a first probe comprises:

i. a first region comprising a first target-specific sequence that independently base- pair hybridizes to a target molecule comprising any of the genes listed in Table 1A; and

ii. a second region that does not overlap with the first region and does not bind to the target molecule; and

wherein a second probe comprises:

i. a first region that hybridizes to the second region of the first probe; and ii. a second region comprising a first label attachment region hybridized to at least one first RNA molecule, wherein the at least one first RNA molecule is attached to one or more label monomers that emit light constituting a first signal, and an at least second label attachment region, which is non-overlapping to the first label attachment region, and which is hybridized to at least one second RNA molecule, wherein the at least one second RNA molecule is attached to one or more label monomers that emit light constituting a second signal, and wherein the second region does not overlap with the first region and does not independently base-pair hybridize with the target nucleic acid; and

wherein the second composition comprises a third probe and a fourth probe,

wherein a third probe comprises:

i. a first region comprising a second target-specific sequence that independently base-pair hybridizes to a target molecule comprising any of the genes listed in Table 1A; and

wherein a fourth probe comprises:

i. a first region that binds to the second region of the third probe; and

ii. a second region comprising at least one affinity moiety, and wherein the first region does not overlap with the second region; and

wherein the first target-specific sequence of the first probe and the second target-specific sequence of a third probe hybridize to different regions of the same target molecule.

13. A composition of claim 12, wherein when a first probe, a second probe, a third probe and a fourth probe are bound to a target molecule, the identity of the first and second signals emitted from the second probe and the location of the signals relative to each other constitute at least part of a code that identifies the target molecule.

14. A kit comprising the composition pair of claim 12 and instructions for use.